Pharmaceutical compositions of Anti-CD20 / Anti-CD3 bispecific antibodies and methods of use

Abstract

To provide pharmaceutical compositions of anti-CD20 / anti-CD3 bispecific antibodies and use methods thereof.SOLUTION: Disclosed is a liquid pharmaceutical composition comprising: about 1 to 25 mg / ml of an anti-CD20 / anti-CD3 bispecific antibody; about 10 to 50 mM of a buffering agent; about ≥200 mM of an isotonic agent; about 0 to 15 mM of methionine; and about ≥0.2 mg / ml of a surfactant, where the anti-CD20 / anti-CD3 bispecific antibody comprises: a) at least one antigen binding domain that specifically binds to CD20; and b) at least one antigen binding domain that specifically binds to CD3 at a pH ranging from about 5.0 to about 6.0.SELECTED DRAWING: None

Description

[Technical field]

[0001] The present invention relates to pharmaceutical compositions of anti-CD20 / anti-CD3 bispecific antibodies and methods of use thereof. [Background technology]

[0002] One of the major challenges in the development of biotechnological therapeutics is protein stability, which must be maintained through multiple process steps until the product is brought to market. Furthermore, protein stability must be maintained not only during storage but also during administration to patients. Therapeutic antibodies can be formulated in aqueous carriers for administration to subjects, for example, by intravenous or subcutaneous administration. During storage, handling, and administration of such pharmaceutical compositions, it is necessary to mitigate possible losses of therapeutic antibodies due to degradation and surface adsorption, such as adsorption of proteins to the surfaces of filters, storage canisters, tubing, syringes, IV fluid bags, and other containers. Both low-concentration and high-concentration formulations pose their own challenges during research and development and manufacturing. For example, low concentrations are more susceptible to surface adsorption, whereas high concentrations can exhibit high viscosity.

[0003] When a pharmaceutical composition contains a relatively low concentration of a therapeutic protein, protein loss can be dramatically increased by these factors, resulting in a reduced therapeutic effect of the pharmaceutical composition.

[0004] Thus, there is a need in the art to develop pharmaceutical formulations of anti-CD20 / anti-CD3 bispecific antibodies (e.g., low dose anti-CD20 / anti-CD3 bispecific antibodies, e.g., low dose anti-CD20 / anti-CD3 T cell engaging bispecific antibodies, e.g., glofitamab) that are stable and protected from loss due to adsorption. Summary of the Invention

[0005] The present invention relates to pharmaceutical compositions of anti-CD20 / anti-CD3 bispecific antibodies (e.g., anti-CD20 / anti-CD3 T-cell engaging bispecific antibodies (TCBs), such as glofitamab, RO7082859, or RG6026), and methods of use thereof. The disclosed compositions and related methods address the problem of delivering anti-CD20 / anti-CD3 bispecific antibodies (e.g., anti-CD20 / anti-CD3 TCBs, such as glofitamab) formulated at low concentrations, allowing patients to receive the intended dose of anti-CD20 / anti-CD3 bispecific antibodies (e.g., anti-CD20 / anti-CD3 TCBs, such as glofitamab) with little or no loss of protein during storage and administration.

[0006] In one aspect, the present invention provides a liquid pharmaceutical composition comprising: At a pH in the range of about 5.0 to about 6.0, about 1 to 25 mg / ml of anti-CD20 / anti-CD3 bispecific antibody; about 10 to 50 mM buffer; about ≧200 mM tonicity agent; about 0-15 mM methionine; and about ≥ 0.2 mg / ml surfactant; and the anti-CD20 / anti-CD3 bispecific antibody comprises a) at least one antigen-binding domain that specifically binds to CD20, (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:1; (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:2; and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 3 and a heavy chain variable region comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5; and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:6 and a light chain variable region comprising At least one antigen-binding domain that specifically binds to CD20 comprising: b) at least one antigen-binding domain that specifically binds to CD3, (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:9; (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 10; and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 11 and a heavy chain variable region comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 13; and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 14 and a light chain variable region comprising and at least one antigen-binding domain that specifically binds to CD3 comprising: The present invention features a liquid pharmaceutical composition comprising:

[0007] In one embodiment, the concentration of the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, e.g., glofitamab) ranges from about 1 to 5 mg / ml. In one embodiment, the concentration of the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, e.g., glofitamab) ranges from about 0.9 to 1.1 mg / ml. In one embodiment, the concentration of the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, e.g., glofitamab) is about 1 mg / ml.

[0008] In one embodiment, an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab) is a) at least one antigen-binding domain that specifically binds to CD20, comprising a heavy chain variable region sequence of SEQ ID NO: 7 and a light chain variable region sequence of SEQ ID NO: 8; b) at least one antigen-binding domain that specifically binds to CD3, comprising a heavy chain variable region sequence of SEQ ID NO: 15 and a light chain variable region sequence of SEQ ID NO: 16; Includes.

[0009] In one embodiment, an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab) is a) a first Fab molecule that specifically binds to CD3, in particular CD3 epsilon, in which the variable domains VL and VH of the Fab light and heavy chains are exchanged with each other; b) a second and a third Fab molecule which specifically bind to CD20, in which in the constant domain CL of the second and third Fab molecules the amino acid at position 124 is substituted by lysine (K) (Kabat numbering) and the amino acid at position 123 is substituted by lysine (K) or arginine (R), in particular by arginine (R) (Kabat numbering), and in the constant domain CH1 of the second and third Fab molecules the amino acid at position 147 is substituted by glutamic acid (E) (EU numbering) and the amino acid at position 213 is substituted by glutamic acid (E) (EU numbering); c) an Fc domain composed of a first subunit and a second subunit capable of stable association; Includes.

[0010] In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody is glofitamab.

[0011] In one embodiment, the buffer is a histidine buffer, optionally a histidine HCl buffer. In one embodiment, the buffer is at a concentration of about 15 to 25 mM. In one embodiment, the buffer is at a concentration of about 20 mM. In one embodiment, the buffer provides a pH of about 5.2 to about 5.8.

[0012] In one embodiment, the tonicity agent is selected from the group of salts, sugars, and amino acids. In one embodiment, the tonicity agent is either sucrose or sodium chloride. In one embodiment, the tonicity agent is sucrose at a concentration of about 200 mM or more. In one embodiment, the tonicity agent is sucrose at a concentration of about 200 mM to 280 mM. In one embodiment, the tonicity agent is sucrose at a concentration of about 240 mM.

[0013] In one embodiment, methionine is at a concentration of about 5-15 mM.

[0014] In one embodiment, methionine is at a concentration of about 10 mM. In one embodiment, the surfactant is at a concentration of about 0.2-0.8 mg / ml. In one embodiment, the surfactant is polysorbate 20 or poloxamer 188. In one embodiment, the surfactant is polysorbate 20 at a concentration of 0.2-0.8 mg / ml. In one embodiment, the surfactant is polysorbate 20 at a concentration of about 0.5 mg / ml.

[0015] In one embodiment, the liquid pharmaceutical composition comprises: At a pH of about 5 to about 6, about 1 to 5 mg / ml of an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab), a) at least one antigen-binding domain that specifically binds to CD20, (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:1; (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:2; and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 3 and a heavy chain variable region comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5; and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:6 and a light chain variable region comprising At least one antigen-binding domain that specifically binds to CD20 comprising: b) at least one antigen-binding domain that specifically binds to CD3, (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:9; (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 10; and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 11 and a heavy chain variable region comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 13; and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 14 and a light chain variable region comprising and at least one antigen-binding domain that specifically binds to CD3 comprising: about 1 to 5 mg / ml of an anti-CD20 / anti-CD3 bispecific antibody comprising; with about 15-25mM histidine buffer; with approximately 200-280 mM sucrose; with approximately 0-15 mM methionine; Approximately 0.2-0.8mg / ml of PS20 Includes.

[0016] In one embodiment, the liquid pharmaceutical composition comprises: At a pH of about 5.5, with glofitamab at approximately 1mg / ml; with about 20 mM histidine buffer; with approximately 240 mM sucrose; with approximately 10 mM methionine; Approximately 0.5mg / ml of PS20 Includes.

[0017] In one embodiment, the invention provides the use of a liquid pharmaceutical composition of any of the preceding aspects and embodiments for the preparation of a medicament useful for the treatment of a cell proliferative disorder.

[0018] In another aspect, the invention features a pharmaceutical composition of any of the preceding aspects and embodiments for use in treating or delaying the progression of a cell proliferative disorder in a subject in need thereof.

[0019] In another aspect, the invention features a pharmaceutical composition of any of the preceding aspects and embodiments for use in treating or delaying progression of a cell proliferative disorder in a subject in need thereof, comprising administering to the subject an effective amount of the pharmaceutical composition of any of the preceding aspects and embodiments.

[0020] In certain embodiments, the cell proliferative disorder is cancer.

[0021] Further aspects of the present invention relate to the invention described herein.

[0022] Each and every embodiment may be combined unless the context clearly indicates otherwise. Each and every embodiment may be applied to each and every aspect of the invention unless the context clearly indicates otherwise.

[0023] Specific embodiments of the present invention will become apparent from the following more detailed description of certain preferred embodiments and the claims.

[0024] The content of the application file contains at least one drawing executed in color. Copies of this patent or this patent application with color drawing(s) will be provided by the Office upon request and payment of the necessary fee. [Brief description of the drawings]

[0025] [Figure 1A-F] Schematic diagram showing the configuration of an exemplary anti-CD20 / anti-CD3 bispecific antibody. [Figure 1G-N] Schematic diagram showing the configuration of an exemplary anti-CD20 / anti-CD3 bispecific antibody. [Diagram 2] Schematic diagram showing the structure of glofitamab. [Diagram 3] Formulation development GLP Tox and implementation into human studies. Surfactant content of formulations F1 to F5, initially and after 6 weeks of storage at 5, 25, or 40°C. [Figure 4A] Formulation development GLP Tox and introduction into human studies, size exclusion chromatography (SEC) of formulations F1 to F5, initially and after 6 weeks of storage at 5, 25, or 40° C. Figure 4A: Main peak. [Figure 4B] Formulation development GLP Tox and introduction into human studies, size exclusion chromatography (SEC) of formulations F1 to F5, initially and after 6 weeks of storage at 5, 25, or 40° C. FIG 4B: High molecular weight (HMW). [Figure 4C] Formulation development GLP Tox and introduction into human studies, size exclusion chromatography (SEC) of formulations F1 to F5, initially and after 6 weeks of storage at 5, 25, or 40° C. Figure 4C: Low molecular weight (LMW). [Figure 5A] Formulation Development GLP Tox and Implementation into Human Studies, Ion Exchange Chromatography (IEC) of Formulations F1 to F5, Initial and After 6 Weeks of Storage at 5, 25, or 40° C. Figure 5A: Main peak. [Figure 5B] Formulation development GLP Tox and introduction into human studies, ion exchange chromatography (IEC) of formulations F1 to F5, initially and after 6 weeks of storage at 5, 25, or 40° C. Figure 5B. HMW. [Figure 5C] Formulation development GLP Tox and introduction into human studies, ion exchange chromatography (IEC) of formulations F1 to F5, initially and after 6 weeks of storage at 5, 25, or 40° C. Figure 5C.LMW. [Figure 6] Analytical results of formulation F1 through week 84 of formulation development. F1 = 5 mg / ml RO7022859 (i.e., glofitamab), 20 mM histidine HCl pH 5.5, 240 mM sucrose, 10 mM methionine, 0.05% (w / v) polysorbate 20. [Figure 7A] Formulation Development GLP Tox and Implementation into Human Studies, huCD20 Binding of Formulations F1 to F5, Initially and After 3 and 6 Weeks of Storage at 5, 25, or 40°C [Figure 7B] Formulation development GLP Tox and introduction into human studies, huCD3 binding of F1 to F5, initially and after 3 and 6 weeks storage at 5, 25, or 40°C. [Figure 8A-B] Development studies for Phase III and commercial formulation. Size-exclusion (SE)-HPLC % HMWS (Figure 8A) and ion-exchange (IE)-HPLC % acidic field (Figure 8B) of glofitamab as a function of protein concentration after 104 weeks of storage at 5°C. [Figure 9A-B] Development studies for Phase III and commercial formulation. Glofitamab SE-HPLC % HMWS (Figure 9A) and % acidic area (Figure 9B) as a function of pH and stabilizer (methionine) addition after 6w storage at 40°C. [Figure 10A-B] Development studies for Phase III and commercial formulation. SE-HPLC % HMWS and IE-HPLC % acidic area of ​​glofitamab including visible particle formation as a function of tonicity agent after 26 weeks storage at 25°C. [Figure 11A-B] Development studies for Phase III and commercial formulation. SE-HPLC % HMWS (FIG. 11A) and IE-HPLC % acidic region (FIG. 11B) of glofitamab including visible particle formation as a function of surfactant after 7 days of shaking at 25° C. [Figure 12] Development studies for phase III and commercial formulation. Glofitamab PS20 content [mg / ml] and visible particle formation as a function of protein concentration initially and after 104 weeks of storage at 5°C. [Figure 13] Long-term stability data: PS20 content of example glofitamab DP batches with respect to stability (storage at 2-8°C). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0026] The present invention relates to pharmaceutical compositions of anti-CD20 / anti-CD3 bispecific antibodies and methods of use thereof. The disclosed compositions and associated methods address the problem of delivering anti-CD20 / anti-CD3 bispecific antibodies formulated at low concentrations, allowing patients to receive the intended dose of anti-CD20 / anti-CD3 bispecific antibodies with little or no loss of the bispecific antibody during storage and administration.

[0027] I. General techniques The practice of the present disclosure will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry, and immunology, which are within the skill of those in the art. Such techniques are fully explained in such publications as, for example, "Molecular Cloning: A Laboratory Manual", 2nd edition (Sambrook et al., 1989); "Oligonucleotide Synthesis" (MJ Gait, ed., 1984); "Animal Cell Culture" (RI Freshney, ed., 1987); "Methods in Enzymology" (Academic Press, Inc.); "Current Protocols in Molecular Biology" (FM Ausubel et al., 1987, and periodic updates); "PCR: The Polymerase Chain Reaction", (Mullis et al., eds., 1994); "A Practical Guide to Molecular Cloning" (Perbal Bernard V., 1988); "Phage Display: A Laboratory Manual" (Barbas et al., 2001).

[0028] II. Definition Terms used herein are used as commonly used in the art unless otherwise defined below.

[0029] As used herein, the term "cluster of differentiation 20" or "CD20" refers to any native CD20 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats), unless otherwise indicated. CD20 (also known as B lymphocyte antigen CD20, B lymphocyte surface antigen B1, Leu-16, Bp35, BM5, and LF5; the human protein is characterized by UniProt database entry number P11836) is a hydrophobic transmembrane protein of approximately 35 kD expressed on pre-B and mature B lymphocytes (Valentine, MA et al., J. Biol. Chem. 264 (1989)11282-11287; Tedder, TF, et al., Proc. Natl. Acad. Sci. USA 85 (1988)208-212; Stamenkovic, I., et al., J. Exp. Med. 167 (1988)1975-1980; Einfeld, DA, et al., EMBO J. 7 (2010)106-1107). (1988)711-717; Tedder, TF, et al., J. Immunol. 142 (1989)2560-2568). The corresponding human gene is transmembrane 4 domain, subfamily A, member 1, also known as MS4A1. This gene encodes a member of the transmembrane 4A gene family. Members of this emerging protein family are characterized by common structural features and similar intron / exon splice boundaries and display unique expression patterns among hematopoietic cells and non-lymphoid tissues. This gene encodes a B-lymphocyte surface molecule that plays a role in the development and differentiation of B cells into plasma cells. This family member is localized to 11q12 within a cluster of family members. The term encompasses "full-length", unprocessed CD20, as well as any form of CD20 that results from processing within the cell. The term also encompasses naturally occurring variants of CD20, such as splice variants or allelic variants. Alternative splicing of this gene results in two transcript variants encoding the same protein.In one embodiment, the CD20 is human CD20.

[0030] The terms "anti-CD20 antibody" and "antibody that binds to CD20" refer to an antibody that is capable of binding to CD20 with sufficient affinity such that the antibody is useful as a diagnostic and / or therapeutic agent in targeting CD20. In one embodiment, the degree of binding of an anti-CD20 antibody to an unrelated, non-CD20 protein is less than about 10% of the binding of the antibody to CD20, as measured, for example, by radioimmunoassay (RIA). In certain embodiments, an antibody that binds to CD20 has an affinity of ≦1 μM, ≦100 nM, ≦10 nM, ≦1 nM, ≦0.1 nM, ≦0.01 nM, or ≦0.001 nM (e.g., 10 -8 M or less, e.g., 10 -8 From 10 -13 M, for example 10 -9 From 10 -13 Dissociation constant (K D In certain embodiments, the anti-CD20 antibody binds to an epitope of CD20 that is conserved among CD20 from different species.

[0031] "Type II anti-CD20 antibody" means an anti-CD20 antibody having the binding characteristics and biological activity of the type II anti-CD20 antibodies described in Cragg et al., Blood 103 (2004) 2738-2743; Cragg et al., Blood 101 (2003) 1045-1052, Klein et al., mAbs 5 (2013), 22-33, and summarized in Table 1 below. TIFF2024138235000001.tif83170

[0032] Examples of Type II anti-CD20 antibodies include, for example, obinutuzumab (GA101), tositumomab (B1), humanized B-Ly1 antibody IgG1 (a chimeric humanized IgG1 antibody as disclosed in WO 2005 / 044859), 11B8 IgG1 (disclosed in WO 2004 / 035607) and AT80 IgG1.

[0033] Examples of Type I anti-CD20 antibodies include, for example, rituximab, ofatumumab, veltuzumab, ocaratuzumab, ocrelizumab, PRO131921, ublituximab, HI47 IgG3 (ECACC, hybridoma), 2C6 IgG1 (disclosed in WO 2005 / 103081), 2F2 IgG1 (disclosed in WO 2004 / 035607 and WO 2005 / 103081), and 2H7 IgG1 (disclosed in WO 2004 / 056312).

[0034] Unless otherwise indicated, "CD3" refers to any native CD3 from any vertebrate source, including mammals such as primates (e.g., humans), non-human primates (e.g., cynomolgus monkeys), and rodents (e.g., mice and rats). The term encompasses "full-length", unprocessed CD3, as well as any form of CD3 resulting from processing within a cell. The term also encompasses naturally occurring variants of CD3, such as splice variants or allelic variants. In one embodiment, the CD3 is human CD3, in particular the epsilon subunit of human CD3 (CD3ε). The amino acid sequence of human CD3ε is shown in UniProt (www.uniprot.org) under accession number P07766 (version 144), or in NCBI (www.ncbi.nlm.nih.gov / ) RefSeq NP_000724.1. The amino acid sequence of CD3ε from the cynomolgus monkey [Macaca fascicularis] is shown in NCBI GenBank number BAB71849.1.

[0035] The terms "anti-CD20 / anti-CD3 antibody," "anti-CD20 / anti-CD3 bispecific antibody," and "bispecific antibody that binds CD20 and CD3" refer to a bispecific antibody that can bind CD20 and CD3 with sufficient affinity such that the antibody is useful as a diagnostic and / or therapeutic agent in targeting CD20 and / or CD3. In one embodiment, the extent of binding of a bispecific antibody that binds CD20 and CD3 to unrelated non-CD3 proteins and / or non-CD20 proteins is less than about 10% of the binding of the antibody to CD3 and / or CD20, as measured, for example, by radioimmunoassay (RIA). In certain embodiments, an anti-CD20 / anti-CD3 bispecific antibody has an affinity of ≦1 μM, ≦100 nM, ≦10 nM, ≦1 nM, ≦0.1 nM, ≦0.01 nM, or ≦0.001 nM (e.g., 10 -8 M or less, e.g., 10 -8 M to 10 -13 M, for example 10 -9 M to 10 -13 Dissociation constant (K D ) respectively. In certain embodiments, the bispecific antibody that binds to CD20 and CD3 binds to an epitope of CD3 that is conserved among CD3 from different species and / or an epitope of CD20 that is conserved among CD20 from different species. One example of an anti-CD20 / anti-CD3 bispecific antibody is glofitamab (WHO Drug Information (International Nonproprietary Names), Recommended INN: List 83, 2020, vol. 34, no. 1, p. 39, anti-CD20 / anti-CD3 T cell engaging bispecific antibody (TCB), CD20-TCB, RO7082859, or RG6026; CAS #: 2229047-91-8).

[0036] The term "amino acid mutation" as used herein is meant to encompass amino acid substitution, deletion, insertion and modification. Any combination of substitution, deletion, insertion and modification can be made to arrive at the final construct, so long as the final construct has the desired characteristics, e.g., reduced binding to Fc receptors. Deletion and insertion of amino acid sequences include amino-terminal and / or carboxy-terminal deletions, as well as insertion of amino acids. In particular, the amino acid mutation is an amino acid substitution. Non-conservative amino acid substitutions, i.e., replacing one amino acid with another amino acid having different structure and / or chemical properties, are particularly preferred, for example, to change the binding properties of the Fc region. Amino acid substitutions include replacement with non-naturally occurring amino acids or replacement with naturally occurring amino acid derivatives of the 20 common amino acids (e.g., 4-hydroxyproline, 3-methylhistidine, ornithine, homoserine, 5-hydroxylysine). Amino acid mutations can be generated using genetic or chemical methods well known in the art. Genetic methods can include site-directed mutagenesis, PCR, gene synthesis, and the like. It is believed that methods other than genetic engineering, such as changing the side chain group of an amino acid by chemical modification, may also be useful. Various notations are used herein to indicate the same amino acid mutation. For example, the substitution of proline at position 329 in the Fc region with glycine is represented as 329G, G329, G 329 , P329G, or Pro329Gly.

[0037] "Affinity" refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., a receptor) and its binding partner (e.g., a ligand). As used herein, "binding affinity" refers to the intrinsic binding affinity reflecting a 1:1 interaction between members of a binding pair (e.g., a receptor and a ligand), unless otherwise indicated. The affinity of a molecule X for a partner Y is usually measured using the dissociation constant (K D ), which can be expressed as the dissociation rate constant and the association rate constant (k off and k on) is the ratio of the rate constants. Thus, equivalent affinities may contain different rate constants, as long as the ratio of the rate constants remains the same. Affinity can be measured by well-established methods known in the art. A particular method for measuring affinity is surface plasmon resonance (SPR).

[0038] An "affinity matured" antibody refers to an antibody that has one or more alterations in one or more hypervariable regions (HVRs) compared to a parent antibody that does not have such alterations, which improve the affinity of the antibody for its antigen.

[0039] The term "antigen-binding moiety" as used herein refers to a polypeptide molecule that specifically binds to an antigenic determinant. In one embodiment, an antigen-binding moiety can direct the entity to which it binds (e.g., a cytokine or a second antigen-binding moiety) to a target site, for example, to a particular type of tumor cell or tumor stroma that bears the antigenic determinant. Antigen-binding moieties include antibodies and fragments thereof, as further defined herein. Preferred antigen-binding moieties include the antigen-binding domain of an antibody, including an antibody heavy chain variable region and an antibody light chain variable region. In some embodiments, an antigen-binding moiety comprises an antibody constant region known in the art, as further defined below. Useful heavy chain constant regions include any of the five isotypes: alpha, delta, epsilon, gamma, or mu. Useful light chain constant regions include any of the two isotypes: kappa and lambda.

[0040] "Specific binding" means that the binding is antigen-selective and can be distinguished from unwanted or non-specific interactions. The ability of an antigen-binding moiety to bind to a specific antigenic determinant can be measured by enzyme-linked immunosorbent assay (ELISA) or other techniques well known to those skilled in the art, such as surface plasmon resonance technology (analysis on a BIACORE® instrument) (Liljeblad et al., Glyco J.17, 323-329 (2000)) and classical binding assays (Heeley, Endocr Res.28, 217-229 (2002)). In one embodiment, the extent of binding of the antigen-binding moiety to an unrelated protein is less than about 10% of the binding of the antigen-binding moiety to the antigen, e.g., as measured by SPR. In certain embodiments, an antigen-binding portion that binds to an antigen, or an antigen-binding molecule comprising an antigen-binding portion, has a specific binding affinity of ≦1 μM, ≦100 nM, ≦10 nM, ≦1 nM, ≦0.1 nM, ≦0.01 nM, or ≦0.001 nM (e.g., 10 -8 M or less, e.g. 10 -8 M to 10 -13 M, for example 10 -9 M to 10 -13 Dissociation constant (K D ).

[0041] "Reduced binding", e.g., reduced binding to Fc receptors, refers to a decrease in affinity for the respective interaction, e.g., as measured by SPR. For clarity, the term also includes a reduction in affinity to zero (or below the detection limit of the analytical method), i.e., a complete cessation of the interaction. Conversely, "increased binding" refers to an increase in binding affinity for the respective interaction.

[0042] As used herein, the term "antigen-binding molecule" in its broadest sense refers to a molecule that specifically binds to an antigenic determinant. Examples of antigen-binding molecules are immunoglobulins and derivatives, such as fragments thereof.

[0043] The term "antigenic determinant" as used herein is synonymous with "antigen" and "epitope" and refers to a site (e.g., a contiguous stretch of amino acids or a conformational structure formed from distinct regions of non-contiguous amino acids) on a polypeptide macromolecule to which an antigen-binding moiety binds and forms an antigen-binding moiety-antigen complex. Useful antigenic determinants can be found, for example, on the surface of tumor cells, on the surface of virus-infected cells, on the surface of other diseased cells, free in serum, and / or in the extracellular matrix (ECM). Unless otherwise indicated, a protein referred to herein as an antigen (e.g., CD3) refers to any native form of the protein from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). In certain embodiments, the antigen is a human protein. The term, when referring to a particular protein herein, encompasses the "full-length," unprocessed protein as well as any form of the protein resulting from processing within the cell. The term also encompasses naturally occurring variants of the protein, such as splice variants or allelic variants. An exemplary human protein useful as an antigen is CD3, in particular the epsilon subunit of CD3 (for human sequence see UniProt no. P07766 (version 130), NCBI RefSeq no. NP_000724.1; for cynomolgus monkey [Macaca fascicularis] sequence see UniProt no. Q95LI5 (version 49), NCBI GenBank no. BAB71849.1). In certain embodiments, the T cell activating bispecific antigen binding molecules described herein bind to an epitope of CD3 or a target cell antigen that is conserved among CD3 or target cell antigens from different species.

[0044] The term "polypeptide" as used herein refers to a molecule consisting of monomers (amino acids) linearly linked by amino bonds (also known as peptide bonds). The term "polypeptide" refers to a chain of two or more amino acids, and not to a specific length of the product. Thus, peptides, dipeptides, tripeptides, oligopeptides, "proteins," "amino acid chains," or any other term referring to a chain of two or more amino acids are included within the definition of "polypeptide," and the term "polypeptide" can be used in place of or interchangeably with any of these terms. The term "polypeptide" is also intended to refer to products of post-expression modifications of polypeptides, including, but not limited to, glycosylation, acetylation, phosphorylation, amidation, derivatization with known protecting / blocking groups, proteolytic cleavage, or modification with non-naturally occurring amino acids. Polypeptides may be obtained from natural biological sources or produced by recombinant technology, but are not necessarily translated from a designated nucleic acid sequence. Polypeptides can be produced by any technique, including chemical synthesis. Polypeptides of the invention are of a size of about 3 or more, 5 or more, 10 or more, 20 or more, 25 or more, 50 or more, 75 or more, 100 or more, 200 or more, 500 or more, 1000 or more, or 2000 or more amino acids. A polypeptide may have a clearly defined three-dimensional structure, but does not necessarily have such a structure. A polypeptide that has a clearly defined three-dimensional structure is said to be "folded" and a polypeptide that does not have a clearly defined three-dimensional structure and can adopt a number of different conformations is said to be "unfolded."

[0045] An "isolated" polypeptide or variant, or derivative thereof, is intended to be a polypeptide that is not in its natural environment. Specific purification is not required. For example, an isolated polypeptide can be removed from its native or natural environment. Recombinantly produced polypeptides and proteins expressed in host cells are considered isolated for purposes of the present invention, as are naturally occurring or recombinant polypeptides that have been separated, fractionated, or partially or substantially purified by any suitable technique.

[0046] "Percent (%) amino acid sequence identity" with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical to those in the reference polypeptide sequence, without considering any conservative substitutions as part of the sequence identity, after aligning the sequences and introducing gaps, if necessary, to obtain the maximum percent sequence identity. Alignment for determining percent amino acid sequence identity can be obtained by various methods within the skill of the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN or MEGALIGN® (DNASTAR®) software. Those skilled in the art can determine the appropriate parameters for aligning sequences, including any algorithms required to achieve maximum alignment over the full length of the sequences being compared. However, for the purposes of this specification, percent amino acid sequence identity values ​​are generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was written by Genentech, Inc., and the source code, together with user documentation, has been filed with the U.S. Copyright Office, Washington DC, 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, California, or can be compiled from its source code. The ALIGN-2 program should be compiled for use on UNIX operating systems, including digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary. In the context of using ALIGN-2 for amino acid sequence comparison, the % amino acid sequence identity of a given amino acid sequence A with (or relative to) a given amino acid sequence B (alternatively, a given amino acid sequence A can be said to have or contain a particular % amino acid sequence identity with (or relative to) a given amino acid sequence B) is calculated as follows: 100 x fraction X / Y where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and Y is the total number of amino acid residues in B. It will be understood that if the length of amino acid sequence A is different from the length of amino acid sequence B, then the % amino acid sequence identity of A to B will differ from the % amino acid sequence identity of B to A. Unless otherwise specified, all % amino acid sequence identity values ​​used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program.

[0047] The term "antibody" herein is used in the broadest sense and encompasses a variety of antibody structures, including, but not limited to, monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit the desired antigen-binding activity.

[0048] The terms "full length antibody," "intact antibody," and "whole antibody" are used interchangeably herein to refer to an antibody having a heavy chain having a structure substantially similar to a native antibody structure or containing an Fc region as defined herein.

[0049] "Antibody fragment" refers to a molecule other than an intact antibody that contains a portion of an intact antibody that binds to the antigen to which the intact antibody binds. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2, diabodies, linear antibodies, single-chain antibody molecules (e.g., scFv), and multispecific antibodies formed from antibody fragments. The term "antibody fragment" as used herein also encompasses single domain antibodies.

[0050] The term "immunoglobulin molecule" refers to a protein having the structure of a naturally occurring antibody. For example, immunoglobulins of the IgG class are heterotetrameric glycoproteins of about 150,000 daltons composed of two light chains and two heavy chains that are disulfide-bonded. From the N-terminus to the C-terminus, each heavy chain has a variable region (VH), also called the variable heavy domain or the heavy chain variable domain, followed by three constant domains (CH1, CH2, and CH3), also called the heavy chain constant region. Similarly, from the N-terminus to the C-terminus, each light chain has a variable region (VL), also called the variable light domain or the light chain variable domain, followed by a constant light (CL) domain, also called the light chain constant region. The heavy chains of immunoglobulins can be assigned to one of five classes called α (IgA), δ (IgD), ε (IgE), γ (IgG) or μ (IgM), some of which can be further divided into subclasses, e.g., γ1 (IgG1), γ2 (IgG2), γ3 (IgG3), γ4 (IgG4), α1 (IgA1) and α2 (IgA2). The light chains of immunoglobulins can be assigned to one of two types, called kappa (κ) and lambda (λ), based on the amino acid sequence of their constant domain. Immunoglobulins essentially consist of two Fab molecules linked via an immunoglobulin hinge region and an Fc domain.

[0051] The term "antigen-binding domain" refers to a portion of an antibody that comprises an area that specifically binds to and is complementary to part or all of an antigen. An antigen-binding domain may be provided, for example, by one or more antibody variable domains (also referred to as antibody variable regions). Preferably, the antigen-binding domain comprises an antibody light chain variable region (VL) and an antibody heavy chain variable region (VH).

[0052] The term "variable region" or "variable domain" refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to an antigen. The heavy and light chain variable domains (VH and VL, respectively) of a natural antibody generally have a similar structure, each containing four conserved framework regions (FR) and three hypervariable regions (HVR). See, for example, Kindt et al., Kuby Immunology, 6 th ed., WH Freeman and Co., page 91 (2007). A single VH or VL domain may be sufficient to confer antigen-binding specificity.

[0053] A "human antibody" is an antibody having an amino acid sequence that corresponds to the amino acid sequence of an antibody produced by a human or a human cell, or to an antibody derived from a non-human source that utilizes the human antibody repertoire, or to a sequence encoding another human antibody. This definition of a human antibody specifically excludes humanized antibodies which contain non-human antigen-binding residues.

[0054] A "humanized" antibody refers to a chimeric antibody that comprises amino acid residues from non-human HVRs and amino acid residues from human FRs. In certain embodiments, a humanized antibody comprises substantially all of at least one, and typically two, variable domains, in which all or substantially all of the HVRs (e.g., CDRs) correspond to those of a non-human antibody and all or substantially all of the FRs correspond to those of a human antibody. A humanized antibody may optionally comprise at least a portion of an antibody constant region derived from a human antibody. A "humanized form" of an antibody, e.g., a non-human antibody, refers to an antibody that has been subjected to humanization.

[0055] The term "hypervariable region" or "HVR" as used herein refers to each of the regions of an antibody variable domain that are hypervariable in sequence ("complementarity determining regions" or "CDRs") and / or that structurally form defined loops ("hypervariable loops") and / or contain residues that contact the antigen ("antigen contacts"). Typically, antibodies contain six HVRs: three in the VH (H1, H2, H3) and three in the VL (L1, L2, L3). Exemplary HVRs of the invention include the following: (a) hypervariable loops occurring at amino acid residues 26-32 (L1), 50-52 (L2), 91-96 (L3), 26-32 (H1), 53-55 (H2), and 96-101 (H3) (Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987)); (b) CDRs occurring at amino acid residues 24-34 (L1), 50-56 (L2), 89-97 (L3), 31-35b (H1), 50-65 (H2), and 95-102 (H3) (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991)); (c) antigenic contacts occurring at amino acid residues 27c-36 (L1), 46-55 (L2), 89-96 (L3), 30-35b (H1), 47-58 (H2), and 93-101 (H3) (MacCallum et al. J. Mol. Biol. 262: 732-745 (1996)); and (d) a combination of (a), (b) and / or (c) comprising HVR amino acid residues 46-56 (L2), 47-56 (L2), 48-56 (L2), 49-56 (L2), 26-35 (H1), 26-35b (H1), 49-65 (H2), 93-102 (H3), and 94-102 (H3).

[0056] Unless otherwise indicated, HVR residues and other residues in the variable domain (e.g., FR residues) are numbered herein according to Kabat et al., supra.

[0057] "Framework" or "FR" refers to variable domain residues other than hypervariable region (HVR) residues. The FR of a variable domain is generally composed of four FR domains: FR1, FR2, FR3, FR4. Thus, the HVR and FR sequences generally appear in a VH (or VL) in the following order: FR1-H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4.

[0058] A "human consensus framework" is a framework that represents the most commonly occurring amino acid residues in a selection of human immunoglobulin VL or VH framework sequences. Generally, the selection of human immunoglobulin VL or VH sequences is from a subgroup of variable domain sequences. Generally, the subgroup of sequences is a subgroup of Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, NIH Publication 91-3242, Bethesda MD (1991), vols. 1-3. In one embodiment, for VL, the subgroup is subgroup kappa I in Kabat et al. (see above). In one embodiment, for VH, the subgroup is subgroup III as in Kabat et al., supra.

[0059] For purposes herein, an "acceptor human framework" is a framework that comprises the amino acid sequence of a light chain variable domain (VL) framework or a heavy chain variable domain (VH) framework derived from a human immunoglobulin framework or a human consensus framework, as defined below. An acceptor human framework "derived from" a human immunoglobulin framework or a human consensus framework may comprise the same amino acid sequence or may contain amino acid sequence changes. In some embodiments, the number of amino acid changes is 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less. In some embodiments, the VL acceptor human framework is identical in sequence to the VL human immunoglobulin framework sequence or the human consensus framework sequence.

[0060] The "class" of an antibody refers to the type of constant domain or constant region carried by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, several of which can be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy chain constant domains that correspond to the different classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively.

[0061] As used herein, the term IgG "isotype" or "subclass" means any of the subclasses of immunoglobulins defined by the chemical and antigenic properties of their constant regions.

[0062] The term "Fc domain" or "Fc region" is used herein to define a C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region. This term includes native sequence Fc regions and variant Fc regions. Although the boundaries of the Fc region of an IgG heavy chain may vary slightly, the Fc region of a human IgG heavy chain is usually defined as from Cys226 or from Pro230 to the carboxyl terminus of the heavy chain. However, antibodies produced by a host cell may undergo post-translational truncation of one or more, particularly one or two, amino acids from the C-terminus of the heavy chain. Thus, upon expression of a particular nucleic acid molecule encoding a full-length heavy chain, an antibody produced by a host cell may contain a full-length heavy chain or a truncated variant of the full-length heavy chain (also referred to herein as a "truncated variant heavy chain"). This is the case when the last two C-terminal amino acids of the heavy chain are glycine (G446) and lysine (K447, EU numbering). Thus, the C-terminal lysine (Lys447) of the Fc region, or the C-terminal glycine (Gly446) and lysine (K447) may or may not be present. Unless otherwise specified herein, the numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also called the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991 (see also above). As used herein, a "subunit" of an Fc domain refers to one of the two polypeptides that form a dimeric Fc domain, i.e., a polypeptide that comprises the C-terminal constant region of an immunoglobulin heavy chain and has the ability to stably self-associate. For example, a subunit of an IgG Fc domain comprises the IgG CH2 and IgG CH3 constant domains.

[0063] A "modification that promotes the association of a first subunit of an Fc domain with a second subunit" is a peptide backbone manipulation or post-translational modification of an Fc domain subunit that reduces or prevents the association of a polypeptide comprising the Fc domain subunit with an identical polypeptide to form a homodimer. As used herein, a modification that promotes association specifically includes separate modifications made to each of the two Fc domain subunits (i.e., the first and second subunits of the Fc domain) that are desired to be associated, which are complementary to each other in order to promote the association of the two Fc domain subunits. For example, a modification that promotes association changes the structure or charge of one or both of these Fc domain subunits such that their association is sterically or electrostatically favorable, respectively. Thus, (hetero)dimerization occurs between a polypeptide comprising a first Fc domain subunit and a polypeptide comprising a second Fc domain subunit, which may be non-identical in the sense that the additional components (e.g., antigen-binding moieties) fused to each of the subunits are not the same. In some embodiments, a modification that promotes association includes amino acid mutations, specifically amino acid substitutions, within the Fc domain. In a particular embodiment, the association-promoting modifications comprise separate amino acid mutations, specifically amino acid substitutions, in each of the two subunits of the Fc domain.

[0064] An "activating Fc receptor" is an Fc receptor that, following engagement by the Fc region of an antibody, triggers signaling events that stimulate a receptor-bearing cell to carry out an effector function. Activating Fc receptors include FcγRIIIa (CD16a), FcγRI (CD64), FcγRIIa (CD32), and FcαRI (CD89).

[0065] The term "effector function", when used in reference to an antibody, refers to a biological activity attributable to the Fc region of an antibody, which varies with the antibody isotype. Examples of antibody effector functions include: C1q binding and complement-dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); antibody-dependent cellular phagocytosis (ADCP); cytokine secretion; immune complex-mediated antigen uptake by antigen-presenting cells; downregulation of cell surface receptors (e.g., B cell receptor); and activation of B cells.

[0066] As used herein, the term "effector cells" refers to a population of lymphocytes that express effector moiety receptors, e.g., cytokine receptors, and / or Fc receptors on their surface, thereby binding effector moieties, e.g., cytokines, and / or the Fc region of an antibody, and contributing to the destruction of target cells, e.g., tumor cells. Effector cells mediate, for example, cytotoxic or phagocytic effects. Effector cells include, but are not limited to, effector T cells, e.g., CD8 + Cytotoxic T cells, CD4 + These include helper T cells, γδ T cells, NK cells, lymphokine-activated killer (LAK) cells, and macrophages / monocytes.

[0067] As used herein, the terms "engineer", "engineered" and "engineering" are intended to include any manipulation of the peptide backbone or post-translational modification of a naturally occurring or recombinant polypeptide or fragment thereof. Engineering includes modification of the amino acid sequence, modification of the glycosylation pattern or modification of the side groups of individual amino acids, as well as combinations of these approaches. In particular, "engineering" with the prefix "glyco" and the term "glycosylation engineering" include metabolic engineering of the glycosylation machinery of a cell, including genetic engineering of the oligosaccharide synthesis pathway to achieve altered glycosylation of glycoproteins expressed in the cell. Additionally, glycosylation engineering includes the effects of mutations and the cellular environment on glycosylation. In one embodiment, glycosylation engineering is alteration of glycosyltransferase activity. In certain embodiments, engineering results in alteration of glucosaminyltransferase activity and / or fucosyltransferase activity. Glycosylation engineering can be used to obtain "host cells with increased GnTIII activity" (e.g., host cells engineered to express elevated levels of one or more polypeptides having β(1,4)-N-acetylglucosaminyltransferase III (GnTIII) activity), "host cells with increased ManII activity" (e.g., host cells engineered to express elevated levels of one or more polypeptides having α-mannosidase II (ManII) activity), or "host cells with reduced α(1,6)fucosyltransferase activity" (e.g., host cells engineered to express reduced levels of α(1,6)fucosyltransferase).

[0068] The terms "host cell", "host cell line" and "host cell culture" are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include "transformants" and "transformed cells", which include the primary transformed cell and its progeny, regardless of the number of passages. The progeny may not be completely identical in nucleic acid content to the parent cell and may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected in the originally transformed cell are included herein. A host cell is any type of cell line that can be used to produce proteins used in the present invention. In one embodiment, the host cell is engineered to allow for the production of antibodies with modified oligosaccharides. In certain embodiments, the host cell is engineered to increase the expression level of one or more polypeptides having β(1,4)-N-acetylglucosaminyltransferase III (GnTIII) activity. In certain embodiments, the host cell is further engineered to increase the expression level of one or more polypeptides having α-mannosidase II (ManII) activity. Host cells include cultured cells, e.g., cultured mammalian cells, such as CHO cells, BHK cells, NS0 cells, SP2 / 0 cells, YO myeloma cells, P3X63 mouse bone marrow cells, PER cells, PER.C6 cells or hybridoma cells, yeast cells, insect cells, and plant cells, as well as cells contained within transgenic animals, transgenic plants, or cultured plant or animal tissues.

[0069] As used herein, the term "polypeptide having GnTIII activity" refers to a polypeptide capable of catalyzing the addition of N-acetylglucosamine (GlcNAc) residues in the β-1,4 linkage to the β-linked mannoside of the trimannosyl core of an N-linked oligosaccharide. This includes fusion polypeptides that exhibit an enzymatic activity similar, but not necessarily identical, to that of β(1,4)-N-acetylglucosaminyltransferase III, also known as β-1,4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyl-transferase (EC 2.4.1.144) according to the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology (NC-IUBMB), with or without dose dependency, as measured in a specific biological assay. If there is a dose dependency, it need not be identical to that of GnTIII, but rather should be substantially similar to the dose dependency for a given activity when compared to GnTIII (i.e., the candidate polypeptide will exhibit greater activity or will exhibit at least about 25-fold less activity than GnTIII, preferably at least about 10-fold less activity, and most preferably at least about 3-fold less activity). In a particular embodiment, the polypeptide having GnTIII activity is a fusion polypeptide comprising the catalytic domain of GnTIII and the Golgi localization domain of a heterologous Golgi resident polypeptide. In particular, the Golgi localization domain is the localization domain of mannosidase II or GnTI, most particularly the localization domain of mannosidase II. Alternatively, the Golgi localization domain is selected from the group consisting of the localization domain of mannosidase I, the localization domain of GnTII, and the localization domain of α1,6 core fucosyltransferase. Methods for making such fusion polypeptides and using them to generate antibodies with enhanced effector function are disclosed in WO 2004 / 065540, U.S. Provisional Patent No. 60 / 495142, and U.S. Patent Publication No. 60 / 495142, the entire contents of which are expressly incorporated herein by reference.

[0070] As used herein, the term "Golgi localization domain" refers to an amino acid sequence of a Golgi resident polypeptide that is responsible for anchoring the polypeptide to a location within the Golgi complex. Generally, the localization domain constitutes the amino-terminal "tail" of the enzyme.

[0071] As used herein, the term "polypeptide having ManII activity" refers to a polypeptide capable of catalyzing the hydrolysis of terminal 1,3- and 1,6-linked α-D-mannose residues of the branched GlcNAcMan5GlcNAc2 mannose intermediate of N-linked oligosaccharides. This includes polypeptides that exhibit activity similar, but not necessarily identical to, that of Golgi α-mannosidase II, also known as mannosyl oligosaccharide 1,3-1,6-α-mannosidase II (EC 3.2.1.114) according to the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology (NC-IUBMB).

[0072] Antibody-dependent cell-mediated cytotoxicity (ADCC) is an immune mechanism that leads to the lysis of antibody-coated target cells by immune effector cells. Target cells are cells to which an antibody or a fragment thereof, including an Fc region, specifically binds via a protein portion that is usually N-terminal to the Fc region. The term "increased / decreased ADCC" as used herein is defined as either an increase / decrease in the number of target cells lysed in a given time by the mechanism of ADCC as defined above, at a given antibody concentration in the medium surrounding the target cells, and / or a decrease / increase in the antibody concentration in the medium surrounding the target cells required to lyse a given number of target cells in a given time by the mechanism of ADCC. The increased / decreased ADCC is relative to the ADCC mediated by the same antibody produced by the same type of host cell, but without manipulation, using the same standard production, purification, formulation, and storage methods (known to those skilled in the art). For example, the increase in ADCC mediated by an antibody produced by a host cell engineered to have an engineered glycosylation pattern (e.g., glycosyltransferase, GnTIII, or other glycosyltransferase) by the methods described herein is relative to ADCC mediated by the same antibody produced by a non-engineered host cell of the same type.

[0073] By "antibody with increased / decreased antibody-dependent cellular cytotoxicity (ADCC)" is meant an antibody with increased / decreased ADCC as determined by any suitable method known to one of skill in the art. One acceptable in vitro ADCC assay is as follows: 1) the assay uses target cells known to express the target antigen recognized by the antigen-binding region of the antibody; 2) the assay uses human peripheral blood mononuclear cells (PBMCs) isolated from the blood of randomly selected healthy donors as effector cells; 3) The assay is carried out according to the following protocol. i) PBMCs were isolated using standard density centrifugation procedures and cultured at 5×10 6 Suspend in RPMI cell culture medium at cells / ml; ii) Target cells are grown by standard tissue culture techniques, harvested from exponential growth phase with greater than 90% viability, washed with RPMI cell culture medium, and incubated with 100 microcuries of 51 Label with 10Cr, wash twice with cell culture medium, and 5 Resuspend in cell culture medium at a density of cells / ml; iii) transferring 100 microliters of the final target cell suspension above into each well of a 96-well microtiter plate; iv) serially diluting the antibody in cell culture medium from 4000 ng / ml to 0.04 ng / ml and adding 50 microliters of the resulting antibody solution to target cells in a 96-well microtiter plate, testing various antibody concentrations in triplicate covering the entire concentration range mentioned above; v) for maximum release (MR) controls, three additional wells in the plate containing labeled target cells receive 50 microliters of a 2% (v / v) aqueous solution of non-ionic detergent (Nonidet, Sigma, St. Louis) in place of the antibody solution (iv above); vi) as a spontaneous release (SR) control, three additional wells in the plate containing labeled target cells receive 50 microliters of RPMI cell culture medium instead of the antibody solution (iv above); vii) the 96-well microtiter plate is then centrifuged at 50×g for 1 minute and incubated at 4° C. for 1 hour; viii) 50 microliters of the PBMC suspension (i above) is added to each well to obtain an effector:target cell ratio of 25:1 and the plate is placed in an incubator at 37°C in a 5% CO2 atmosphere for 4 hours; ix) harvesting cell-free supernatant from each well and quantifying experimentally released radioactivity (ER) using a gamma counter; x) The percentage of specific lysis is calculated for each antibody concentration according to the formula (ER-MR) / (MR-SR) x 100, where ER is the average radioactivity quantified for that antibody concentration (see ix above), MR is the average radioactivity quantified for the MR control (see v above) (see ix above), and SR is the average radioactivity quantified for the SR control (see vi above) (see ix above); 4) "Increased / decreased ADCC" is defined as either the increase in the maximum percentage of specific lysis observed within the antibody concentration range tested above, and / or the decrease / increase in antibody concentration required to achieve half the maximum percentage of specific lysis observed within the antibody concentration range tested above. The increased / decreased ADCC measured in the above assays is relative to the ADCC mediated by the same antibody produced by the same type of host cell, but without manipulation, using the same standard production, purification, formulation, and storage methods known to those of skill in the art.

[0074] As used herein, the term "monoclonal antibody" refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical and / or bind the same epitope, except for possible variant antibodies (which may, for example, include naturally occurring mutations or arise during the production of the monoclonal antibody preparation, and such variants are usually present in small amounts). In contrast to polyclonal antibody preparations, which usually contain different antibodies against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on the antigen. Thus, the modifier "monoclonal" indicates the character of the antibody as being obtained from a population of substantially homogeneous antibodies, and should not be construed as requiring production of the antibody by any particular method. For example, monoclonal antibodies used in accordance with the present invention can be produced by a variety of techniques, including, but not limited to, hybridoma methods, recombinant DNA methods, phage display methods, and methods utilizing transgenic animals containing all or part of the human immunoglobulin loci, and such methods and other exemplary methods for producing monoclonal antibodies are described herein.

[0075] "Naked antibody" refers to an antibody that is not conjugated to a heterologous moiety (e.g., a cytotoxic moiety) or radiolabel. The naked antibody may be present in a pharmaceutical formulation.

[0076] "Native antibodies" refer to naturally occurring immunoglobulin molecules with various structures. For example, native IgG antibodies are heterotetrameric glycoproteins of about 150,000 daltons composed of two identical light chains and two identical heavy chains that are disulfide-bonded. From the N-terminus to the C-terminus, each heavy chain has a variable region (VH), also called the variable heavy domain or the heavy chain variable domain, followed by three constant domains (CH1, CH2, and CH3). Similarly, from the N-terminus to the C-terminus, each light chain has a variable region (VL), also called the variable light domain or the light chain variable domain, followed by one constant light (CL) domain. The light chain of an antibody may be assigned to one of two types, called kappa (κ) and lambda (λ), based on the amino acid sequence of its constant domain.

[0077] As used herein, the terms "first," "second," "third," etc., in reference to antigen-binding moieties or domains are used for convenience of distinguishing when more than one of each type of moiety or domain is present. The use of these terms is not intended to confer a particular order or orientation unless expressly indicated as such.

[0078] The terms "multispecific" and "bispecific" mean that an antigen-binding molecule can specifically bind to at least two distinct antigenic determinants. Typically, a bispecific antigen-binding molecule comprises two antigen-binding sites, each of which is specific for a different antigenic determinant. In certain embodiments, a bispecific antigen-binding molecule can simultaneously bind to two antigenic determinants (particularly two antigenic determinants expressed on two distinct cells).

[0079] As used herein, the term "valent" or "valency" refers to the presence of a specific number of antigen-binding sites in an antigen-binding molecule. Thus, the term "monovalent binding to an antigen" refers to the presence of one (and not more than one) antigen-binding site specific for an antigen in an antigen-binding molecule.

[0080] "Antigen-binding site" refers to the site of an antigen-binding molecule that confers interaction with an antigen, i.e., one or more amino acid residues. For example, the antigen-binding site of an antibody comprises amino acid residues of the complementarity determining regions (CDRs). A naturally occurring immunoglobulin molecule typically has two antigen-binding sites, while a Fab molecule typically has a single antigen-binding site.

[0081] As used herein, "activating T cell antigen" refers to an antigenic determinant expressed by T lymphocytes, particularly cytotoxic T lymphocytes, which can induce or enhance T cell activation upon interaction with an antigen-binding molecule. Specifically, interaction of an antigen-binding molecule with a T cell activation antigen can induce T cell activation by triggering a cascade of signal transduction in the T cell receptor complex. An exemplary activating T cell antigen is CD3. In one particular embodiment, the T cell activation antigen is CD3, particularly the epsilon subunit of CD3 (see UniProt no. P07766 (version 130), NCBI RefSeq no. NP_000724.1 for human sequence; UniProt no. Q95LI5 (version 49), NCBI GenBank no. BAB71849.1 for cynomolgus monkey [Macaca fascicularis] sequence).

[0082] As used herein, "T cell activation" refers to one or more cellular responses selected from proliferation, differentiation, cytokine secretion, release of cytotoxic effector molecules, cytotoxic activity, and expression of activation markers of T lymphocytes, particularly cytotoxic T lymphocytes. The T cell activation therapeutic agent used in the present invention can induce T cell activation. Suitable assays for measuring T cell activation are known in the art and described herein.

[0083] As used herein, "target cell antigen" refers to an antigenic determinant displayed on the surface of a target cell, e.g., a cell within a tumor, such as a cancer cell or a cell of the tumor stroma. In a particular embodiment, the target cell antigen is CD20, in particular human CD20 (see UniProt number P11836).

[0084] As used herein, "B cell antigen" refers to an antigenic determinant present on the surface of a B lymphocyte, particularly a malignant B lymphocyte (in which case the antigen is also referred to as a "malignant B cell antigen").

[0085] As used herein, "T cell antigen" refers to an antigenic determinant presented on the surface of T lymphocytes, particularly cytotoxic T lymphocytes.

[0086] A "Fab molecule" refers to a protein consisting of the VH and CH1 domains of an immunoglobulin heavy chain (a "Fab heavy chain") and the VL and CL domains of a light chain (a "Fab light chain").

[0087] By "fused" it is meant that the components (eg, a Fab molecule and an Fc domain subunit) are linked together by a peptide bond, either directly or via one or more peptide linkers.

[0088] An "effective amount" of an agent refers to the amount necessary to induce a physiological change in a cell or tissue to which the agent is administered.

[0089] A "therapeutically effective amount" of an agent, e.g., a pharmaceutical composition, refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired therapeutic or prophylactic result. A therapeutically effective amount of an agent, for example, eliminates, reduces, delays, minimizes, or prevents the side effects of a disease.

[0090] "Therapeutic agent" refers to an active ingredient, e.g., of a pharmaceutical composition, that is administered to a subject with the intent of altering the natural history of a disease in the subject being treated, which may be performed prophylactically or during the course of clinical pathology. "Immunotherapeutic agent" refers to a therapeutic agent that is administered to a subject with the intent of restoring or enhancing the subject's immune response, e.g., against a tumor.

[0091] The term "pharmaceutical composition" refers to a formulation in a form that effectively utilizes the biological activity of the active ingredients contained therein and does not contain additional components that are unacceptably toxic to the subject to which the composition is administered.

[0092] "Pharmaceutically acceptable carrier" refers to an ingredient in a pharmaceutical composition, other than an active ingredient, that is non-toxic to a subject. Pharmaceutically acceptable carriers include, but are not limited to, buffers, additives, stabilizers, or preservatives.

[0093] The term "package insert" or "instructions for use" is used to refer to instructions customarily included in the commercial packaging of a therapeutic product, which contain information about the indications, usage, dosage, administration, concomitant therapy, contraindications and / or precautions concerning the use of that therapeutic product.

[0094] The term "combination therapy" as referred to herein encompasses combined administration (where two or more therapeutic agents are contained in the same or separate formulations) and separate administration, where administration of an antibody as reported herein may occur prior to, concurrently with and / or following administration of one or more additional therapeutic agents, preferably one or more antibodies.

[0095] By "crossover" Fab molecule (also called "Crossfab") is meant a Fab molecule in which the variable or constant domains of the Fab heavy and light chains are exchanged (i.e. replaced by each other), i.e. the crossover Fab molecule comprises a peptide chain composed of the light chain variable domain VL and the heavy chain constant domain 1 CH1 (VL-CH1, in the N-terminal to C-terminal direction) and a peptide chain composed of the heavy chain variable domain VH and the light chain constant domain CL (VH-CL, in the N-terminal to C-terminal direction). Briefly, in a crossover Fab molecule in which the variable domains of the Fab light chain and the Fab heavy chain are exchanged, the peptide chain comprising the heavy chain constant domain 1 CH1 is referred to herein as the "heavy chain" of the (crossover) Fab molecule. Conversely, in a crossover Fab molecule in which the constant domains of the Fab light chain and the Fab heavy chain are exchanged, the peptide chain comprising the heavy chain variable domain VH is referred to herein as the "heavy chain" of the (crossover) Fab molecule.

[0096] In contrast, a "conventional" Fab molecule refers to a Fab molecule in its native format, i.e., a Fab molecule comprising a heavy chain consisting of the heavy chain variable and constant domains (from N-terminus to C-terminus, VH-CH1) and a light chain consisting of the light chain variable and constant domains (from N-terminus to C-terminus, VL-CL).

[0097] The term "polynucleotide" refers to an isolated nucleic acid molecule or construct, such as messenger RNA (mRNA), viral-derived RNA, or plasmid DNA (pDNA). A polynucleotide may contain conventional phosphodiester bonds or unconventional bonds (e.g., amide bonds as found in peptide nucleic acids (PNA)). The term "nucleic acid molecule" refers to any one or more nucleic acid segments, e.g., DNA or RNA fragments, present in a polynucleotide.

[0098] By "isolated" nucleic acid molecule or polynucleotide is intended a nucleic acid molecule, DNA or RNA, that has been removed from its natural environment. For example, a recombinant polynucleotide encoding a polypeptide contained in a vector is considered isolated for the purposes of the present invention. Further examples of isolated polynucleotides include recombinant polynucleotides maintained in heterologous host cells or purified (partially or substantially) polynucleotides in solution. Isolated polynucleotides include polynucleotide molecules contained in cells that normally contain the polynucleotide molecule, but the polynucleotide molecule is present extrachromosomally or at a chromosomal location that is different from its native chromosomal location. Isolated RNA molecules include in vivo or in vitro RNA transcripts of the invention, and positive and negative stranded forms, double stranded forms. Isolated polynucleotides or nucleic acids of the present invention further include such molecules produced synthetically. Polynucleotides or nucleic acids may or may not also contain regulatory elements such as promoters, ribosome binding sites or transcription terminators.

[0099] A nucleic acid or polynucleotide having a nucleotide sequence that is, for example, at least 95% "identical" to a reference nucleotide sequence of the present invention means that the nucleotide sequence of the polynucleotide is identical to the reference sequence, except that the nucleotide sequence of the polynucleotide may contain up to 5 point mutations per 100 nucleotides of the reference nucleotide sequence. In other words, to obtain a polynucleotide having a nucleotide sequence that is at least 95% identical to the reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or replaced with another nucleotide, or up to 5% of the number of nucleotides in the reference sequence may be inserted into the reference sequence. Such modifications of the reference sequence may occur at the 5' or 3' terminal position of the reference nucleotide sequence, or at any position between these terminal positions, either individually interspersed among residues in the reference sequence or interspersed in one or more contiguous groups within the reference sequence. As a practical matter, whether any particular polynucleotide sequence is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the invention can be determined using computer programs such as those described above for polypeptides (e.g., ALIGN-2).

[0100] The term "expression cassette" refers to a recombinantly or synthetically produced polynucleotide with a set of specific nucleic acid elements that allow transcription of a specific nucleic acid in a target cell. A recombinant expression cassette can be incorporated into a plasmid, chromosome, mitochondrial DNA, plastid DNA, virus, or nucleic acid fragment. Typically, the recombinant expression cassette portion of an expression vector includes, among other sequences, a nucleic acid sequence to be transcribed and a promoter. In a particular embodiment, an expression cassette of the invention comprises a polynucleotide sequence encoding a bispecific antigen-binding molecule of the invention, or a fragment thereof.

[0101] The term "vector" or "expression vector" is synonymous with "expression construct" and refers to a DNA molecule that is used to introduce and direct the expression of a particular gene to which it is operably linked in a target cell. This term includes vectors as self-replicating nucleic acid structures and vectors integrated into the genome of a host cell into which it is introduced. The expression vector of the present invention comprises an expression cassette. The expression vector allows transcription of large amounts of stable mRNA. Once the expression vector is inside the target cell, the ribonucleic acid molecule or protein encoded by the gene is produced by the cellular transcription and / or translation machinery. In one embodiment, the expression vector of the present invention comprises an expression cassette comprising a polynucleotide sequence encoding a bispecific antigen binding molecule or fragment thereof of the present invention.

[0102] As used herein, the term "about" refers to the normal error range for the respective value, which is readily understood by one of ordinary skill in the art. Reference herein to "about" a value or parameter includes (describes) an embodiment for that value or parameter itself.

[0103] "B cell proliferative disorder" refers to a disease in which the number of B cells in a patient is increased compared to the number of B cells in a healthy individual, particularly a disease in which an increased number of B cells is the cause or evidence of the disease. "CD20-positive B cell proliferative disorder" is a B cell proliferative disorder in which B cells, particularly malignant B cells (in addition to normal B cells), express CD20.

[0104] Exemplary B cell proliferative disorders include non-Hodgkin's lymphoma (NHL), diffuse large B cell lymphoma (DLBCL; e.g., relapsed or refractory DLBCL not otherwise specified (NOS)), high-grade B cell lymphoma (HGBCL; e.g., HGBCL NOS, double matched HGBCL and triple matched HGBCL), primary mediastinal large B cell lymphoma (PMBCL), and DLBCL arising from FL transformed FL; trFL); follicular lymphoma (FL) (including Grade 1-3b FL); mantle cell lymphoma (MCL); and marginal zone lymphoma (MZL) (including splenic, nodal or extranodal MZL). In one embodiment, the CD20-positive B cell proliferative disorder is relapsed or refractory NHL (e.g., relapsed or refractory DLBCL, relapsed or refractory FL, or relapsed or refractory MCL).

[0105] "Refractory disease" is defined as no complete response to first-line therapy. In one embodiment, refractory disease is defined as no response to prior therapy or relapse within 6 months of prior therapy. In one embodiment, refractory disease is characterized by one or more of the following: progressive disease (PD) as best response to first-line therapy, stable disease (SD) as best response after at least 4 cycles of first-line therapy (e.g., 4 cycles of rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate (Oncovin), and prednisone (also abbreviated R-CHOP)), or partial response (PR) as best response after at least 6 cycles, and biopsy-proven residual disease or disease progression after partial response. "Recurrent disease" is defined as complete response to first-line therapy. In one embodiment, disease recurrence is biopsy-proven. In one embodiment, the patient has relapsed after or failed to respond to at least two prior systemic treatment regimens, including at least one prior regimen comprising an anthracycline and at least one prior regimen comprising an anti-CD20 directed therapy.

[0106] An "individual" or "subject" is a mammal. Mammals include, but are not limited to, domestic animals (e.g., cows, sheep, cats, dogs, horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). Preferably, the individual or subject is a human. In one example, each subject in the subject population is a human. In one example, each subject in the reference subject population is a human.

[0107] As used herein, "treatment" (and grammatical variations such as "treat" or "treating") refers to a clinical intervention that attempts to alter the natural course of a disease in the individual being treated, and may be performed for prophylaxis or during the course of clinical pathology. Desirable effects of treatment include, but are not limited to, preventing the onset or recurrence of a disease, alleviating symptoms, reducing the direct or indirect pathological consequences of a disease, preventing metastasis, slowing the rate of disease progression, improving or mitigating the disease state, and remission or improving prognosis. In some embodiments, the methods of the invention are used to delay the onset of a disease or to slow the progression of a disease.

[0108] As used herein, "delaying progression" of a disorder or disease means postponing, preventing, slowing, retarding, stabilizing, and / or delaying the onset of a disease or disorder (e.g., CD20-positive B-cell proliferative disorder, e.g., NHL, e.g., DLBCL). Such a delay may be of various durations, depending on the disease being treated and / or the medical history of the individual. As will be apparent to one of skill in the art, a sufficient or significant delay can, in effect, encompass prevention, in that the individual does not develop the disease. For example, in late-stage cancer, the onset of central nervous system (CNS) metastases may be delayed.

[0109] By "reduce" or "inhibit" is meant the ability to cause an overall reduction, for example, of 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or more. For clarity, the term also includes reduction to zero (or below the detection limit of the analytical method), i.e., complete disappearance or elimination. In certain embodiments, reduction or inhibition may refer to a reduction or inhibition of undesirable events, such as cytokine-driven toxicity (e.g., cytokine release syndrome (CRS)), infusion-related reactions (IRR), macrophage activation syndrome (MAS), neurotoxicity, severe tumor lysis syndrome (TLS), neutropenia, thrombocytopenia, elevated liver enzymes, and / or central nervous system (CNS) toxicity, following treatment with an anti-CD20 / anti-CD3 bispecific antibody using a step-up dosing regimen of the invention, as compared to a preset administration of an unaltered target dose of the bispecific antibody. In other embodiments, reducing or inhibiting may refer to antibody effector functions mediated by the antibody Fc region, including complement dependent cytotoxicity (CDC), antibody dependent cellular cytotoxicity (ADCC), and antibody dependent cellular phagocytosis (ADCP). In other embodiments, reducing or inhibiting may refer to symptoms of the CD20-positive B-cell proliferative disorder being treated (e.g., NHL (e.g., DLBCL), FL (e.g., relapsed and / or refractory FL, or transformed FL), MCL, high-grade B-cell lymphoma, or PMLBCL), the presence or size of metastases, or the size of the primary tumor.

[0110] As used herein, "administration" refers to a method of giving a dose of an anti-CD20 / anti-CD3 bispecific antibody pharmaceutical composition to a subject. The pharmaceutical compositions described herein can be administered intravenously (e.g., intravenous infusion).

[0111] As used herein, "buffer" refers to a buffered solution (also referred to herein as a "buffering agent") that resists changes in pH by the action of its acid-base conjugate components. In some embodiments, the buffers of the present invention have a pH ranging from about 5 to about 6. Exemplary buffering agents for use in the present invention include, but are not limited to, histidine (e.g., histidine HCl), acetate, phosphate, succinate, or combinations thereof. In some embodiments, the histidine is histidine hydrochloride (histidine HCl), histidine acetate, sodium phosphate monobasic, sodium phosphate dibasic, sodium phosphate tribasic, potassium phosphate monobasic, potassium phosphate dibasic, potassium phosphate tribasic, or mixtures thereof.

[0112] The pharmaceutical composition according to the invention may also comprise one or more isotonicity agents. The term "isotonicity agent" refers to a pharma- ceutically acceptable additive used to adjust the tonicity of the formulation. The formulation may be hypotonic, isotonic or hypertonic. Generally, isotonicity relates to the osmolality of a solution, usually relative to the osmolality of human serum (approximately 250-350 mOsmol / kg). The formulations of the invention may be hypotonic, isotonic or hypertonic, but are preferably isotonic. A hypertonic formulation is a liquid or a liquid reconstituted from a solid form (e.g., a lyophilized form), and exhibits a solution that has the same tonicity as some other solution to which it is compared, e.g., physiological salt solution and serum. Suitable isotonicity agents include, but are not limited to, salts such as sodium or potassium chloride, glycerin and any component derived from amino acids or sugars, especially glucose. The isotonicity agent is generally used in an amount of ≧200 mM.

[0113] Among the stabilizers and tonicity agents there are groups of compounds that can function both ways, i.e. can be stabilizers and tonicity agents at the same time. Examples can be found in the groups of sugars, amino acids, polyols, cyclodextrins, polyethylene glycols and salts. An example of a sugar that can be both a stabilizer and tonicity agent at the same time is trehalose.

[0114] As used herein, "surfactant" refers to a surface active agent, preferably a non-ionic surfactant.Examples of surfactants herein include polysorbates (e.g., polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 65, polysorbate 80, polysorbate 85); poloxamers (e.g., poloxamer 188); TRITON®; sodium octyl glucoside; lauryl sulfobetaine, myristyl sulfobetaine, linoleyl sulfobetaine, or stearyl sulfobetaine; lauryl sarcosine, myristyl sarcosine, linoleyl sarcosine, or stearyl sarcosine; Linoleyl betaine, myristyl betaine, or cetyl betaine; lauroamidopropyl betaine, cocamidopropyl betaine, linoleamidopropyl betaine, myristamidopropyl betaine, palmidopropyl betaine, or isostearamidopropyl betaine (e.g., lauroamidopropyl); myristamidopropyl dimethylamine, palmidopropyl dimethylamine, or isostearamidopropyl dimethylamine; sodium methyl cocoyl taurate, or disodium methyl oleyl taurate; and MONAQUAT TM series (Mona Industries, Inc., Paterson, NJ); polyethyl glycol, polypropylene glycol, and copolymers of ethylene and propylene glycol (e.g., PLURONIC® type block copolymers, e.g., PLURONIC® F-68); and the like. In one embodiment, the surfactant herein is polysorbate 20 (PS20). In yet another embodiment, the surfactant herein is poloxamer 188 (P188).

[0115] A "preservative" is a compound that can be optionally included in the formulation to substantially reduce bacterial activity in the formulation, thus facilitating, for example, the production of a multi-use formulation. Examples of possible preservatives include octadecyldimethylbenzyl ammonium chloride, hexamethonium chloride, benzalkonium chloride (a mixture of alkylbenzyldimethylammonium chlorides in which the alkyl group is a long-chain compound) and benzethonium chloride. Other types of preservatives include aromatic alcohols such as phenol, butyl, and benzyl alcohol, alkyl parabens such as methyl or propyl paraben, catechol, resorcinol, cyclohexanol; 3-pentanol, and m-cresol. In one embodiment, the preservative herein is benzyl alcohol. In some embodiments, the formulation does not contain a preservative.

[0116] A "stable" pharmaceutical composition is a pharmaceutical formulation in which the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, e.g., glofitamab) essentially retains its physical and / or chemical stability and / or biological activity upon storage. Preferably, the formulation essentially retains its physical and chemical stability, as well as its biological activity upon storage (e.g., frozen storage). The storage period is generally selected based on the intended shelf life of the formulation. Various analytical techniques for measuring protein stability are available in the art and are reviewed, for example, in Peptide and Protein Drug Delivery, 247-301, Vincent Lee Ed., Marcel Dekker, Inc., New York, NY, Pubs. (1991) and Jones, A. Adv. Drug Delivery Rev. 10: 29-90 (1993). Stability is measured at a selected amount of light exposure and / or temperature for a selected period of time. Stability can be assessed by assessment of aggregate formation (e.g., using size exclusion chromatography, by measuring turbidity, and / or by visual inspection); assessment of ROS formation (e.g., by using a light stress assay or a 2,2'-azobis(2-amidinopropane) dihydrochloride (AAPH) stress assay); oxidation of specific amino acid residues of the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 The anti-CD20 / anti-CD3 bispecific antibody may be qualitatively and / or quantitatively evaluated in a variety of different ways, including by: (i) measuring the Met residue of TCB, e.g., glofitamab); by assessing charge heterogeneity using cation exchange chromatography, imaging capillary isoelectric focusing chromatography, or capillary zone electrophoresis; by amino- or carboxy-terminal sequence analysis; by mass spectrometry; by SDS-PAGE analysis to compare reduced and intact anti-CD20 / anti-CD3 bispecific antibodies; by peptide map (e.g., trypsin or LYS-C) analysis; by assessing the biological activity or target binding function (e.g., binding to T cells and / or B cells) of the anti-CD20 / anti-CD3 bispecific antibody, and the like.The instability may involve any one or more of aggregation, deamidation (e.g., Asn deamidation), oxidation (e.g., Met oxidation and / or Trp oxidation), isomerization (e.g., Asp isomerization), clipping / hydrolysis / fragmentation (e.g., hinge region fragmentation), succinimide formation, unpaired cysteines, N-terminal extensions, C-terminal processing, and differential glycosylation, and the like.

[0117] The term "liquid" as used herein in relation to a formulation according to the present invention means a formulation that is liquid at a temperature of at least about 2 to about 8°C under atmospheric pressure.

[0118] In this application, unless otherwise specified, the techniques utilized can be found in any of several well-known references such as Molecular Cloning: A Laboratory Manual (Sambrook, et al., 1989, Cold Spring Harbor Laboratory Press), PCR Protocols: A Guide to Methods and Applications (Innis, et al. 1990. Academic Press, San Diego, CA), and Harlow and Lane (1988) Antibodies: A Laboratory Manual ch.14 (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY).

[0119] Procedures involving the use of commercially available kits and reagents, where appropriate, are generally performed according to manufacturer-defined protocols and / or parameters unless otherwise specified. Thus, before describing the present methods and uses, it should be understood that the present invention is not limited to the specific methodology, protocols, cell lines, animal species or genera, constructs, and reagents so described, which may, of course, vary. It should also be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention, which is limited only by the appended claims.

[0120] III. Pharmaceutical Compositions The present invention provides pharmaceutical compositions comprising low concentrations of anti-CD20 / anti-CD3 bispecific antibodies (e.g., anti-CD20 / anti-CD3 TCBs, e.g., glofitamab), for example, for the treatment of B-cell proliferative disorders (e.g., non-Hodgkin's lymphoma, NHL), and uses thereof. The pharmaceutical compositions of the present invention can be formulated to carry low concentrations of anti-CD20 / anti-CD3 bispecific antibodies (e.g., anti-CD20 / anti-CD3 TCBs, e.g., glofitamab), and are stable against protein loss due to adsorption during storage and clinical administration. Adsorption can be a significant issue with low concentrations of antibodies that require further dilution and handling before clinical administration, resulting in low titers. Glofitamab is administered in doses of 2.5 mg and 10 mg (stepwise dosing) and a maintenance dose of 30 mg (target dose, flat dose). Glofitamab is intended for IV administration by IV bag infusion after dilution with 0.9% or 0.45% sodium chloride. Dosage is made possible in an IV bag with dosing solution concentrations of 0.05 mg / ml to 0.6 mg / ml.

[0121] In one embodiment, a liquid pharmaceutical composition is provided comprising: At a pH in the range of about 5.0 to about 6.0, about 1 to 25 mg / ml of an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab); about 10 to 50 mM buffer; about ≧200 mM tonicity agent; about 0-15 mM methionine; and About ≧0.2 mg / ml of surfactant.

[0122] In one embodiment, a liquid pharmaceutical composition is provided comprising: At a pH in the range of about 5.0 to about 6.0, about 5 mg / ml of an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab); about 10 to 50 mM buffer; about ≧200 mM tonicity agent; about 0-15 mM methionine; and About ≧0.2 mg / ml of surfactant.

[0123] In one embodiment, a liquid pharmaceutical composition is provided comprising: At a pH in the range of about 5.0 to about 6.0, about 0.9 to 1.1 mg / ml of an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab); about 10 to 50 mM buffer; about ≧200 mM tonicity agent; about 0-15 mM methionine; and About ≧0.2 mg / ml of surfactant.

[0124] In one embodiment, a liquid pharmaceutical composition is provided comprising: At a pH in the range of about 5.0 to about 6.0, about 1 mg / ml of an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab); about 10 to 50 mM buffer; about ≧200 mM tonicity agent; about 0-15 mM methionine; and About ≧0.2 mg / ml of surfactant.

[0125] In one embodiment, the concentration of the anti-CD20 / anti-CD3 bispecific antibody ranges from about 1 to 5 mg / ml. In one embodiment, the concentration of the anti-CD20 / anti-CD3 bispecific antibody is about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1 mg / ml, about 1.1 mg / ml, about 1.5 mg / ml, about 2 mg / ml, about 3 mg / ml, about 4 mg / ml, or about 5 mg / ml. In one embodiment, the concentration of the anti-CD20 / anti-CD3 bispecific antibody is about 6 mg / ml, about 7 mg / ml, about 8 mg / ml, about 9 mg / ml, about 10 mg / ml, about 11 mg / ml, about 12 mg / ml, about 13 mg / ml, about 14 mg / ml, about 15 mg / ml, about 16 mg / ml, about 17 mg / ml, about 18 mg / ml, about 19 mg / ml, about 20 mg / ml, about 21 mg / ml, about 22 mg / ml, about 23 mg / ml, about 24 mg / ml, about 25 mg / ml, about 26 mg / ml, about 27 mg / ml, about 28 mg / ml, about 29 mg / ml, or about 30 mg / ml.

[0126] In one embodiment, the concentration of the anti-CD20 / anti-CD3 bispecific antibody ranges from about 0.9-1.1 mg / ml. In one embodiment, the concentration of the anti-CD20 / anti-CD3 bispecific antibody is about 1 mg / ml.

[0127] In one embodiment, the liquid pharmaceutical composition comprises an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab) comprising at least one antigen binding domain that specifically binds to CD20, (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:1; (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:2; and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 3 and a heavy chain variable region comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5; and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:6 and a light chain variable region comprising The present invention relates to an anti-CD20 / anti-CD3 bispecific antibody comprising:

[0128] In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, e.g., glofitamab) of the liquid pharmaceutical composition comprises at least one antigen binding domain that specifically binds to CD20, the at least one antigen binding domain comprising a heavy chain variable region sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 7 and a light chain variable region sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 8. In a further embodiment, the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, e.g., glofitamab) comprises at least one antigen binding domain that specifically binds to CD20, the at least one antigen binding domain comprising a heavy chain variable region sequence of SEQ ID NO: 7 and a light chain variable region sequence of SEQ ID NO: 8.

[0129] In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab) of the liquid pharmaceutical composition comprises at least one antigen binding domain that specifically binds to CD3, (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:9; (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 10; and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 11 and a heavy chain variable region comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 13; and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 14 and a light chain variable region comprising The antibody comprises at least one antigen-binding domain that specifically binds to CD3, the antigen-binding domain comprising:

[0130] In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, e.g., glofitamab) of the liquid pharmaceutical composition comprises at least one antigen binding domain that specifically binds to CD3, the antigen binding domain comprising a heavy chain variable region sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 15 and a light chain variable region sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 16. In a further embodiment, the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, e.g., glofitamab) comprises at least one antigen binding domain that specifically binds to CD3, the heavy chain variable region sequence being at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 16.

[0131] In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab) of the liquid pharmaceutical composition is a) at least one antigen-binding domain that specifically binds to CD20, (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:1; (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:2; and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 3 and a heavy chain variable region comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5; and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:6 and a light chain variable region comprising At least one antigen-binding domain that specifically binds to CD20 comprising: b) at least one antigen-binding domain that specifically binds to CD3, (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:9; (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 10; and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 11 and a heavy chain variable region comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 13; and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 14 and a light chain variable region comprising and at least one antigen-binding domain that specifically binds to CD3 comprising: Includes.

[0132] In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab) of the liquid pharmaceutical composition is (i) at least one antigen-binding domain that specifically binds to CD20, comprising a heavy chain variable region sequence of SEQ ID NO: 7 and a light chain variable region sequence of SEQ ID NO: 8; (ii) at least one antigen-binding domain that specifically binds to CD3, comprising a heavy chain variable region sequence of SEQ ID NO: 15 and a light chain variable region sequence of SEQ ID NO: 16; Includes.

[0133] In one embodiment, the antigen-binding domain that specifically binds to CD3 of an anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, e.g., glofitamab) is an antibody fragment, in particular a Fab molecule or an scFv molecule, more particularly a Fab molecule. In a particular embodiment, the antigen-binding domain that specifically binds to CD3 of an anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, e.g., glofitamab) is a crossover Fab molecule in which the variable or constant domains of the Fab heavy and light chains are exchanged (i.e., replaced by each other).

[0134] In one embodiment, the antigen-binding domain that specifically binds to CD20 of an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab) is an antibody fragment, in particular a Fab molecule or an scFv molecule, more particularly a Fab molecule. In a particular embodiment, the antigen-binding domain that specifically binds to CD20 of an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab) is a conventional Fab molecule.

[0135] In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, e.g., glofitamab) of the liquid pharmaceutical composition comprises at least one antigen binding domain that specifically binds to CD20 and at least one antigen binding domain that specifically binds to CD3. In one embodiment, the anti-CD20 / anti-CD3 antibody of the liquid pharmaceutical composition comprises a first antigen binding domain that specifically binds to CD3 and a second and a third antigen binding domain that specifically bind to CD20. In one embodiment, the first antigen binding domain is a crossover Fab molecule and each of the second and third antigen binding domains is a conventional Fab molecule. In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, e.g., glofitamab) further comprises an Fc domain. The anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, e.g., glofitamab) of the liquid pharmaceutical composition may comprise modifications in the Fc region and / or antigen binding domain as described herein. In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, e.g., glofitamab) of the liquid pharmaceutical composition comprises an IgG1 Fc domain comprising one or more amino acid substitutions that reduce binding to Fc receptors and / or effector function. In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, e.g., glofitamab) of the liquid pharmaceutical composition comprises an IgG1 Fc domain comprising the amino acid substitutions L234A, L235A, and P329G (EU numbering).

[0136] In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab) of the liquid pharmaceutical composition is (i) an antigen-binding domain that specifically binds CD3 fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain; (ii) a first antigen-binding domain that specifically binds CD20 fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of an antigen-binding domain that specifically binds CD3; (iii) a second antigen-binding domain that specifically binds CD20 fused at the C-terminus of the Fab heavy chain to the N-terminus of a second subunit of the Fc domain; Includes.

[0137] In certain embodiments, the anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab) of the liquid pharmaceutical composition is a) a first Fab molecule that specifically binds to CD3, in particular CD3 epsilon, in which the variable domains VL and VH of the Fab light and heavy chains are exchanged with each other; (b) a second and a third Fab molecule which specifically bind to CD20, in which in the constant domain CL of the second and third Fab molecules the amino acid at position 124 is substituted by lysine (K) (Kabat numbering) and the amino acid at position 123 is substituted by lysine (K) or arginine (R), in particular by arginine (R) (Kabat numbering), and in the constant domain CH1 of the second and third Fab molecules the amino acid at position 147 is substituted by glutamic acid (E) (EU numbering) and the amino acid at position 213 is substituted by glutamic acid (E) (EU numbering); c) an Fc domain composed of a first subunit and a second subunit capable of stable association; Includes.

[0138] In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab) of the liquid pharmaceutical composition comprises two antigen binding domains that specifically bind to CD20 and one antigen binding domain that specifically binds to CD3.

[0139] In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody (eg, anti-CD20 / anti-CD3 TCB, eg, glofitamab) of the liquid pharmaceutical composition is bivalent for CD20 and monovalent for CD3.

[0140] In one embodiment, the first Fab molecule of a) is fused at the C-terminus of its Fab heavy chain to the N-terminus of one of the subunits of the Fc domain of c), the second Fab molecule of b) is fused at the C-terminus of its Fab heavy chain to the N-terminus of the heavy chain of the first Fab molecule of a) and the third Fab molecule of b) is fused at the C-terminus of its Fab heavy chain to the N-terminus of the other subunit of the Fc domain of c). In one embodiment, the first Fab molecule of a) comprises a heavy chain variable region that is at least 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 15 and a light chain variable region that is at least 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 16.

[0141] In a still further embodiment, the first Fab molecule of a) comprises the heavy chain variable region sequence of SEQ ID NO:15 and the light chain variable region sequence of SEQ ID NO:16.

[0142] In one embodiment, the second and third Fab molecules of b) each comprise a heavy chain variable region that is at least 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO:7 and a light chain variable region that is at least 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO:8.

[0143] In one embodiment, the second and third Fab molecules of b) comprise the heavy chain variable region sequence of SEQ ID NO:7 and the light chain variable region sequence of SEQ ID NO:8, respectively.

[0144] In certain embodiments, an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab) comprises a polypeptide that is at least 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 17, a polypeptide that is at least 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 18, a polypeptide that is at least 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 19, and a polypeptide that is at least 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 20. In further particular embodiments, the bispecific antibody comprises the polypeptide sequence of SEQ ID NO: 17, the polypeptide sequence of SEQ ID NO: 18, the polypeptide sequence of SEQ ID NO: 19, and the polypeptide sequence of SEQ ID NO: 20. In a more specific embodiment, the bispecific antibody comprises one polypeptide chain comprising the amino acid sequence of SEQ ID NO: 17, one polypeptide chain comprising the amino acid sequence of SEQ ID NO: 18, one polypeptide chain comprising the amino acid sequence of SEQ ID NO: 19, and two polypeptide chains each comprising the amino acid sequence of SEQ ID NO: 20.

[0145] Certain anti-CD20 / anti-CD3 bispecific antibodies are described in PCT Publication No. WO 2016 / 020309 and European Patent Application Nos. EP15188093 and EP16169160, each of which is incorporated by reference in its entirety.

[0146] In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody (eg, an anti-CD20 / anti-CD3 TCB, such as glofitamab) of the liquid pharmaceutical composition specifically binds to CDε.

[0147] In one embodiment, the anti-CD20 / anti-CD3CD3 antibody of the liquid pharmaceutical composition is selected from the group consisting of antibody H2C (WO 2008 / 119567), antibody V9 (Rodrigues et al., Int J Cancer Suppl 7, 45-50 (1992) and U.S. Pat. No. 6,054,297), antibody FN18 (Nooij et al., Eur J Immunol 19, 981-984 (1986)), antibody SP34 (Pessano et al., EMBO J 4, 337-340 (1985)), antibody OKT3 (Kung et al., Science 206, 347-349 (1979)), antibody WT31 (Spits et al., J Immunol.135, 1922 (1985)), antibody UCHT1 (Burns et al., J Immunol. Immunol. 129, 1451-1457 (1982)), antibody 7D6 (Coulie et al., Eur J Immunol. 21-1709 (1991)), or antibody Leu-4. In some embodiments, the anti-CD20 / anti-CD3 bispecific antibody of the liquid pharmaceutical composition may compete for binding with the antibodies described in WO 2005 / 040220, WO 2005 / 118635, WO 2007 / 042261, WO 2008 / 119567, WO 2008 / 119565, WO 2012 / 162067, WO 2013 / 158856, WO 2013 / 188693, WO 2013 / 186613, WO 2014 / 110 601, 2014 / 145806, 2014 / 191113, 2014 / 047231, 2015 / 095392, 2015 / 181098, 2015 / 001085, 2015 / 104346, 2015 / 172800, 2016 / 020444, or 2016 / 014974.

[0148] In some embodiments, the anti-CD20 / anti-CD3 bispecific antibody of the liquid pharmaceutical composition may comprise an antibody or antigen-binding portion from rituximab, obinutuzumab, ocrelizumab, ofatumumab, ocaratuzumab, veltuzumab, and brituximab.

[0149] In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody is glofitamab.

[0150] In some embodiments, the anti-CD20 / anti-CD3 bispecific antibodies may consist of generic, biosimilar, or non-comparable biological versions of the antibodies named herein.

[0151] In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody of the liquid pharmaceutical composition provided herein is glofitamab. Glofitamab (WHO National Drug Information (International Non-Proprietary Names of Medicines), Recommended INN: List 83, 2020, Vol. 34, No. 1, p. 39, also known as: CD20-TCB, RO7082859, or RG6026; CAS number: 2229047-91-8) is a novel T-cell-engaging bispecific (TCB) full-length antibody with a 2:1 molecular configuration that bivalently binds to CD20 on B cells and monovalently binds to CD3, particularly the CD3 epsilon chain (CD3e), on T cells. Its CD3 binding region is fused head-to-tail to one of the CD20 binding regions via a flexible linker. This structure gives glofitamab superior in vitro potency to other CD20-CD3 bispecific antibodies in a 1:1 configuration and produces significant antitumor effects in preclinical DLBCL models. The bivalency of CD20 preserves this potency in the presence of competing anti-CD20 antibodies, providing the opportunity for pretreatment or cotreatment with these agents. Glofitamab contains an engineered heterodimeric Fc region that completely abolishes binding to FcgR and C1q. By simultaneously binding to CD3e of the T cell receptor (TCR) complex on T cells and to human CD20-expressing tumor cells, it induces tumor cell lysis in addition to T cell activation, proliferation, and cytokine release. Glofitamab-induced lysis of B cells is CD20-specific and does not occur in the absence of CD20 expression or simultaneous binding (crosslinking) of T cells to CD20-expressing cells. In addition to killing, T cells undergo activation upon CD3 crosslinking, detected by an increase in T cell activation markers (CD25 and CD69), cytokine release (IFNγ, TNFα, IL-2, IL-6, IL-10), cytotoxic granule release (granzyme B), and T cell proliferation. A schematic of the molecular structure of glofitamab is shown in Figure 2. The sequence of glofitamab is summarized in Table 2. TIFF2024138235000002.tif85170

[0152] In some embodiments, the buffer is histidine, acetate, phosphate, succinate, citrate, or a combination thereof. In some embodiments, the histidine is histidine acetate. Alternative buffers include histidine hydrochloride (histidine HCl), histidine acetate, sodium phosphate monobasic, sodium phosphate dibasic, sodium phosphate tribasic, potassium phosphate monobasic, potassium phosphate dibasic, potassium phosphate tribasic, or mixtures thereof. In certain embodiments, the liquid pharmaceutical composition comprises a histidine buffer, i.e., a buffer having histidine, typically L-histidine, as a buffering agent. In certain embodiments, the buffer comprises L-histidine, i.e., a buffer comprising L-histidine, or a mixture of L-histidine and L-histidine HCl, and pH adjustment is achieved using hydrochloric acid. L-histidine HCl buffer can be prepared by dissolving the appropriate amounts of L-histidine and L-histidine hydrochloride in water, or by dissolving the appropriate amount of L-histidine in water and adjusting the pH to the desired value by the addition of hydrochloric acid.

[0153] In certain embodiments, the buffering agent (e.g., histidine, e.g., L-histidine HCl) is at a concentration of 10 mM to 50 mM. For example, the buffering agent can be at a concentration of 10 mM to 15 mM, or 15 mM to 20 mM, e.g., 6 mM to 18 mM, 7 mM to 16 mM, 8 mM to 15 mM, or 9 mM to 12 mM, e.g., about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, about 15 mM, about 16 mM, about 17 mM, about 18 mM, about 19 mM, or about 20 mM. In particular, the buffering agent (e.g., histidine, e.g., L-histidine HCl) is at a concentration of about 15 to 25 mM. In one embodiment, the buffering agent (eg, histidine, eg, L-histidine HCl) is at a concentration of about 20 mM.

[0154] Regardless of the buffer used, the pH can be adjusted with acids or bases known in the art, such as hydrochloric acid, acetic acid, phosphoric acid, sulfuric acid, and citric acid, sodium hydroxide, and potassium hydroxide, to a pH value ranging from about 5.0 to about 6.0, preferably from about 5.2 to about 5.8.

[0155] The inventors of the present invention have provided an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab), comprising: a) at least one antigen-binding domain that specifically binds to CD20, (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:1; (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:2; and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 3 and a heavy chain variable region comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5; and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:6 and a light chain variable region comprising At least one antigen-binding domain that specifically binds to CD20 comprising: b) at least one antigen-binding domain that specifically binds to CD3, (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:9; (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 10; and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 11 and a heavy chain variable region comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 13; and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 14 and a light chain variable region comprising and at least one antigen-binding domain that specifically binds to CD3 comprising: It has been discovered that anti-CD20 / anti-CD3 bispecific antibodies comprising are particularly stable in compositions having a pH of about 5.2 to about 5.8. In one embodiment, the buffer provides a pH of about 5.2 to about 5.8, particularly a pH of about 5.5.

[0156] In some embodiments, the pharmaceutical composition comprises an isotonicity agent, such as a sugar, an amino acid, a salt, etc. In embodiments where the isotonicity agent is a sugar, the sugar can be, for example, sucrose, glucose, glycerol, or trehalose. In certain embodiments, the sugar is sucrose, optionally D-sucrose. In some embodiments, the isotonicity agent is either sucrose or sodium chloride. The isotonicity agent (e.g., a sugar, such as sucrose) can be at a concentration of at least about ≧200 mM. For example, the tonicity agent (e.g., a sugar, e.g., sucrose) may be, for example, from 200 mM to 220 mM, 220 mM to 240 mM, 240 mM to 260 mM, 260 mM to 280 mM, 280 mM to 300 mM, 300 mM to 320 mM, 320 mM to 340 mM, 340 mM to 360 mM, 360 mM to 380 mM, 380 mM to 400 mM, 400 mM to 420 mM, 420 mM to 440 mM, 440 mM to 460 mM, 460 mM to 480 mM, 480 mM to 500 mM, 480 mM to 520 mM, 480 mM to 540 mM, 480 mM to 560 mM, 480 mM to 580 mM, 480 mM to 590 mM, 480 mM to 600 mM, 480 mM to 610 mM, 480 mM to 620 mM, 480 mM to 630 mM, 480 mM to 700 mM, 480 mM to 710 mM, 480 mM to 720 mM, 480 mM to 730 mM, 480 mM to 740 mM, 480 mM to 750 mM, 480 mM to 760 mM, 480 mM to 770 mM, 480 mM to 780 mM, 480 mM to 790 mM, 480 mM to 800 mM, 480 mM to 810 mM, 480 mM to 820 mM, 480 mM to 830 mM, 480 mM to 840 mM, 480 mM to 85 The concentration of the tonicity agent may be about 200 mM to 280 mM. In some embodiments, the concentration of the tonicity agent may be about 240 mM to 440 mM, 440 mM to 460 mM, 460 mM to 480 mM, or 480 mM to 500 mM, for example, 200 mM to 300 mM, for example, about 200 mM, about 210 mM, about 220 mM, about 230 mM, about 240 mM, about 250 mM, about 260 mM, about 270 mM, about 280 mM, about 290 mM, about 300 mM, about 350 mM, about 400 mM, about 450 mM, or about 500 mM. In some embodiments, the concentration of the tonicity agent is about 200 mM to 280 mM. In some embodiments, the concentration of the tonicity agent is about 240 mM. In one particular embodiment, the tonicity agent is sucrose and is present at a concentration of at least about 200 mM, i.e., ≧about 200 mM. In another particular embodiment, the tonicity agent is sucrose (e.g., D-sucrose) and is present at a concentration of about 200 mM to 280 mM. In one particular embodiment, the tonicity agent is sucrose (e.g., D-sucrose) and is present at a concentration of about 240 mM.

[0157] In some embodiments, the liquid pharmaceutical composition comprises methionine as a stabilizer.

[0158] Any suitable concentration of the stabilizer methionine can be used.For example, in some embodiments of any of the aforementioned pharmaceutical compositions, the concentration of the stabilizer (e.g., methionine) is about 0.01 mM to about 15 mM, for example, about 0.01 mM, about 0.05 mM, about 0.1 mM, about 0.2 mM, about 0.3 mM, about 0.4 mM, about 0.5 mM, about 0.6 mM, about 0.7 mM, about 0.8 mM, about 0.9 mM, about 1 mM, about 2 mM, about 3 mM, about 4 mM, about 5 mM, about 6 mM, about 7 mM, about 8 mM, about 9 mM, about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, or about 15 mM.

[0159] In certain embodiments, the concentration of methionine is about 5 mM to 15 mM. In certain embodiments, the concentration of methionine is about 10 mM.

[0160] Any of the pharmaceutical compositions described herein may contain a surfactant.Any suitable surfactant may be used.In some embodiments, the surfactant is a non-ionic surfactant (e.g., polysorbate (polyoxyethylene (n) sorbitan monolaurate), poloxamer, polyoxyethylene alkyl ether, alkylphenyl polyoxyethylene ether, or combinations thereof). In some embodiments, the non-ionic surfactant is a polysorbate (e.g., polysorbate 20 (polyoxyethylene (20) sorbitan monolaurate (PS20), TWEEN 20®); e.g., specially purified PS20 (PS20 purified by a proprietary flash chromatography process, available from Avantor Performance Materials, LLC, Center Valley, PA, US)) or polysorbate 80 (polyoxyethylene (20) sorbitan monooleate (PS80), e.g., TWEEN 80®; e.g., specially purified PS80 (Avantor)). In certain embodiments, the polysorbate is polysorbate 20. In other embodiments, the non-ionic surfactant is a poloxamer (e.g., poloxamer 188, poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol)).

[0161] The pharmaceutical surfactant may be at a concentration of at least about ≧0.2 mg / ml, ie, at least ≧about 0.02% (w / v).

[0162] In some embodiments of any of the pharmaceutical compositions described herein, the concentration of the surfactant (e.g., PS20 or P188) is about 0.01% (w / v) to about 2% (w / v), e.g., about 0.01%, about 0.02%, about 0.03%, about 0.04%, about 0.05%, about 0.06%, about 0.07%, about 0.08%, about 0.09%, about 0.1%, about 0.15%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 1.1%, about 1.2%, about 1.3%, about 1.4%, about 1.5%, about 1.6%, about 1.7%, about 1.8%, about 1.9%, or about 2% (w / v).

[0163] In some embodiments, the concentration of the surfactant (e.g., PS20 or P188) is about 0.1 to 1 mg / ml, i.e., 0.01% (w / v) to about 0.1% (w / v). In some embodiments, the concentration of the surfactant (e.g., PS20 or P188) is about 0.2 to 1 mg / ml, i.e., 0.02% (w / v) to about 0.1% (w / v). In some embodiments, the concentration of the surfactant (e.g., PS20 or P188) is about 0.2 to 0.8 mg / ml, i.e., 0.02% (w / v) to about 0.08% (w / v). In some embodiments, the concentration of the surfactant (e.g., PS20 or P188) is about 0.5 mg / ml, i.e., about 0.05% (w / v).

[0164] In certain embodiments, the surfactant is P188 and the concentration of P188 is about 0.05% (w / v), 0.07% (w / v), or 0.1% (w / v).

[0165] In a particular embodiment, the surfactant is PS20 and the concentration of PS20 is at least about ≧0.2 mg / ml, ie, a concentration of at least about ≧0.02% (w / v) PS20.

[0166] In certain embodiments, the surfactant is PS20 and the concentration of PS20 is about 0.2-0.8 mg / ml, i.e., about 0.02% (w / v) to about 0.08% (w / v). In certain embodiments, the surfactant is PS20 and the concentration of PS20 is about 0.5 mg / ml, i.e., about 0.05% (w / v). In certain embodiments, the surfactant is PS20 and the concentration of PS20 is at least about ≧0.02% (w / v) PS20. In certain embodiments, the surfactant is PS20 and the concentration of PS20 is about 0.02% (w / v) to about 0.08% (w / v). In certain embodiments, the surfactant is PS20 and the concentration of PS20 is about 0.05% (w / v).

[0167] In one embodiment, the liquid pharmaceutical composition according to the invention comprises: At a pH of about 5 to about 6, about 1 to 5 mg / ml of an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab), a) at least one antigen-binding domain that specifically binds to CD20, (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:1; (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:2; and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 3 and a heavy chain variable region comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5; and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:6 and a light chain variable region comprising At least one antigen-binding domain that specifically binds to CD20 comprising: b) at least one antigen-binding domain that specifically binds to CD3, (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:9; (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 10; and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 11 and a heavy chain variable region comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 13; and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 14 and a light chain variable region comprising and at least one antigen-binding domain that specifically binds to CD3 comprising: about 1 to 5 mg / ml of an anti-CD20 / anti-CD3 bispecific antibody comprising; with about 15-25mM histidine buffer; with approximately 200-280 mM sucrose; with approximately 0-15 mM methionine; Approximately 0.2-0.8mg / ml of PS20 Includes.

[0168] In one embodiment, the liquid pharmaceutical composition according to the invention comprises: At a pH of about 5.2 to about 5.8, about 1 to 5 mg / ml of an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab), a) at least one antigen-binding domain that specifically binds to CD20, (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:1; (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:2; and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 3 and a heavy chain variable region comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5; and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:6 and a light chain variable region comprising At least one antigen-binding domain that specifically binds to CD20 comprising: b) at least one antigen-binding domain that specifically binds to CD3, (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:9; (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 10; and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 11 and a heavy chain variable region comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 13; and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 14 and a light chain variable region comprising and at least one antigen-binding domain that specifically binds to CD3 comprising: about 1 to 5 mg / ml of an anti-CD20 / anti-CD3 bispecific antibody comprising; with about 15-25mM histidine buffer; with approximately 200-280 mM sucrose; with approximately 0-15 mM methionine; Approximately 0.2-0.8mg / ml of PS20 Includes.

[0169] In one embodiment, the liquid pharmaceutical composition according to the present invention comprises: At a pH of about 5.2 to about 5.8, about 0.9 to 1.1 mg / ml of an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab), a) at least one antigen-binding domain that specifically binds to CD20, (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:1; (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:2; and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 3 and a heavy chain variable region comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5; and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:6 and a light chain variable region comprising At least one antigen-binding domain that specifically binds to CD20 comprising: b) at least one antigen-binding domain that specifically binds to CD3, (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:9; (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 10; and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 11 and a heavy chain variable region comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 13; and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 14 and a light chain variable region comprising and at least one antigen-binding domain that specifically binds to CD3 comprising: about 1 mg / ml of an anti-CD20 / anti-CD3 bispecific antibody comprising; with about 15-25mM histidine buffer; with approximately 200-280 mM sucrose; with approximately 0-15 mM methionine; Approximately 0.2-0.8mg / ml of PS20 Includes.

[0170] In one embodiment, the liquid pharmaceutical composition comprises: At a pH of about 5.2 to about 5.8, about 1 mg / ml of an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab), a) at least one antigen-binding domain that specifically binds to CD20, (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:1; (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:2; and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 3 and a heavy chain variable region comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5; and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:6 and a light chain variable region comprising At least one antigen-binding domain that specifically binds to CD20 comprising: b) at least one antigen-binding domain that specifically binds to CD3, (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:9; (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 10; and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 11 and a heavy chain variable region comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 13; and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 14 and a light chain variable region comprising and at least one antigen-binding domain that specifically binds to CD3 comprising: about 1 mg / ml of an anti-CD20 / anti-CD3 bispecific antibody comprising; with about 15-25mM histidine buffer; with approximately 200-280 mM sucrose; with approximately 0-15 mM methionine; Approximately 0.2-0.8mg / ml of PS20 Includes.

[0171] In one embodiment, the liquid pharmaceutical composition comprises: At a pH of about 5.5, about 1 mg / ml of an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab), a) at least one antigen-binding domain that specifically binds to CD20, (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:1; (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:2; and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 3 and a heavy chain variable region comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5; and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:6 and a light chain variable region comprising At least one antigen-binding domain that specifically binds to CD20 comprising: b) at least one antigen-binding domain that specifically binds to CD3, (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:9; (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 10; and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 11 and a heavy chain variable region comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 13; and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 14 and a light chain variable region comprising and at least one antigen-binding domain that specifically binds to CD3 comprising: about 1 mg / ml of an anti-CD20 / anti-CD3 bispecific antibody comprising; with about 20 mM histidine buffer; with approximately 240 mM sucrose; with approximately 10 mM methionine; Approximately 0.5mg / ml of PS20 Includes.

[0172] In one embodiment, the liquid pharmaceutical composition according to the invention comprises: At a pH of about 5.2 to about 5.8, about 1 to 5 mg / ml of an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab), (i) at least one antigen-binding domain that specifically binds to CD20, comprising a heavy chain variable region sequence of SEQ ID NO: 7 and a light chain variable region sequence of SEQ ID NO: 8; (ii) at least one antigen-binding domain that specifically binds to CD3, comprising a heavy chain variable region sequence of SEQ ID NO: 15 and a light chain variable region sequence of SEQ ID NO: 16; about 1 to 5 mg / ml of an anti-CD20 / anti-CD3 bispecific antibody comprising; with about 15-25mM histidine buffer; with approximately 200-280 mM sucrose; with approximately 0-15 mM methionine; Approximately 0.2-0.8mg / ml of PS20 Includes.

[0173] In one embodiment, the liquid pharmaceutical composition according to the invention comprises: At a pH of about 5.2 to about 5.8, about 0.9 to about 1.1 mg / ml of an anti-CD20 / anti-CD3 bispecific antibody, (i) at least one antigen-binding domain that specifically binds to CD20, comprising a heavy chain variable region sequence of SEQ ID NO: 7 and a light chain variable region sequence of SEQ ID NO: 8; (ii) at least one antigen-binding domain that specifically binds to CD3, comprising a heavy chain variable region sequence of SEQ ID NO: 15 and a light chain variable region sequence of SEQ ID NO: 16; about 0.9 to about 1.1 mg / ml of an anti-CD20 / anti-CD3 bispecific antibody comprising: with about 15-25mM histidine buffer; with approximately 200-280 mM sucrose; with approximately 0-15 mM methionine; Approximately 0.2-0.8mg / ml of PS20 Includes.

[0174] In one embodiment, the liquid pharmaceutical composition according to the present invention comprises: At a pH of about 5.2 to about 5.8, about 1 mg / ml of an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab), (i) at least one antigen-binding domain that specifically binds to CD20, comprising a heavy chain variable region sequence of SEQ ID NO: 7 and a light chain variable region sequence of SEQ ID NO: 8; (ii) at least one antigen-binding domain that specifically binds to CD3, comprising a heavy chain variable region sequence of SEQ ID NO: 15 and a light chain variable region sequence of SEQ ID NO: 16; about 1 mg / ml of an anti-CD20 / anti-CD3 bispecific antibody comprising; with about 15-25mM histidine buffer; with approximately 200-280 mM sucrose; with approximately 0-15 mM methionine; Approximately 0.2-0.8mg / ml of PS20 Includes.

[0175] In one embodiment, the liquid pharmaceutical composition according to the present invention comprises: At a pH of about 5.5, about 1 mg / ml of an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab), (i) at least one antigen-binding domain that specifically binds to CD20, comprising a heavy chain variable region sequence of SEQ ID NO: 7 and a light chain variable region sequence of SEQ ID NO: 8; (ii) at least one antigen-binding domain that specifically binds to CD3, comprising a heavy chain variable region sequence of SEQ ID NO: 15 and a light chain variable region sequence of SEQ ID NO: 16; about 1 mg / ml of an anti-CD20 / anti-CD3 bispecific antibody comprising; with about 20 mM histidine buffer; with approximately 240 mM sucrose; with approximately 10 mM methionine; Approximately 0.5mg / ml of PS20 Includes.

[0176] In one embodiment, the liquid pharmaceutical composition according to the invention comprises: At a pH of about 5.2 to about 5.8, with glofitamab at approximately 1 to 5 mg / ml; with about 15-25mM histidine buffer; with approximately 200-280 mM sucrose; with approximately 0-15 mM methionine; Approximately 0.2-0.8mg / ml of PS20 Includes.

[0177] In one embodiment, the liquid pharmaceutical composition according to the invention comprises: At a pH of about 5.2 to about 5.8, with about 0.9 to about 1.1 mg / ml glofitamab; with about 15-25mM histidine buffer; with approximately 200-280 mM sucrose; with approximately 0-15 mM methionine; Approximately 0.2-0.8mg / ml of PS20 Includes.

[0178] In one embodiment, the liquid pharmaceutical composition according to the invention comprises: at a pH of about 5.2 to about 5.8; with glofitamab at approximately 1mg / ml; with about 15-25mM histidine buffer; with approximately 200-280 mM sucrose; with approximately 0-15 mM methionine; Approximately 0.2-0.8mg / ml of PS20 Includes.

[0179] In one embodiment, the liquid pharmaceutical composition according to the invention comprises: At a pH of about 5.5, with glofitamab at approximately 1mg / ml; with about 20 mM histidine buffer; with approximately 240 mM sucrose; with approximately 10 mM methionine; Approximately 0.5mg / ml of PS20 Includes.

[0180] The formulations may also contain adjuvants such as preservatives, wetting agents, emulsifying agents, and dispersing agents. Prevention of the presence of microorganisms can be ensured by both sterilization procedures and the inclusion of various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, and the like. Preservatives are generally used in amounts of about 0.001 to about 2% (w / v). Preservatives include, but are not limited to, ethanol, benzyl alcohol, phenol, m-cresol, p-chloro-m-cresol, methyl or propyl paraben, and benzalkonium chloride.

[0181] IV. Therapeutic Agents for Use in the Pharmaceutical Compositions of the Invention A. Anti-CD20 / anti-CD3 bispecific antibody The present invention relates to novel pharmaceutical compositions of anti-CD20 / anti-CD3 bispecific antibodies (e.g., anti-CD20 / anti-CD3 T cell engaging bispecific antibodies (TCBs), e.g., glofitamab). In one embodiment, the antibodies are monoclonal antibodies. In one embodiment, the anti-CD20 / anti-CD3 bispecific antibodies are polyclonal antibodies. In one embodiment, the anti-CD20 / anti-CD3 bispecific antibodies are human antibodies. In one embodiment, the anti-CD20 / anti-CD3 bispecific antibodies (e.g., anti-CD20 / anti-CD3 TCBs, e.g., glofitamab) are humanized antibodies. In one embodiment, the anti-CD20 / anti-CD3 bispecific antibodies are chimeric antibodies. In one embodiment, the anti-CD20 / anti-CD3 bispecific antibodies are full-length antibodies. In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, e.g., glofitamab) is an IgG class antibody, in particular an IgG1 subclass antibody. In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, e.g., glofitamab) is a recombinant antibody.

[0182] In certain embodiments, the anti-CD20 / anti-CD3 bispecific antibody comprises a human antibody. Antibody fragments include, but are not limited to, Fab, Fab', Fab'-SH, F(ab')2, Fv, and scFv fragments, as well as other fragments described below. For a review of specific antibody fragments, see Hudson et al. Nat. Med. 9:129-134 (2003). For a review of scFv fragments, see, e.g., Plueckthun, in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., (Springer-Verlag, New York), pp. 269-315 (1994). See also WO 93 / 16185 and U.S. Patent Nos. 5,571,894 and 5,587,458. For a description of Fab and F(ab')2 fragments that contain salvage receptor binding epitope residues and have increased in vivo half-lives, see U.S. Patent No. 5,869,046. In one embodiment, the antibody fragment is a Fab fragment or an scFv fragment.

[0183] Diabodies are antibody fragments with two antigen-binding sites that can be bivalent or bispecific. See, e.g., EP 404,097, WO 1993 / 01161, Hudson et al. Nat. Med. 9:129-134 (2003); and Hollinger et al. Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993). Triabodies and tetrabodies are also described in Hudson et al., Nat. Med. 9:129-134 (2003).

[0184] Single domain antibodies are antibody fragments that contain all or a portion of the heavy chain variable domain or all or a portion of the light chain variable domain of an antibody. In certain embodiments, single domain antibodies are human single domain antibodies (Domantis, Inc., Waltham, MA; see, e.g., U.S. Patent No. 6,248,516).

[0185] Antibody fragments can be produced by a variety of techniques, including, but not limited to, proteolytic digestion of intact antibodies, and production by recombinant host cells (eg, E. coli or phages), as described herein.

[0186] In a particular embodiment, the anti-CD20 / anti-CD3 bispecific antibody is a chimeric antibody. Some chimeric antibodies are described, for example, in US Patent No. 4,816,567 and Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984). In one example, the chimeric antibody comprises a non-human variable region (e.g., a variable region derived from a mouse, rat, hamster, rabbit, or a non-human primate, such as a monkey) and a human constant region. In a further example, the chimeric antibody is a "class-switched" antibody in which the class or subclass has been changed from that of the parent antibody. The chimeric antibody includes an antigen-binding fragment thereof.

[0187] In certain embodiments, the anti-CD20 / anti-CD3 bispecific antibody is a humanized antibody. Typically, a non-human antibody is humanized to reduce immunogenicity to humans while retaining the specificity and affinity of the parent non-human antibody. In general, a humanized antibody comprises one or more variable domains in which the HVRs (e.g., CDRs) (or portions thereof) are derived from a non-human antibody and the FRs (or portions thereof) are derived from human antibody sequences. The humanized antibody also optionally comprises at least a portion of a human constant region. In some embodiments, some FR residues of the humanized antibody are replaced with the corresponding residues from the non-human antibody (e.g., the antibody from which the HVR residues are derived), e.g., to restore or improve antibody specificity or affinity.

[0188] Humanized antibodies and methods for their production are reviewed, e.g., by Almagro and Fransson, Front. Biosci. 13:1619-1633 (2008), and further described in, e.g., Riechmann et al., Nature 332:323-329 (1988); Queen et al., Proc. Nat'l Acad. Sci. USA 86:10029-10033 (1989), U.S. Pat. Nos. 5,821,337, 7,527,791, 6,982,321, and 7,087,409, Kashmiri et al., Methods 36:25-34 (2005) (describing grafting of specificity determining regions (SDRs)), Padlan, Mol. Immunol. 28:489-498 (1991) (describing "resurfacing"), Dall'Acqua et al., Methods 36:43-60 (2005) (describing "FR shuffling"), and Osbourn et al., Methods 36:61-68 (2005) and Klimka et al., Br. J. Cancer, 83:252-260 (2000) (describing a "guided selection" approach to FR shuffling).

[0189] Human framework regions that can be used for humanization include, but are not limited to, framework regions selected using the "best-fit" method (see, e.g., Sims et al., J. Immunol. 151:2296 (1993)); framework regions derived from consensus sequences of human antibodies of a particular subgroup of light or heavy chain variable regions (see, e.g., Carter et al., Proc. Natl. Acad. Sci. USA, 89:4285 (1992); and Presta et al., J. Immunol., 151:2623 (1993)); human mature (somatically mutated) framework regions or human germline framework regions (see, e.g., Almagro and Fransson, Front. Biosci. 13:1619-1633 (2008)); and framework regions derived from screening of FR libraries (see, e.g., Baca et al., J. Biol. Chem. 272:10678-10684 (2008)). (1997) and Rosok et al., J. Biol. Chem. 271:22611-22618 (1996).

[0190] In certain embodiments, the anti-CD20 / anti-CD3 bispecific antibody is a human antibody. Human antibodies can be produced using various techniques known in the art. Human antibodies are generally described in van Dijk and van de Winkel, Curr. Opin. Pharmacol. 5: 36874 (2001), and Lonberg, Curr. Opin. Immunol. 20:450459 (2008).

[0191] Human antibodies may be prepared by administering immunogens to transgenic animals that have been modified to produce intact human antibodies or intact antibodies with human variable regions in response to antigenic challenge. Such animals typically contain all or part of a human immunoglobulin locus that replaces the endogenous immunoglobulin locus or is present extrachromosomally or randomly integrated into the animal's chromosomes. In such transgenic mice, the endogenous immunoglobulin locus is generally inactivated. For a review of methods for obtaining human antibodies from transgenic animals, see Lonberg, Nat. Biotech. 23:1117-1125 (2005). See also, e.g., U.S. Patent Nos. 6,075,181 and 6,150,584, which describe XENOMOUSE™ technology, 5,770,429, which describes HuMab® technology, 7,041,870, which describes KM MOUSE® technology, and U.S. Patent Application Publication No. 2007 / 0061900, which describes VelociMouse® technology. The human variable regions from intact antibodies produced by such animals may be further modified, for example, by combining with a different human constant region.

[0192] Human antibodies can also be produced by hybridoma-based methods. Human myeloma cell lines and mouse-human heteromyeloma cell lines for producing human monoclonal antibodies have been described. (See, e.g., Kozbor J. Immunol., 133: 3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987); and Boerner et al., J. Immunol., 147: 86 (1991).) Human antibodies generated via human B-cell hybridoma technology are also described in Li et al., Proc. Natl. Acad. Sci. USA, 103:3557-3562 (2006). Further methods include those described, for example, in U.S. Patent No. 7,189,826 (describing production of monoclonal human IgM antibodies from hybridoma cell lines) and Ni, Xiandai Mianyixue, 26(4):265-268 (2006) (describing human-human hybridomas). Human hybridoma technology (trioma technology) is also described in Vollmers and Brandlein, Histology and Histopathology, 20(3):927-937 (2005) and Vollmers and Brandlein, Methods and Findings in Experimental and Clinical Pharmacology, 27(3):185-91 (2005).

[0193] Human antibodies can also be made by isolating Fv clone variable domain sequences selected from a human-derived phage display library. Such variable domain sequences can then be combined with the desired human constant domains. Techniques for selecting human antibodies from antibody libraries are described below.

[0194] Binding domains contained in anti-CD20 / anti-CD3 bispecific antibodies (e.g., anti-CD20 / anti-CD3 TCBs, e.g., glofitamab) can be isolated by screening combinatorial libraries for binding sites with the desired activity. For example, various methods are known in the art for generating phage display libraries and screening such libraries for antibodies with the desired binding characteristics. Such methods are reviewed, for example, in Hoogenboom et al. in Methods in Molecular Biology 178:1-37 (O'Brien et al., ed., Human Press, Totowa, NJ, 2001); McCafferty et al., Nature 348:552-554; Clackson et al., Nature 352:624-628 (1991); et al., J.Mol.Biol.222:581-597(1992);Marks and Bradbury,in Methods in Molecular Biology 248:161-175(Lo,ed.,Human Press,Totowa,NJ,2003);Sidhu et al.,J.Mol.Biol. 338(2):299-310(2004);Lee et al., J. Mol. Biol. 340(5):1073-1093 (2004); Fellouse, Proc. Natl. Acad. Sci. USA 101(34):12467-12472 (2004); and Lee et al., J. Immunol. Methods 284(1-2):119-132 (2004).

[0195] In a particular phage display method, repertoires of VH and VL genes can be cloned separately by polymerase chain reaction (PCR), randomly recombined in a phage library, and then screened for antigen-binding phages as described by Winter et al., Ann. Rev. Immunol., 12:433-455 (1994). Phages typically display antibody fragments as either single-chain Fv (scFv) fragments or Fab fragments. Libraries from immune sources provide high affinity antibodies to the immunogen without the need to construct hybridomas. Alternatively, naive repertoires can be cloned (e.g., from humans) without immunization to provide a single source of antibodies to a wide range of non-self antigens and also self antigens, as described by Griffiths et al., EMBO J, 12:725-734 (1993). Finally, naive libraries can also be generated synthetically by cloning unrearranged V gene segments from stem cells and using PCR primers containing random sequences to encode highly variable CDR3 regions and achieve rearrangement in vitro as described in Hoogenboom and Winter, J. Mol. Biol., 227:381-388 (1992). Patent publications describing human antibody phage libraries include, for example: U.S. Pat. No. 5,750,373, and U.S. Patent Application Publication Nos. 2005 / 0079574, 2005 / 0119455, 2005 / 0266000, 2007 / 0117126, 2007 / 0160598, 2007 / 0237764, 2007 / 0292936, and 2009 / 0002360.

[0196] Antibodies or antibody fragments isolated from a human antibody library are considered herein to be human antibodies or human antibody fragments.

[0197] Techniques for making bispecific antibodies include, but are not limited to, recombinant coexpression of two immunoglobulin heavy-light chain pairs with different specificities (see Milstein and Cuello, Nature 305: 537 (1983)), WO 93 / 08829, and Traunecker et al., EMBO J. 10: 3655 (1991)), and "knobs-into-holes" engineering (see, e.g., U.S. Pat. No. 5,731,168). Multispecific antibodies can also be produced by engineering electrostatic steering effects to create antibody Fc-heterodimeric molecules (WO 2009 / 089004A1); cross-linking two or more antibodies or fragments (see, e.g., U.S. Pat. No. 4,676,980, and Brennan et al., Science, 229: 81 (1985)); using leucine zippers to produce bispecific antibodies (see, e.g., Kostelny et al., J. Immunol., 148(5):1547-1553 (1992)); using "diabody" technology to create bispecific antibody fragments (see, e.g., Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993)); and using single-chain Fv (sFv) dimers (see, e.g., Gruber et al., J. Immunol., 1999). 152:5368 (1994)); as well as by preparing trispecific antibodies as described, for example, in Tutt et al. J. Immunol. 147: 60 (1991).

[0198] Engineered antibodies with three or more functional antigen binding sites, including "Octopus antibodies," are also included herein (see, eg, US Patent Application Publication No. 2006 / 0025576A1).

[0199] The anti-CD20 / anti-CD3 bispecific antibodies herein also include "dual acting FAbs" or "DAFs" that contain antigen binding sites that bind to two different antigens (see, e.g., U.S. Patent Publication No. 2008 / 0069820).

[0200] "Crossmab" antibodies are also included herein (see, e.g., WO2009080251, WO2009080252, WO2009080253, WO2009080254).

[0201] Another technique for generating bispecific antibody fragments is the "bispecific T cell engager" or BiTE® technique (see, for example, WO 2004 / 106381, WO 2005 / 061547, WO 2007 / 042261, and WO 2008 / 119567). This approach utilizes two antibody variable domains arranged on a single polypeptide. For example, a single polypeptide chain comprises two short chain Fv (scFv) fragments, each having a variable heavy (VH) and variable light (VL) domain separated by a polypeptide linker of sufficient length to allow intramolecular association between the two domains. This single polypeptide further comprises a polypeptide spacer sequence between the two scFv fragments. Each scFv recognizes a different epitope, and these epitopes may be specific for different cell types, such that cells of two different cell types are brought into close proximity or tethered when each scFv engages its cognate epitope. One particular embodiment of this approach comprises an scFv that recognizes a cell surface antigen expressed by an immune cell, e.g., a CD3 polypeptide on a T cell, which is linked to another scFv that recognizes a cell surface antigen expressed by a target cell, such as a malignant or tumor cell.

[0202] Because it is a single polypeptide, the bispecific T cell engager can be expressed using any prokaryotic or eukaryotic cell expression system known in the art, such as CHO cell lines. However, specific purification techniques (see, for example, EP1691833) may be required to separate the monomeric bispecific T cell engager from other multimeric species that may have biological activities other than the intended activity of the monomer. In one exemplary purification scheme, a solution containing the secreted polypeptides is first subjected to metal affinity chromatography, and the polypeptides are eluted using a gradient of imidazole concentrations. This eluate is further purified using anion exchange chromatography, and the polypeptides are eluted using a gradient of sodium chloride concentrations. Finally, this eluate is subjected to size exclusion chromatography to separate the monomers from the multimeric species.

[0203] In certain embodiments, anti-CD20 / anti-CD3 bispecific antibodies can be further modified to contain additional non-proteinaceous moieties that are known in the art and readily available. Suitable moieties for derivatization of anti-CD20 / anti-CD3 bispecific antibodies (e.g., anti-CD20 / anti-CD3 TCBs, e.g., glofitamab) include, but are not limited to, water-soluble polymers. Non-limiting examples of water-soluble polymers include, but are not limited to, polyethylene glycol (PEG), ethylene glycol / propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone, poly-1,3-dioxolane, poly-1,3,6-trioxane, ethylene / maleic anhydride copolymers, polyamino acids (either homopolymers or random copolymers), and dextran or poly(n-vinylpyrrolidone) polyethylene glycol, polypropylene glycol homopolymer, polypropylene oxide / ethylene oxide copolymer, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof. Polyethylene glycol propionaldehyde may be advantageous in manufacturing due to its stability in water. The polymer may be of any molecular weight and may be branched or unbranched. The number of polymers attached to the antibody may vary, and when multiple polymers are attached, they may be the same or different molecules. In general, the number and / or type of polymers used for derivatization may be determined based on considerations including, but not limited to, the particular property or function of the antibody to be improved, whether the antibody derivative will be used therapeutically under defined conditions, etc.

[0204] The anti-CD20 / anti-CD3 bispecific antibodies may be conjugated to one or more cytotoxic agents, such as chemotherapeutic agents or drugs, growth inhibitory agents, toxins (e.g., protein toxins, or enzymatically active toxins of bacterial, fungal, plant or animal origin, or fragments thereof), or radioactive isotopes.

[0205] In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody comprises an antibody-drug conjugate (ADC), in which the antibody is conjugated to an antibody or a combination thereof, including, but not limited to, a maytansinoid (see U.S. Pat. Nos. 5,208,020, 5,416,064, and European Patent No. 0425235B1); an auristatin, such as monomethyl auristatin drug moieties DE and DF (MMAE and MMAF) (see U.S. Pat. No. 5,208,020, 5,416,064, and European Patent No. 0425235B1); ,635,483, 5,780,588, and 7,498,298); dolastatins; calicheamicin or derivatives thereof (see U.S. Pat. Nos. 5,712,374, 5,714,586, 5,739,116, 5,767,285, 5,770,701, 5,770,710, 5,773,001, and 5,877,296; Hinman et al., Cancer Res. 53:3336-3342 (1993); and Lode et al., Cancer Res. 58:2925-2928 (1998)); anthracyclines such as daunomycin and doxorubicin (see, e.g., Kratz et al., Current Med. Chem. 13:477-523 (2006); Jeffrey et al., Bioorganic & Med. Chem. Letters 16:358-362 (2006); Torgov et al., Bioconj. Chem. 16:717-721 (2005); Nagy et al., Proc. Natl. Acad. Sci. USA 97:829-834 (2000); Dubowchik et al., Bioorg. & Med. Chem. Letters 12:1529-1532 (2003)); (2002); King et al., J. Med. Chem. 45:4336-4343 (2002); and U.S. Patent No. 6,630,579); methotrexate; vindesine; taxanes, such as docetaxel, paclitaxel, larotaxel, tesetaxel, and ortataxel; trichothecenes; and CC1065.

[0206] In another embodiment, the anti-CD20 / anti-CD3 bispecific antibody is conjugated to an enzymatically active toxin or fragment thereof, including, but not limited to, diphtheria A chain, non-binding active fragment of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii protein, diansin protein, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), Momordica charantia inhibitor, curcin, crotin, Saponaria officinalis inhibitor, gelonin, mitogenin, restrictocin, phenomycin, enomycin, and the trichothecenes.

[0207] In another embodiment, the anti-CD20 / anti-CD3 bispecific antibody is conjugated to a radioactive atom to form a radioconjugate. A variety of radioisotopes are available for the production of radioconjugates. Examples include At 211 , I 131 , I 125 , Y 90 , Re 186 , Re 188 , Sm 153 , Bi 212 , P 32 , Pb 212 Radioactive conjugates, when used for detection, include radioactive atoms for scintigraphic examinations, such as Tc 99m Or I 123 , or spin labels for nuclear magnetic resonance (NMR) imaging (also known as magnetic resonance imaging, MRI), such as iodine-123 again, iodine-131, indium-111, fluorine-19, carbon-13, nitrogen-15, oxygen-17, gadolinium, manganese or iron.

[0208] Conjugates of anti-CD20 / anti-CD3 bispecific antibodies and cytotoxic agents may be made using a variety of bifunctional protein coupling agents, such as N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP), succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), iminothiolane (IT), bifunctional derivatives of imidoesters (e.g., dimethyl adipimidate HCl), active esters (e.g., disuccinimidyl suberate), aldehydes (e.g., glutaraldehyde), bis-azido compounds (e.g., bis(p-azidobenzoyl)hexanediamine), bis-diazonium derivatives (e.g., bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (e.g., toluene 2,6-diisocyanate), and bis-active fluorine compounds (e.g., 1,5-difluoro-2,4-dinitrobenzene). For example, ricin immunotoxins can be prepared as described in Vitetta et al., Science 238:1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylenetriaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotides to antibodies. See WO 94 / 11026. The linker may be a "cleavable linker" that facilitates the release of the cytotoxic drug inside the cell. For example, an acid-labile linker, a peptidase-sensitive linker, a photolabile linker, a dimethyl linker or a disulfide-containing linker (Chari et al., Cancer Res. 52:127-131 (1992); U.S. Pat. No. 5,208,020) may be used.

[0209] In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, e.g., glofitamab) is indicated for the treatment of a cell proliferative disorder (e.g., cancer). In one embodiment, the cell proliferative disorder is cancer. In one embodiment, the cancer is a B-cell proliferative disorder. In one embodiment, the cancer is a CD20-positive B-cell proliferative disorder. In one embodiment, the cancer is a non-Hodgkin's lymphoma (NHL). In one embodiment, the NHL is diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL), DLBCL arising from follicular lymphoma (FL) [transformed FL; trFL], primary mediastinal large B-cell lymphoma (PMBCL), or marginal zone lymphoma (MZL). MZL is classified into splenic MZL, nodal MZL, and extranodal MZL. In one embodiment, the NHL is mantle cell lymphoma (MCL). In one embodiment, the NHL is grade 1-3a follicular lymphoma (FL). In some embodiments, the CD20-positive B cell proliferative disorder is a relapsed or refractory B cell proliferative disorder. In one embodiment, the relapsed or refractory B cell proliferative disorder is relapsed or refractory NHL (e.g., relapsed or refractory DLBCL, relapsed or refractory FL, or relapsed or refractory MCL).

[0210] In one embodiment, an anti-CD20 / anti-CD3 bispecific antibody (eg, an anti-CD20 / anti-CD3 TCB, such as glofitamab) specifically binds to CD3ε.

[0211] In one embodiment, the anti-CD20 / anti-CD3 CD3 antibody is antibody H2C (WO 2008 / 119567), antibody V9 (Rodrigues et al., Int J Cancer Suppl 7, 45-50 (1992) and US Patent No. 6054297), antibody FN18 (Nooij et al., Eur J Immunol 19, 981-984 (1986)), antibody SP34 (Pessano et al., EMBO J 4, 337-340 (1985)), antibody OKT3 (Kung et al., Science 206, 347-349 (1979)), antibody WT31 (Spits et al., J Immunol.135, 1922 (1985)), antibody UCHT1 (Burns et al., J Immunol. 129, 1451-1457 (1982)), antibody 7D6 (Coulie et al., Eur J Immunol. 21-1709 (1991)), or antibody Leu-4. In some embodiments, the anti-CD20 / anti-CD3 bispecific antibody may compete for binding with the antibodies described in WO 2005 / 040220, WO 2005 / 118635, WO 2007 / 042261, WO 2008 / 119567, WO 2008 / 119565, WO 2012 / 162067, WO 2013 / 158856, WO 2013 / 188693, WO 2013 / 186613, WO 2014 / 110601, The antibody may also include an antigen-binding portion that specifically binds to CD3 as described in US Pat. Nos. 2014 / 145806, 2014 / 191113, 2014 / 047231, 2015 / 095392, 2015 / 181098, 2015 / 001085, 2015 / 104346, 2015 / 172800, 2016 / 020444, or 2016 / 014974.

[0212] In some embodiments, the anti-CD20 / anti-CD3 bispecific antibody may comprise an antibody or antigen-binding portion from rituximab, obinutuzumab, ocrelizumab, ofatumumab, ocaratuzumab, veltuzumab, and brituximab.

[0213] In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody is glofitamab.

[0214] In some embodiments, the anti-CD20 / anti-CD3 bispecific antibodies may consist of generic, biosimilar, or non-comparable biological versions of the antibodies named herein.

[0215] In one embodiment, an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab) comprises at least one antigen binding domain that specifically binds to CD20, (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:1; (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:2; and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 3 and a heavy chain variable region comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5; and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:6 and a light chain variable region comprising and at least one antigen-binding domain comprising:

[0216] In one embodiment, an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab) comprises at least one antigen binding domain that specifically binds to CD20, the antigen binding domain comprising a heavy chain variable region sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 7 and a light chain variable region sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 8. In a further embodiment, an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab) comprises at least one antigen binding domain that specifically binds to CD20, the antigen binding domain comprising a heavy chain variable region sequence of SEQ ID NO: 7 and a light chain variable region sequence of SEQ ID NO: 8.

[0217] In one embodiment, an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab) comprises at least one antigen binding domain that specifically binds CD3, (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:9; (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 10; and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 11 and a heavy chain variable region comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 13; and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 14 and a light chain variable region comprising and at least one antigen-binding domain comprising:

[0218] In one embodiment, an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab) comprises at least one antigen binding domain that specifically binds to CD3, the antigen binding domain comprising a heavy chain variable region sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 15 and a light chain variable region sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 16. In a further embodiment, an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab) comprises at least one antigen binding domain that specifically binds to CD3, the heavy chain variable region sequence being at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 16.

[0219] In one embodiment, an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab) is a) at least one antigen-binding domain that specifically binds to CD20, (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:1; (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:2; and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO:3 and a heavy chain variable region comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5; and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:6 and a light chain variable region comprising At least one antigen-binding domain that specifically binds to CD20 comprising: b) at least one antigen-binding domain that specifically binds to CD3, (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:9; (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 10; and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 11 and a heavy chain variable region comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 13; and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 14 and a light chain variable region comprising and at least one antigen-binding domain that specifically binds to CD3 comprising:

[0220] In one embodiment, an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab) is (i) at least one antigen-binding domain that specifically binds to CD20, comprising a heavy chain variable region sequence of SEQ ID NO: 7 and a light chain variable region sequence of SEQ ID NO: 8; (ii) at least one antigen-binding domain that specifically binds to CD3, comprising a heavy chain variable region sequence of SEQ ID NO: 15 and a light chain variable region sequence of SEQ ID NO: 16; Includes.

[0221] In one embodiment, the antigen-binding domain of an anti-CD20 / anti-CD3 bispecific antibody that specifically binds to CD3 is an antibody fragment, in particular a Fab molecule or an scFv molecule, more particularly a Fab molecule. In a particular embodiment, the antigen-binding domain of an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab), that specifically binds to CD3, is a crossover Fab molecule in which the variable or constant domains of the Fab heavy and light chains are exchanged (i.e., replaced by one another).

[0222] In one embodiment, an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab) comprises at least one antigen binding domain that specifically binds CD20 and at least one antigen binding domain that specifically binds CD3. In one embodiment, an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab) comprises a first antigen binding domain that specifically binds CD3 and a second and a third antigen binding domain that specifically binds CD20. In one embodiment, the first antigen binding domain is a crossover Fab molecule and each of the second and the third antigen binding domains is a conventional Fab molecule. In one embodiment, an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab) further comprises an Fc domain. An anti-CD20 / anti-CD3 bispecific antibody may comprise modifications of the Fc region and / or the antigen binding domain as described herein. In one embodiment, an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab) comprises an IgG1 Fc domain comprising one or more amino acid substitutions that reduce Fc receptor binding and / or effector function. In one embodiment, an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab) comprises an IgG1 Fc domain comprising the amino acid substitutions L234A, L235A, and P329G (EU numbering).

[0223] In one embodiment, an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab) is (i) an antigen-binding domain that specifically binds CD3 fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain; (ii) a first antigen-binding domain that specifically binds CD20 fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of an antigen-binding domain that specifically binds CD3; (iii) a second antigen-binding domain that specifically binds CD20 fused at the C-terminus of the Fab heavy chain to the N-terminus of a second subunit of the Fc domain; Includes.

[0224] In certain embodiments, an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab) comprises: a) a first Fab molecule that specifically binds to CD3, in particular CD3 epsilon, in which the variable domains VL and VH of the Fab light and heavy chains are exchanged with each other; b) a second and a third Fab molecule which specifically bind to CD20, in which in the constant domain CL of the second and third Fab molecules the amino acid at position 124 is substituted by lysine (K) (Kabat numbering) and the amino acid at position 123 is substituted by lysine (K) or arginine (R), in particular by arginine (R) (Kabat numbering), and in the constant domain CH1 of the second and third Fab molecules the amino acid at position 147 is substituted by glutamic acid (E) (EU numbering) and the amino acid at position 213 is substituted by glutamic acid (E) (EU numbering); c) an Fc domain composed of a first subunit and a second subunit capable of stable association; Includes.

[0225] In one embodiment, an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab) comprises two antigen-binding domains that specifically bind to CD20 and one antigen-binding domain that specifically binds to CD3.

[0226] In one embodiment, an anti-CD20 / anti-CD3 bispecific antibody (eg, an anti-CD20 / anti-CD3 TCB, such as glofitamab) is bivalent for CD20 and monovalent for CD3.

[0227] In one embodiment, the first Fab molecule of a) is fused at the C-terminus of its Fab heavy chain to the N-terminus of one of the subunits of the Fc domain of c), the second Fab molecule of b) is fused at the C-terminus of its Fab heavy chain to the N-terminus of the heavy chain of the first Fab molecule of a) and the third Fab molecule of b) is fused at the C-terminus of its Fab heavy chain to the N-terminus of the other subunit of the Fc domain of c). In one embodiment, the first Fab molecule of a) comprises a heavy chain variable region that is at least 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 15 and a light chain variable region that is at least 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 16.

[0228] In a still further embodiment, the first Fab molecule of a) comprises the heavy chain variable region sequence of SEQ ID NO:15 and the light chain variable region sequence of SEQ ID NO:16.

[0229] In one embodiment, the second and third Fab molecules of b) each comprise a heavy chain variable region that is at least 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO:7 and a light chain variable region that is at least 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO:8.

[0230] In one embodiment, the second and third Fab molecules of b) comprise the heavy chain variable region sequence of SEQ ID NO:7 and the light chain variable region sequence of SEQ ID NO:8, respectively.

[0231] In particular embodiments, the anti-CD20 / anti-CD3 bispecific antibody comprises a polypeptide that is at least 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 17, a polypeptide that is at least 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 18, a polypeptide that is at least 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 19, and a polypeptide that is at least 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 20. In further particular embodiments, the bispecific antibody comprises the polypeptide sequence of SEQ ID NO: 17, the polypeptide sequence of SEQ ID NO: 18, the polypeptide sequence of SEQ ID NO: 19 and the polypeptide sequence of SEQ ID NO: 20. In a more specific embodiment, the bispecific antibody comprises one polypeptide chain comprising the amino acid sequence of SEQ ID NO: 17, one polypeptide chain comprising the amino acid sequence of SEQ ID NO: 18, one polypeptide chain comprising the amino acid sequence of SEQ ID NO: 19, and two polypeptide chains each comprising the amino acid sequence of SEQ ID NO: 20.

[0232] Certain anti-CD20 / anti-CD3 bispecific antibodies are described in PCT Publication No. WO 2016 / 020309 and European Patent Application Nos. EP 15188093 and EP 16169160, each of which is incorporated by reference in its entirety. In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody of the pharmaceutical composition of the invention is glofitamab.

[0233] B. Antibody Formats 1. Structure of anti-CD20 / anti-CD3 bispecific antibody The components of the anti-CD20 / anti-CD3 bispecific antibody can be fused to each other in a variety of configurations, exemplary configurations are shown in FIG.

[0234] In certain embodiments, the antigen-binding moiety contained in the anti-CD20 / anti-CD3 bispecific antibody is a Fab molecule. In such embodiments, the first, second, third, etc. antigen-binding moieties may be referred to herein as first, second, third, etc. Fab molecules, respectively. Furthermore, in certain embodiments, the anti-CD20 / anti-CD3 bispecific antibody comprises an Fc domain composed of a first subunit and a second subunit capable of stably associating.

[0235] In some embodiments, the first Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first or second subunit of the Fc domain.

[0236] In one such embodiment, the second Fab molecule is fused to the N-terminus of the Fab heavy chain of the first Fab molecule at the C-terminus of the Fab heavy chain. In a specific such embodiment, the anti-CD20 / anti-CD3 bispecific antibody consists essentially of a first and a second Fab molecule, an Fc domain composed of a first and a second subunit, and optionally one or more peptide linkers, where the first Fab molecule is fused to the N-terminus of the first or second subunit of the Fc domain at the C-terminus of the Fab heavy chain, and the second Fab molecule is fused to the N-terminus of the Fab heavy chain of the first Fab molecule at the C-terminus of the Fab heavy chain. Such a structure is shown diagrammatically in Figures 1G and 1K. Optionally, the Fab light chain of the first Fab molecule and the Fab light chain of the second Fab molecule may further be fused to each other.

[0237] In another embodiment, the second Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first or second subunit of the Fc domain. In a specific such embodiment, the antibody consists essentially of a first and a second Fab molecule, an Fc domain composed of the first and second subunits, and optionally one or more peptide linkers, where the first and the second Fab molecule are each fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain. Such a structure is shown diagrammatically in Figures 1A and 1D. The first and the second Fab molecule may be fused to the Fc domain directly or via a peptide linker. In a particular embodiment, the first and the second Fab molecule are each fused to the Fc domain by an immunoglobulin hinge region. In a specific embodiment, the immunoglobulin hinge region is a human IgG1 hinge region, and in particular, the Fc domain is an IgG1 Fc domain.

[0238] In other embodiments, the second Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first or second subunit of the Fc domain. In one such embodiment, the first Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second Fab molecule. In a specific such embodiment, the antibody consists essentially of a first and a second Fab molecule, an Fc domain composed of first and second subunits, and optionally one or more peptide linkers, where the first Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second Fab molecule, and the second Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first or second subunit of the Fc domain. Such structures are shown diagrammatically in Figures 1H and 1L. Optionally, the Fab light chain of the first Fab molecule and the Fab light chain of the second Fab molecule may further be fused to each other.

[0239] Fab molecules can be fused to the Fc domain or to each other directly or through a peptide linker comprising one or more amino acids, typically about 2-20 amino acids. Peptide linkers are known in the art and described herein. Suitable non-immunogenic peptide linkers include, for example, (G4S) n (SEQ ID NO: 21), (SG4) n (SEQ ID NO: 22), or G4 (SG4) n (SEQ ID NO:23) peptide linkers are included. "n" is usually an integer from 1 to 10, typically from 2 to 4. In one embodiment, the peptide linker has a length of at least 5 amino acids, in one embodiment from 5 to 100, and in a further embodiment from 10 to 50 amino acids. In one embodiment, the peptide linker has a length of (GxS) n or (GxS) n G m [wherein G=glycine, S=serine, (x=3, n=3, 4, 5 or 6, m=0, 1, 2 or 3) or (x=4, n=2, 3, 4 or 5, m=0, 1, 2 or 3)], in one embodiment x=4, n=2 or 3, in a further embodiment x=4, n=2. In one embodiment, the peptide linker is (G4S)2 (SEQ ID NO: 24). A particularly suitable peptide linker for fusing the Fab light chains of the first and second Fab molecules to each other is (G4S)2 (SEQ ID NO: 24). An exemplary peptide linker suitable for connecting the Fab heavy chains of the first and second Fab molecules comprises the sequence (D)-(G4S)2 (SEQ ID NO: 24 and 25). Another suitable such linker comprises the sequence (G4S)4 (SEQ ID NO: 26). In addition, the linker may comprise (part of) an immunoglobulin hinge region. In particular, when a Fab molecule is fused to the N-terminus of an Fc domain subunit, the fusion may be via the immunoglobulin hinge region or part thereof, with or without an additional peptide linker.

[0240] Antibodies having a single antigen-binding moiety (e.g., a Fab molecule) capable of specifically binding to a target cell antigen (e.g., as shown in Figures 1A, 1D, 1G, 1H, 1K, or 1L) are useful, particularly when internalization of the target cell antigen is expected following binding of the high affinity antigen-binding moiety. In such cases, the presence of more than one antigen-binding moiety specific for a target cell antigen may promote internalization of the target cell antigen, thereby reducing its availability.

[0241] However, in many other cases, it will be advantageous to have an antibody that comprises two or more antigen-binding portions (e.g., Fab molecules) specific for target cell antigens (see examples shown in Figures 1B, 1C, 1E, 1F, 1I, 13J, 1M, or 1N), for example to optimize targeting to a target site or to allow cross-linking of target cell antigens.

[0242] Thus, in certain embodiments, an anti-CD20 / anti-CD3 bispecific antibody comprises two anti-CD20 binding moieties, e.g., two Fab molecules that target CD20. In one embodiment, the two Fab molecules that target CD20 are conventional Fab molecules. In one embodiment, the two Fab molecules that target CD20 comprise the same heavy and light chain amino acid sequences and have the same domain organization (i.e., conventional or crossover).

[0243] In an alternative embodiment, the anti-CD20 / anti-CD3 bispecific antibody comprises two anti-CD3 binding moieties, e.g., two Fab molecules targeting CD3. In one such embodiment, the two Fab molecules targeting CD3 are both crossover Fab molecules (Fab molecules in which the variable domains VH and VL or the constant domains CL and CH1 of the Fab heavy and light chains have been swapped / replaced by each other). In one such embodiment, the two Fab molecules targeting CD3 comprise the same heavy and light chain amino acid sequences and have the same domain organization (i.e., conventional or crossover).

[0244] In one embodiment, a third Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first or second subunit of the Fc domain.

[0245] In certain embodiments, the second and third Fab molecules are each fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain, and the first Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second Fab molecule. In a specific such embodiment, the antibody consists essentially of first, second and third Fab molecules, an Fc domain composed of the first and second subunits, and optionally one or more peptide linkers, and the first Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second Fab molecule, the second Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain, and the third Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second subunit of the Fc domain. Such structures are shown diagrammatically in Figures 1B and 1E (embodiments in which the third Fab molecule is a conventional Fab molecule, identical to the second Fab molecule) and in Figures 1I and 1M (embodiments in which the third Fab molecule is a crossover Fab molecule, preferably identical to the first Fab molecule). The second and third Fab molecules may be fused to an Fc domain directly or via a peptide linker. In a particular embodiment, the second and third Fab molecules are each fused to an Fc domain via an immunoglobulin hinge region. In a specific embodiment, the immunoglobulin hinge region is a human IgG1 hinge region, and in particular, the Fc domain is an IgG1 Fc domain. Optionally, the Fab light chain of the first Fab molecule and the Fab light chain of the second Fab molecule may further be fused to each other.

[0246] In another embodiment, the second and third Fab molecules are each fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain, and the first Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second Fab molecule. In a specific such embodiment, the antibody consists essentially of first, second and third Fab molecules, an Fc domain composed of the first and second subunits, and optionally one or more peptide linkers, wherein the first Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second Fab molecule, the second Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain, and the third Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second subunit of the Fc domain. Such structures are shown diagrammatically in Figures 1C and 1F (embodiments in which the third Fab molecule is a conventional Fab molecule and is identical to the second Fab molecule) and in Figures 1J and 1N (embodiments in which the third Fab molecule is a crossover Fab molecule and is identical to the first Fab molecule). The first and third Fab molecules may be fused to an Fc domain directly or via a peptide linker. In certain embodiments, the second and third Fab molecules are each fused to an Fc domain via an immunoglobulin hinge region. In a specific embodiment, the immunoglobulin hinge region is a human IgG1 hinge region, and in particular, the Fc domain is an IgG1 Fc domain. Optionally, the Fab light chain of the first Fab molecule and the Fab light chain of the second Fab molecule may further be fused to each other.

[0247] In the structure of an antibody in which the Fab molecule is fused at the C-terminus of the Fab heavy chain via an immunoglobulin hinge region to the N-terminus of each of the Fc domain subunits, the two Fab molecules, the hinge region, and the Fc domain essentially form an immunoglobulin molecule. In a particular embodiment, the immunoglobulin molecule is an immunoglobulin of the IgG class. In a more particular embodiment, the immunoglobulin is an immunoglobulin of the IgG1 subclass. In another embodiment, the immunoglobulin is an immunoglobulin of the IgG4 subclass. In a further particular embodiment, the immunoglobulin is a human immunoglobulin. In other embodiments, the immunoglobulin is a chimeric immunoglobulin or a humanized immunoglobulin.

[0248] In some of the antibodies, the Fab light chain of the first Fab molecule and the Fab light chain of the second Fab molecule are fused to each other, optionally via a peptide linker. Depending on the configuration of the first and second Fab molecules, the Fab light chain of the first Fab molecule can be fused at its C-terminus to the N-terminus of the Fab light chain of the second Fab molecule, or the Fab light chain of the second Fab molecule can be fused at its C-terminus to the N-terminus of the Fab light chain of the first Fab molecule. Fusion of the Fab light chains of the first and second Fab molecules further reduces mispairing of mismatched Fab heavy and light chains and also reduces the number of plasmids required for expression of some of the antibodies.

[0249] In certain embodiments, the antibody comprises a Fab light chain variable region of a first Fab molecule that shares a carboxy-terminal peptide bond with a Fab heavy chain constant region of a first Fab molecule (i.e., the first Fab molecule comprises a crossover Fab heavy chain, in which the heavy chain variable region is replaced by a light chain variable region), and then a Fab heavy chain constant region of the first Fab molecule that shares a carboxy-terminal peptide bond with an Fc domain subunit (VL (1) -CH1 (1) The Fab heavy chain of the second Fab molecule shares a carboxy-terminal peptide bond with an Fc domain subunit (VH (2) -CH1 (2)In some embodiments, the antibody comprises a polypeptide (VH -CH2-CH3(-CH4)) in which the Fab heavy chain variable region of the first Fab molecule shares a carboxy-terminal peptide bond with the Fab light chain constant region of the first Fab molecule. (1) -CL (1) ) and the Fab light chain polypeptide of the second Fab molecule (VL (2) -CL (2) In certain embodiments, the polypeptides are covalently linked, for example by disulfide bonds.

[0250] In certain embodiments, the antibody comprises a Fab heavy chain variable region of a first Fab molecule that shares a carboxy-terminal peptide bond with a Fab light chain constant region of a first Fab molecule (i.e., the first Fab molecule comprises a crossover Fab heavy chain, in which the heavy chain constant region is replaced by a light chain constant region), and a Fab light chain constant region of the first Fab molecule that shares a carboxy-terminal peptide bond with an Fc domain subunit (VH (1) -CL (1) The Fab heavy chain of the second Fab molecule shares a carboxy-terminal peptide bond with an Fc domain subunit (VH (2) -CH1 (2) In some embodiments, the antibody comprises a polypeptide (VL -CH2-CH3(-CH4)) in which the Fab light chain variable region of the first Fab molecule shares a carboxy-terminal peptide bond with the Fab heavy chain constant region of the first Fab molecule. (1) -CH1 (1) ) and the Fab light chain polypeptide of the second Fab molecule (VL (2) -CL (2) In certain embodiments, the polypeptides are covalently linked, for example by disulfide bonds.

[0251] In some embodiments, the antibody comprises a Fab light chain variable region of a first Fab molecule that shares a carboxy-terminal peptide bond with a Fab heavy chain constant region of a first Fab molecule (i.e., the first Fab molecule comprises a crossover Fab heavy chain, in which the heavy chain variable region is replaced by a light chain variable region), which in turn shares a carboxy-terminal peptide bond with a Fab heavy chain of a second Fab molecule, which in turn shares a carboxy-terminal peptide bond with an Fc domain subunit (VL (1) -CH1 (1) -VH (2) -CH1 (2) In other embodiments, the antibody comprises a Fab heavy chain of the second Fab molecule that shares a carboxy-terminal peptide bond with a Fab light chain variable region of the first Fab molecule, which in turn shares a carboxy-terminal peptide bond with a Fab heavy chain constant region of the first Fab molecule (i.e., the first Fab molecule comprises a crossover Fab heavy chain, in which the heavy chain variable region is replaced by a light chain variable region), which in turn shares a carboxy-terminal peptide bond with an Fc domain subunit (VH (2) -CH1 (2) -VL (1) -CH1 (1) -CH2-CH3(-CH4)) polypeptide.

[0252] In some of these embodiments, the antibody comprises a crossover Fab light chain polypeptide (VH) of a first Fab molecule in which the Fab heavy chain variable region of the first Fab molecule shares a carboxy-terminal peptide bond with the Fab light chain constant region of the first Fab molecule. (1) -CL (1) ) and the Fab light chain polypeptide of the second Fab molecule (VL (2) -CL (2)In other of these embodiments, where appropriate, the antibody further comprises a Fab heavy chain variable region of a first Fab molecule that shares a carboxy-terminal peptide bond with a Fab light chain constant region of the first Fab molecule, which in turn shares a carboxy-terminal peptide bond with a Fab light chain polypeptide of a second Fab molecule (VH (1) -CL (1) -VL (2) -CL (2) ) polypeptide, or the Fab light chain polypeptide of the second Fab molecule, shares a carboxy-terminal peptide bond with the Fab heavy chain variable region of the first Fab molecule, which in turn shares a carboxy-terminal peptide bond with the Fab light chain constant region of the first Fab molecule (VL (2) -CL (2) -VH (1) -CL (1) ) polypeptides.

[0253] The antibody according to these embodiments comprises (i) an Fc domain subunit polypeptide (CH2-CH3(-CH4)), or (ii) a polypeptide in which the Fab heavy chain of the third Fab molecule shares a carboxy-terminal peptide bond with the Fc domain subunit (VH (3) -CH1 (3) -CH2-CH3(-CH4)) and the Fab light chain polypeptide of the third Fab molecule (VL (3) -CL (3) In certain embodiments, the polypeptides are covalently linked, for example by a disulfide bond.

[0254] In some embodiments, the antibody comprises a Fab heavy chain variable region of a second Fab molecule that shares a carboxy-terminal peptide bond with a Fab light chain constant region of a first Fab molecule (i.e., the first Fab molecule comprises a crossover Fab heavy chain, in which the heavy chain constant region is replaced with a light chain constant region), which in turn shares a carboxy-terminal peptide bond with a Fab heavy chain of a second Fab molecule, which in turn shares a carboxy-terminal peptide bond with an Fc domain subunit (VH(1) -CL (1) -VH (2) -CH1 (2) In other embodiments, the antibody comprises a Fab heavy chain of the second Fab molecule that shares a carboxy-terminal peptide bond with a Fab heavy chain variable region of the first Fab molecule, which in turn shares a carboxy-terminal peptide bond with a Fab light chain constant region of the first Fab molecule (i.e., the first Fab molecule comprises a crossover Fab heavy chain, in which the heavy chain constant region is replaced by a light chain constant region), which in turn shares a carboxy-terminal peptide bond with an Fc domain subunit (VH (2) -CH1 (2) -VH (1) -CL (1) -CH2-CH3(-CH4)) polypeptide.

[0255] In some of these embodiments, the antibody comprises a crossover Fab light chain polypeptide (VL) of a first Fab molecule in which the Fab light chain variable region of the first Fab molecule shares a carboxy-terminal peptide bond with the Fab heavy chain constant region of the first Fab molecule. (1) -CH1 (1) ) and the Fab light chain polypeptide of the second Fab molecule (VL (2) -CL (2) In other of these embodiments, where appropriate, the antibody further comprises a Fab light chain variable region of a first Fab molecule that shares a carboxy-terminal peptide bond with a Fab heavy chain constant region of a first Fab molecule, which in turn shares a carboxy-terminal peptide bond with a Fab light chain polypeptide of a second Fab molecule (VL (1) -CH1 (1) -VL (2) -CL (2) ) polypeptide, or the Fab light chain polypeptide of the second Fab molecule, shares a carboxy-terminal peptide bond with the Fab heavy chain variable region of the first Fab molecule, which in turn shares a carboxy-terminal peptide bond with the Fab light chain constant region of the first Fab molecule (VL(2) -CL (2) -VH (1) -CL (1) ) polypeptides.

[0256] The antibody according to these embodiments comprises (i) an Fc domain subunit polypeptide (CH2-CH3(-CH4)), or (ii) a polypeptide in which the Fab heavy chain of the third Fab molecule shares a carboxy-terminal peptide bond with the Fc domain subunit (VH (3) -CH1 (3) -CH2-CH3(-CH4)) and the Fab light chain polypeptide of the third Fab molecule (VL (3) -CL (3) In certain embodiments, the polypeptides are covalently linked, for example by a disulfide bond.

[0257] In certain embodiments, the antibody comprises a polypeptide (VH) in which the Fab heavy chain of a first Fab molecule shares a carboxy-terminal peptide bond with a Fab light chain variable region of a second Fab molecule, which in turn shares a carboxy-terminal peptide bond with a Fab heavy chain constant region of a second Fab molecule (i.e., the second Fab molecule comprises a crossover Fab heavy chain, in which the heavy chain variable region is replaced by a light chain variable region). (1) -CH1 (1) -VL (2) -CH1 (2) In some embodiments, the antibody comprises a polypeptide in which the Fab heavy chain variable region of the second Fab molecule shares a carboxy-terminal peptide bond with the Fab light chain constant region of the second Fab molecule (VH (2) -CL (2) ) and the Fab light chain polypeptide of the first Fab molecule (VL (1) -CL (1) ).

[0258] In certain embodiments, the antibody comprises a Fab light chain variable region of a second Fab molecule that shares a carboxy-terminal peptide bond with a Fab heavy chain constant region of a second Fab molecule (i.e., the second Fab molecule comprises a crossover Fab heavy chain, in which the heavy chain variable region is replaced by a light chain variable region), and then the Fab heavy chain constant region of the second Fab molecule comprises a polypeptide (VL (2) -CH1 (2) -VH (1) -CH1 (1) In some embodiments, the antibody comprises a polypeptide in which the Fab heavy chain variable region of the second Fab molecule shares a carboxy-terminal peptide bond with the Fab light chain constant region of the second Fab molecule (VH (2) -CL (2) ) and the Fab light chain polypeptide of the first Fab molecule (VL (1) -CL (1) ).

[0259] In certain embodiments, the antibody comprises a Fab heavy chain variable region of a second Fab molecule that shares a carboxy-terminal peptide bond with a Fab light chain constant region of a second Fab molecule (i.e., the second Fab molecule comprises a crossover Fab heavy chain, in which the heavy chain constant region is replaced by a light chain constant region), which in turn comprises a polypeptide (VH (2) -CL (2) -VH (1) -CH1 (1) In some embodiments, the antibody comprises a polypeptide in which the Fab light chain variable region of the second Fab molecule shares a carboxy-terminal peptide bond with the Fab heavy chain constant region of the second Fab molecule (VL (2) -CH1 (2) ) and the Fab light chain polypeptide of the first Fab molecule (VL (1) -CL (1) ).

[0260] In certain embodiments, the antibody comprises a polypeptide (VH) in which the Fab heavy chain of a third Fab molecule shares a carboxy-terminal peptide bond with the Fab heavy chain of a first Fab molecule, which in turn shares a carboxy-terminal peptide bond with the Fab light chain variable region of a second Fab molecule, which in turn shares a carboxy-terminal peptide bond with the Fab heavy chain constant region of a second Fab molecule (i.e., the second Fab molecule comprises a crossover Fab heavy chain, in which the heavy chain variable region has been replaced by a light chain variable region). (3) -CH1 (3) -VH (1) -CH1 (1) -VL (2) -CH1 (2) In some embodiments, the antibody comprises a polypeptide in which the Fab heavy chain variable region of the second Fab molecule shares a carboxy-terminal peptide bond with the Fab light chain constant region of the second Fab molecule (VH (2) -CL (2) ) and the Fab light chain polypeptide of the first Fab molecule (VL (1) -CL (1) In some embodiments, the antibody further comprises a Fab light chain polypeptide (VL) of a third Fab molecule. (3) -CL (3) ).

[0261] In certain embodiments, the antibody comprises a polypeptide (VH) in which the Fab heavy chain of a third Fab molecule shares a carboxy-terminal peptide bond with the Fab heavy chain of a first Fab molecule, which in turn shares a carboxy-terminal peptide bond with the Fab heavy chain variable region of a second Fab molecule, which in turn shares a carboxy-terminal peptide bond with the Fab light chain constant region of a second Fab molecule (i.e., the second Fab molecule comprises a crossover Fab heavy chain, in which the heavy chain constant region has been replaced by a light chain constant region). (3) -CH1 (3) -VH (1) -CH1 (1) -VH (2) -CL (2)In some embodiments, the antibody comprises a polypeptide in which the Fab light chain variable region of the second Fab molecule shares a carboxy-terminal peptide bond with the Fab heavy chain constant region of the second Fab molecule (VL (2) -CH1 (2) ) and the Fab light chain polypeptide of the first Fab molecule (VL (1) -CL (1) In some embodiments, the antibody further comprises a Fab light chain polypeptide (VL) of a third Fab molecule. (3) -CL (3) ).

[0262] In certain embodiments, the antibody comprises a polypeptide (VL) in which the Fab light chain variable region of a second Fab molecule shares a carboxy-terminal peptide bond with the Fab heavy chain constant region of a second Fab molecule (i.e., the second Fab molecule comprises a crossover Fab heavy chain, in which the heavy chain variable region is replaced by a light chain variable region), which in turn shares a carboxy-terminal peptide bond with the Fab heavy chain of a first Fab molecule, which in turn shares a carboxy-terminal peptide bond with the Fab heavy chain of a third Fab molecule. (2) -CH1 (2) -VH (1) -CH1 (1) -VH (3) -CH1 (3) In some embodiments, the antibody comprises a polypeptide in which the Fab heavy chain variable region of the second Fab molecule shares a carboxy-terminal peptide bond with the Fab light chain constant region of the second Fab molecule (VH (2) -CL (2) ) and the Fab light chain polypeptide of the first Fab molecule (VL (1) -CL (1) In some embodiments, the antibody further comprises a Fab light chain polypeptide (VL) of a third Fab molecule. (3) -CL (3) ).

[0263] In certain embodiments, the antibody comprises a polypeptide (VH) in which the Fab heavy chain variable region of a second Fab molecule shares a carboxy-terminal peptide bond with the Fab light chain constant region of a second Fab molecule (i.e., the second Fab molecule comprises a crossover Fab heavy chain, in which the heavy chain constant region is replaced by a light chain constant region), which in turn shares a carboxy-terminal peptide bond with the Fab heavy chain of a first Fab molecule, which in turn shares a carboxy-terminal peptide bond with the Fab heavy chain of a third Fab molecule. (2) -CL (2) -VH (1) -CH1 (1) -VH (3) -CH1 (3) In some embodiments, the antibody comprises a polypeptide in which the Fab light chain variable region of the second Fab molecule shares a carboxy-terminal peptide bond with the Fab heavy chain constant region of the second Fab molecule (VL (2) -CH1 (2) ) and the Fab light chain polypeptide of the first Fab molecule (VL (1) -CL (1) In some embodiments, the antibody further comprises a Fab light chain polypeptide (VL) of a third Fab molecule. (3) -CL (3) ).

[0264] In certain embodiments, the antibody comprises a Fab heavy chain of a first Fab molecule that shares a carboxy-terminal peptide bond with a Fab light chain variable region of a second Fab molecule, which in turn shares a carboxy-terminal peptide bond with a Fab heavy chain constant region of a second Fab molecule (i.e., the second Fab molecule comprises a crossover Fab heavy chain in which the heavy chain variable region has been replaced by a light chain variable region), which in turn shares a carboxy-terminal peptide bond with a Fab light chain variable region of a third Fab molecule, which in turn shares a carboxy-terminal peptide bond with a Fab heavy chain constant region of a third Fab molecule (i.e., the third Fab molecule comprises a crossover Fab heavy chain in which the heavy chain variable region has been replaced by a light chain variable region) (VH (1) -CH1 (1) -VL (2) -CH1 (2) -VL (3) -CH1 (3) In some embodiments, the antibody comprises a polypeptide (VH) in which the Fab heavy chain variable region of the second Fab molecule shares a carboxy-terminal peptide bond with the Fab light chain constant region of the second Fab molecule. (2) -CL (2) ) and the Fab light chain polypeptide of the first Fab molecule (VL (1) -CL (1) In some embodiments, the antibody further comprises a polypeptide in which the Fab heavy chain variable region of the third Fab molecule shares a carboxy-terminal peptide bond with the Fab light chain constant region of the third Fab molecule (VH (3) -CL (3) ).

[0265] In certain embodiments, the antibody comprises a Fab heavy chain of a first Fab molecule that shares a carboxy-terminal peptide bond with a Fab heavy chain variable region of a second Fab molecule, which in turn shares a carboxy-terminal peptide bond with a Fab light chain constant region of a second Fab molecule (i.e., the second Fab molecule comprises a crossover Fab heavy chain, in which the heavy chain constant region has been replaced by a light chain constant region), which in turn shares a carboxy-terminal peptide bond with a Fab heavy chain variable region of a third Fab molecule, which in turn shares a carboxy-terminal peptide bond with a Fab light chain constant region of a third Fab molecule (i.e., the third Fab molecule comprises a crossover Fab heavy chain, in which the heavy chain constant region has been replaced by a light chain constant region) (VH (1) -CH1 (1) -VH (2) -CL (2) -VH (3) -CL (3) In some embodiments, the antibody comprises a polypeptide (VL) in which the Fab light chain variable region of the second Fab molecule shares a carboxy-terminal peptide bond with the Fab heavy chain constant region of the second Fab molecule. (2) -CH1 (2) ) and the Fab light chain polypeptide of the first Fab molecule (VL (1) -CL (1) In some embodiments, the antibody further comprises a polypeptide in which the Fab light chain variable region of the third Fab molecule shares a carboxy-terminal peptide bond with the Fab heavy chain constant region of the third Fab molecule (VL (3) -CH1 (3) ).

[0266] In certain embodiments, the antibody comprises a Fab light chain variable region of a third Fab molecule that shares a carboxy-terminal peptide bond with a Fab heavy chain constant region of a third Fab molecule (i.e., the third Fab molecule comprises a crossover Fab heavy chain, in which the heavy chain variable region is replaced by a light chain variable region), which in turn shares a carboxy-terminal peptide bond with a Fab light chain variable region of a second Fab molecule, which in turn shares a carboxy-terminal peptide bond with a Fab heavy chain constant region of a second Fab molecule (i.e., the second Fab molecule comprises a crossover Fab heavy chain, in which the heavy chain variable region is replaced by a light chain variable region), which in turn shares a carboxy-terminal peptide bond with the Fab heavy chain constant region of the first Fab molecule (VL (3) -CH1 (3) -VL (2) -CH1 (2) -VH (1) -CH1 (1) In some embodiments, the antibody comprises a polypeptide (VH) in which the Fab heavy chain variable region of the second Fab molecule shares a carboxy-terminal peptide bond with the Fab light chain constant region of the second Fab molecule. (2) -CL (2) ) and the Fab light chain polypeptide of the first Fab molecule (VL (1) -CL (1) In some embodiments, the antibody further comprises a polypeptide in which the Fab heavy chain variable region of the third Fab molecule shares a carboxy-terminal peptide bond with the Fab light chain constant region of the third Fab molecule (VH (3) -CL (3) ).

[0267] In certain embodiments, the antibody comprises a Fab heavy chain variable region of a third Fab molecule that shares a carboxy-terminal peptide bond with a Fab light chain constant region of a third Fab molecule (i.e., the third Fab molecule comprises a crossover Fab heavy chain and the heavy chain constant region has been replaced by a light chain constant region), which in turn shares a carboxy-terminal peptide bond with a Fab heavy chain variable region of a second Fab molecule, which in turn shares a carboxy-terminal peptide bond with a Fab light chain constant region of a second Fab molecule (i.e., the second Fab molecule comprises a crossover Fab heavy chain and the heavy chain constant region has been replaced by a light chain constant region), which in turn shares a carboxy-terminal peptide bond with the Fab heavy chain of the first Fab molecule (VH (3) -CL (3) -VH (2) -CL (2) -VH (1) -CH1 (1) In some embodiments, the antibody comprises a polypeptide (VL) in which the Fab light chain variable region of the second Fab molecule shares a carboxy-terminal peptide bond with the Fab heavy chain constant region of the second Fab molecule. (2) -CH1 (2) ) and the Fab light chain polypeptide of the first Fab molecule (VL (1) -CL (1) In some embodiments, the antibody further comprises a polypeptide in which the Fab light chain variable region of the third Fab molecule shares a carboxy-terminal peptide bond with the Fab heavy chain constant region of the third Fab molecule (VL (3) -CH1 (3) ).

[0268] According to any of the above embodiments, the components of the antibody (e.g., Fab molecules, Fc domains) may be fused directly or via a variety of linkers, particularly peptide linkers comprising one or more amino acids (typically about 2-20 amino acids) as described herein or known in the art. Suitable non-immunogenic peptide linkers include, for example, (G4S)n (SEQ ID NO: 21), (SG4) n (SEQ ID NO: 22), or G4 (SG4) n (SEQ ID NO:23) A peptide linker is included, where n is an integer generally from 1 to 10, typically from 2 to 4.

[0269] 2. Fc domain The anti-CD20 / anti-CD3 bispecific antibody may comprise an Fc domain consisting of a pair of polypeptide chains that comprise the heavy chain domain of an antibody molecule. For example, the Fc domain of an immunoglobulin G (IgG) molecule is a dimer, each subunit of which contains the CH2 and CH3 IgG heavy chain constant domains. The two subunits of the Fc domain are capable of stable binding to each other.

[0270] In one embodiment, the Fc domain is an IgG Fc domain. In a particular embodiment, the Fc domain is an IgG1 Fc domain. In another embodiment, the Fc domain is an IgG4 Fc domain. In a more particular embodiment, the Fc domain is an IgG4 Fc domain comprising an amino acid substitution at position S228 (Kabat numbering), in particular the amino acid substitution S228P. This amino acid substitution reduces Fab arm exchange in vivo of IgG4 antibodies (see Stubenrauch et al., Drug Metabolism and Disposition 38, 84-91 (2010)). In a further particular embodiment, the Fc domain is human.

[0271] (i) Fc domain modifications that promote heterodimerization Anti-CD20 / anti-CD3 bispecific antibodies may contain different components (e.g., antigen-binding domains) fused to one or the other of the two subunits of the Fc domain, which are therefore typically contained in two non-identical polypeptide chains. Recombinant co-expression of these polypeptides and subsequent dimerization results in several possible combinations of the two polypeptides. Therefore, to increase the yield and purity of such antibodies in recombinant production, it would be advantageous to include modifications in the Fc domain of the antibody that promote the association of the desired polypeptides.

[0272] Thus, in certain embodiments, the Fc domain comprises a modification that promotes the association of the first and second subunits of the Fc domain. The most extensive site of protein-protein interaction between the two subunits of the human IgG Fc domain is in the CH3 domain of the Fc domain. Thus, in one embodiment, the modification is in the CH3 domain of the Fc domain.

[0273] Several approaches for modifications in the CH3 domain of an Fc domain to enhance heterodimerization have been fully described, for example, in WO 96 / 27011, WO 98 / 050431, EP 1870459, WO 2007 / 110205, WO 2007 / 147901, WO 2009 / 089004, WO 2010 / 129304, WO 2011 / 90754, WO 2011 / 143545, WO 2012058768, WO 2013157954, WO 2013096291. Typically, in all such approaches, both the CH3 domain of the first subunit of the Fc domain and the CH3 domain of the second subunit of the Fc domain are engineered in a complementary manner such that each CH3 domain (or the heavy chain containing it) is directed not to homodimerize with itself but to heterodimerize with another CH3 domain that has been engineered in a complementary manner (so that the first CH3 domain and the second CH3 domain heterodimerize and no homodimers are formed between the two first CH3 domains or the two second CH3 domains). These different approaches for improving heavy chain heterodimerization are considered as different alternatives, in combination with heavy chain-light chain modifications (e.g., exchange / replacement of variable or constant regions in one Fab arm or introduction of substitutions of oppositely charged amino acids at the CH1 / CL interface) to reduce light chain mispairing and Bence-Jones type by-products.

[0274] In a specific embodiment, the modification that promotes association of the first and second subunits of the Fc domain is a so-called "knob-into-hole" modification, which comprises a "knob" modification on one of the two subunits of the Fc domain and a "hole" modification on the other of the two subunits of the Fc domain.

[0275] The "knob-into-hole" technique has been described, for example, in U.S. Patent Nos. 5,731,168; 7,695,936; Ridgway et al., Prot Eng. 9, 617-621 (1996), and Carter, J Immunol Meth. 248, 7-15 (2001). In general, this method introduces a protrusion ("knob") at the interface of a first polypeptide and a corresponding cavity ("hole") at the interface of a second polypeptide, such that the protrusion can be positioned within the cavity, promoting heterodimer formation and discouraging homodimer formation. The protrusion is constructed by replacing a small amino acid side chain from the interface of the first polypeptide with a larger side chain (e.g., tyrosine or tryptophan). A complementary cavity of the same or similar size as the protrusion is created at the interface of the second polypeptide by replacing the large amino acid side chain with a smaller amino acid side chain (e.g., alanine or threonine).

[0276] Thus, in one particular embodiment, in the CH3 domain of a first subunit of the Fc domain, an amino acid residue is replaced with an amino acid residue having a larger side chain volume, thereby generating a protrusion within the CH3 domain of the first subunit that can be positioned within a cavity within the CH3 domain of the second subunit, and in the CH3 domain of a second subunit of the Fc domain, an amino acid residue is replaced with an amino acid residue having a smaller side chain volume, thereby generating a cavity within the CH3 domain of the second subunit that can be positioned within the protrusion within the CH3 domain of the first subunit.

[0277] Preferably, said amino acid residue having a larger side chain volume is selected from the group consisting of arginine (R), phenylalanine (F), tyrosine (Y), and tryptophan (W).

[0278] Preferably, said amino acid residue having a smaller side chain volume is selected from the group consisting of alanine (A), serine (S), threonine (T), and valine (V).

[0279] The protrusions and cavities can be generated by altering the nucleic acid encoding the polypeptide, for example, by site-specific mutagenesis or peptide synthesis.

[0280] In a particular embodiment, in the CH3 domain of the first subunit of the Fc domain (the "knob" subunit), the threonine residue at position 366 is replaced with a tryptophan residue (T366W), and in the CH3 domain of the second subunit of the Fc domain (the "hole" subunit), the tyrosine residue at position 407 is replaced with a valine residue (Y407V). In one embodiment, the second subunit of the Fc domain furthermore replaces the threonine residue at position 366 with a serine residue (T366S) and the leucine residue at position 368 with an alanine residue (L368A) (EU numbering).

[0281] In a further embodiment, the first subunit of the Fc domain furthermore replaces the serine residue at position 354 with a cysteine ​​residue (S354C) or the glutamic acid residue at position 356 with a cysteine ​​residue (E356C), and the second subunit of the Fc domain furthermore replaces the tyrosine residue at position 349 with a cysteine ​​residue (Y349C) (EU numbering). The introduction of these two cysteine ​​residues allows the formation of a disulfide bridge between the two subunits of the Fc domain, further stabilizing the dimer (Carter, J Immunol Methods 248, 7-15 (2001)).

[0282] In one particular embodiment, the first subunit of the Fc domain comprises the amino acid substitutions S354C and T366W, and the second subunit of the Fc domain comprises the amino acid substitutions Y349C, T366S, L368A and Y407V (EU numbering).

[0283] In certain embodiments, the CD3 antigen binding moieties described herein are fused to the first subunit of the Fc domain (including the "knob" modification). Without wishing to be bound by theory, the fusion of the CD3 antigen binding moiety to the knob-containing subunit of the Fc domain (further) minimizes the generation of bispecific antibodies comprising two CD3 antigen binding moieties (steric clash of the two knob-containing polypeptides).

[0284] Other techniques of CH3 modification to strengthen heterodimers are contemplated as alternatives and are described, for example, in WO 96 / 27011, WO 98 / 050431, EP 1870459, WO 2007 / 110205, WO 2007 / 147901, WO 2009 / 089004, WO 2010 / 129304, WO 2011 / 90754, WO 2011 / 143545, WO 2012 / 058768, WO 2013 / 157954, WO 2013 / 096291.

[0285] In one embodiment, the heterodimerization approach described in EP1870459A1 is used instead. This approach is based on the introduction of oppositely charged amino acids at specific amino acid positions in the CH3 / CH3 domain interface between the two subunits of the Fc domain. One preferred embodiment is the amino acid mutations R409D and K370E in one of the two CH3 domains (of the Fc domain) and D399K and E357K in the other CH3 domain of the Fc domain (EU numbering).

[0286] In another embodiment the anti-CD20 / anti-CD3 bispecific antibody comprises the amino acid mutation T366W in the CH3 domain of the first subunit of the Fc domain and the amino acid mutations T366S, L368A and Y407V in the CH3 domain of the second subunit of the Fc domain, and further comprises the amino acid mutations R409D and K370E in the CH3 domain of the first subunit of the Fc domain and the amino acid mutations D399K and E357K in the CH3 domain of the second subunit of the Fc domain (EU numbering).

[0287] In another embodiment the anti-CD20 / anti-CD3 bispecific antibody comprises the amino acid mutations S354C and T366W in the CH3 domain of the first subunit of the Fc domain and the amino acid mutations Y349C, T366S, L368A and Y407V in the CH3 domain of the second subunit of the Fc domain, or the antibody comprises the amino acid mutations Y349C and T366W in the CH3 domain of the first subunit of the Fc domain and the amino acid mutations S354C, T366S, L368A and Y407V in the CH3 domain of the second subunit of the Fc domain and further the amino acid mutations R409D and K370E in the CH3 domain of the first subunit of the Fc domain and the amino acid mutations D399K and E357K in the CH3 domain of the second subunit of the Fc domain (all EU numbering).

[0288] In one embodiment, the heterodimerization method described in WO 2013 / 157953 is used instead. In one embodiment, the first CH3 domain comprises the amino acid mutation T366K and the second CH3 domain comprises the amino acid mutation L351D (EU numbering). In a further embodiment, the first CH3 domain comprises the further amino acid mutation L351K. In a further embodiment, the second CH3 domain further comprises an amino acid mutation selected from Y349E, Y349D and L368E, preferably L368E (EU numbering).

[0289] In one embodiment, the heterodimerization approach described in WO 2012 / 058768 is used instead. In one embodiment, the first CH3 domain comprises the amino acid mutations L351Y, Y407A and the second CH3 domain comprises the amino acid mutations T366A and K409F. In a further embodiment, the second CH3 domain comprises, for example, (a) T411N, T411R, T411Q, T411K, T411D, T411E or T411W at positions T411, D399, S400, F405, N390 or K392; (b) D399R, D399W, D399Y or D399K; (c) S400E, S409F, S411G, S411H, S411I or S411I; In a further embodiment, the first CH3 domain comprises the amino acid mutations L351Y and Y407A and the second CH3 domain comprises the amino acid mutations T366V and K409F. In a further embodiment, the first CH3 domain comprises the amino acid mutations Y407A and the second CH3 domain comprises the amino acid mutations T366A and K409F. In a further embodiment, the second CH3 domain further comprises the amino acid mutations K392E, T411E, D399R, and S400R (EU numbering).

[0290] In one embodiment, the heterodimerization approach described in WO 2011 / 143545 is alternatively used, e.g., with amino acid modifications at positions selected from the group consisting of 368 and 409 (EU numbering).

[0291] In one embodiment, the heterodimerization approach described in WO 2011 / 090762, which also uses the knobs-into-holes technology described above, is used instead. In one embodiment, the first CH3 domain comprises the amino acid mutation T366W and the second CH3 domain comprises the amino acid mutation Y407A. In one embodiment, the first CH3 domain comprises the amino acid mutation T366Y and the second CH3 domain comprises the amino acid mutation Y407T (EU numbering).

[0292] In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody or the Fc domain of the anti-CD20 / anti-CD3 bispecific antibody is of the IgG2 subclass and the heterodimerization approach described in WO 2010 / 129304 is used.

[0293] In an alternative embodiment, the modification that promotes the association of the first and second subunits of the Fc domain comprises a modification that mediates an electrostatic steering effect, e.g., as described in PCT Publication WO 2009 / 089004. Typically, this method involves the replacement of one or more amino acid residues at the interface of the two Fc domain subunits with a charged amino acid residue, such that homodimer formation is electrostatically unfavorable and heterodimerization is electrostatically favorable. In one such embodiment, the first CH3 domain comprises an amino acid substitution of K392 or N392 with a negatively charged amino acid (e.g., glutamic acid (E) or aspartic acid (D), preferably K392D or N392D) and the second CH3 domain comprises an amino acid substitution of D399, E356, D356 or E357 with a positively charged amino acid (e.g., lysine (K) or arginine (R), preferably D399K, E356K, D356K or E357K, more preferably D399K and E356K). In a further embodiment, the first CH3 domain further comprises an amino acid substitution of K409 or R409 with a negatively charged amino acid (e.g., glutamic acid (E) or aspartic acid (D), preferably K409D or R409D). In a further embodiment, the first CH3 domain additionally or alternatively comprises an amino acid substitution of K439 and / or K370 with a negatively charged amino acid (e.g., glutamic acid (E), or aspartic acid (D)) (EU numbering).

[0294] In yet further embodiments, the heterodimerization approach described in WO 2007 / 147901 is alternatively used. In one embodiment, the first CH3 domain comprises the amino acid mutations K253E, D282K, and K322D, and the second CH3 domain comprises the amino acid mutations D239K, E240K, and K292D (EU numbering).

[0295] In yet another embodiment, the heterodimerization approach described in WO 2007 / 110205 may be used.

[0296] In one embodiment, the first subunit of the Fc domain comprises the amino acid substitutions K392D and K409D, and the second subunit of the Fc domain comprises the amino acid substitutions D356K, and D399K (EU numbering).

[0297] (ii) Fc domain modifications that reduce Fc receptor binding and / or effector function The Fc domain confers desirable pharmacokinetic properties to antibodies such as anti-CD20 / anti-CD3 bispecifics, including a long serum half-life that contributes to good accumulation in target tissues, and a desirable tissue-blood distribution ratio. However, at the same time, the Fc domain may cause undesirable targeting of the antibody to cells expressing Fc receptors, rather than to the preferred antigen-bearing cells. Furthermore, the simultaneous activation of the Fc receptor signaling pathway may lead to cytokine release, which, in combination with other immunostimulatory properties that the antibody may possess and the long half-life of the antibody, may result in excessive activation of cytokine receptors, causing severe side effects when administered systemically.

[0298] Thus, in certain embodiments, the Fc domain of the anti-CD20 / anti-CD3 bispecific antibody exhibits reduced binding affinity to Fc receptors and / or reduced effector function when compared to the negative IgG1 Fc domain. In one such embodiment, the Fc domain (or a molecule comprising said Fc domain, e.g. an antibody) exhibits less than 50% of the binding affinity to Fc receptors, preferably less than 20%, more preferably less than 10%, most preferably less than 5%, compared to a natural IgG1 Fc domain (or a corresponding molecule comprising a natural IgG1 Fc domain), and / or exhibits less than 50% of the effector function, preferably less than 20%, more preferably less than 10%, most preferably less than 5%, compared to a natural IgG1 Fc domain (or a corresponding molecule comprising a natural IgG1 Fc domain). In one embodiment, the Fc domain (or a molecule comprising said Fc domain, e.g. an antibody) does not substantially bind to Fc receptors and / or does not induce effector function. In a particular embodiment, the Fc receptor is an Fcγ receptor. In some embodiments, the Fc receptor is a human Fc receptor. In some embodiments, the Fc receptor is an activating Fc receptor. In a specific embodiment, the Fc receptor is an activating human Fcγ receptor, more specifically human FcγRIIIa, FcγRI or FcγRIIa, most specifically human FcγRIIIa. In some embodiments, the effector function is one or more selected from the group of CDC, ADCC, ADCP and cytokine secretion. In one particular embodiment, the effector function is ADCC. In one embodiment, the Fc domain exhibits substantially similar binding affinity to neonatal Fc receptor (FcRn) compared to a native IgG1 Fc domain. Substantially similar binding affinity to FcRn is achieved when the Fc domain (or a molecule, e.g., an antibody, comprising said Fc domain) exhibits a binding affinity to FcRn that is greater than about 70%, particularly greater than about 80%, and even more particularly greater than about 90% of that of a native IgG1 Fc domain (or a corresponding molecule comprising a native IgG1 Fc domain).

[0299] In certain embodiments, the Fc domain is engineered to reduce the binding affinity and / or effector function to the Fc receptor compared to a non-engineered Fc domain. In certain embodiments, the Fc domain comprises one or more amino acid mutations that reduce the binding affinity and / or effector function of the Fc domain to the Fc receptor. Typically, the same one or more amino acid mutations are present in each of the two subunits of the Fc domain. In one embodiment, the amino acid mutations reduce the binding affinity of the Fc domain to the Fc receptor. In certain embodiments, the amino acid mutations reduce the binding affinity of the Fc domain to the Fc receptor by at least 2-fold, at least 5-fold, or at least 10-fold. In embodiments where there is more than one amino acid mutation that reduces the binding affinity of the Fc domain to the Fc receptor, a combination of these amino acid mutations can reduce the binding affinity of the Fc domain to the Fc receptor by at least 10-fold, at least 20-fold, or even at least 50-fold. In one embodiment, the molecule, e.g., antibody, comprising an engineered Fc domain exhibits less than 20%, particularly less than 10%, or even less than 5% of the binding affinity to an Fc receptor compared to the corresponding molecule comprising a non-engineered Fc domain. In a particular embodiment, the Fc receptor is an Fcγ receptor. In some embodiments, the Fc receptor is a human Fc receptor. In some embodiments, the Fc receptor is an activating Fc receptor. In a specific embodiment, the Fc receptor is an activating human Fcγ receptor, more particularly human FcγRIIIa, FcγRI or FcγRIIa, most particularly human FcγRIIIa. Preferably, the binding to each of these receptors is reduced. In some embodiments, the binding affinity to the complementary component, particularly the binding affinity to C1q, is also reduced. In one embodiment, the binding affinity to the neonatal Fc receptor (FcRn) is not reduced.Substantially similar binding to FcRn, i.e., preservation of the binding affinity of the Fc domain to said receptor, is achieved when the Fc domain (or a molecule comprising said Fc domain, e.g., an antibody) exhibits greater than about 70% of the binding affinity to FcRn of a non-engineered form of the Fc domain (or a corresponding molecule comprising said non-engineered form of the Fc domain). The Fc domain, or a molecule comprising said Fc domain (e.g., an antibody), may exhibit greater than about 80%, and in some cases greater than about 90%, of such affinity. In certain embodiments, the Fc domain is engineered to have reduced effector function compared to a non-engineered Fc domain. The reduced effector function may include, but is not limited to, one or more of reduced complement-dependent cytotoxicity (CDC), reduced antibody-dependent cell-mediated cytotoxicity (ADCC), reduced antibody-dependent cellular phagocytosis (ADCP), reduced cytokine secretion, reduced immune complex-mediated antigen uptake by antigen-presenting cells, reduced binding to NK cells, reduced binding to macrophages, reduced binding to monocytes, reduced binding to polymorphonuclear cells, reduced direct signaling to induce apoptosis, reduced cross-linking of target-bound antibodies, reduced dendritic cell maturation, or reduced T cell priming. In one embodiment, the reduced effector function is one or more selected from the group of reduced CDC, reduced ADCC, reduced ADCP, and reduced cytokine secretion. In one particular embodiment, the reduced effector function is reduced ADCC. In one embodiment, the reduced ADCC is less than 20% of the ADCC induced by a non-engineered Fc domain (or a corresponding molecule comprising a non-engineered Fc domain).

[0300] In one embodiment, the amino acid mutation that reduces the binding affinity and / or effector function of the Fc domain to the Fc receptor is an amino acid substitution. In one embodiment, the Fc domain comprises an amino acid substitution at a position selected from the group of E233, L234, L235, N297, P331, and P329 (EU numbering). In a more specific embodiment, the Fc domain comprises an amino acid substitution at a position selected from the group of L234, L235, and P329 (EU numbering). In some embodiments, the Fc domain comprises the amino acid substitutions L234A and L235A (EU numbering). In such an embodiment, the Fc domain is an IgG1 Fc domain, in particular a human IgG1 Fc domain. In one embodiment, the Fc domain comprises an amino acid substitution at position P329. In a more specific embodiment, the amino acid substitution is P329A or P329G, in particular P329G (EU numbering). In one embodiment, the Fc domain comprises an amino acid substitution at position P329 and a further amino acid substitution at a position selected from E233, L234, L235, N297, and P331 (EU numbering). In a more specific embodiment, the further amino acid substitution is E233P, L234A, L235A, L235E, N297A, N297D, or P331S. In a particular embodiment, the Fc domain comprises amino acid substitutions at positions P329, L234, and L235 (EU numbering). In a more specific embodiment, the Fc domain comprises the amino acid mutations L234A, L235A, and P329G ("P329G LALA"). In such an embodiment, the Fc domain is an IgG1 Fc domain, in particular a human IgG1 Fc domain. The "P329G LALA" combination of amino acid substitutions almost completely abolishes Fcγ receptor (and complement) binding of human IgG1 Fc domains, as described in WO 2012 / 130831, which is incorporated herein by reference in its entirety. WO 2012 / 130831 also describes methods for preparing such mutant Fc domains and determining their properties (such as Fc receptor binding or effector function).

[0301] IgG4 antibodies exhibit reduced binding affinity to Fc receptors and reduced effector functions compared to IgG1 antibodies. Thus, in some embodiments, the Fc domain is an IgG4 Fc domain, in particular a human IgG4 Fc domain. In one embodiment, the IgG4 Fc domain comprises an amino acid substitution at position S228, in particular the amino acid substitution S228P (EU numbering). To further reduce its binding affinity to Fc receptors and / or its effector functions, in one embodiment, the IgG4 Fc domain comprises an amino acid substitution at position L235, in particular the amino acid substitution L235E (EU numbering). In another embodiment, the IgG4 Fc domain comprises an amino acid substitution at position P329, in particular the amino acid substitution P329G (EU numbering). In a particular embodiment, the IgG4 Fc domain comprises amino acid substitutions at positions S228, L235, and P329, in particular the amino acid substitutions S228P, L235E, and P329G (EU numbering). Such IgG4 Fc domain variants and their Fcγ receptor binding properties are described in PCT Publication No. WO 2012 / 130831, which is incorporated herein by reference in its entirety.

[0302] In particular embodiments, the Fc domain exhibiting reduced binding affinity to an Fc receptor and / or reduced effector function compared to a native IgG1 Fc domain is a human IgG1 Fc domain comprising the amino acid substitutions L234A, L235A and optionally P329G, or a human IgG4 Fc domain comprising the amino acid substitutions S228P, L235E and optionally P329G (EU numbering).

[0303] In certain embodiments, N-glycosylation of the Fc domain is removed. In one such embodiment, the Fc domain comprises an amino acid substitution at position N297, in particular replacing asparagine with alanine (N297A) or aspartic acid (N297D) or glycine (N297G) (EU numbering).

[0304] In addition to the Fc domains described herein and in WO 2012 / 130831, Fc domains with reduced Fc receptor binding and / or effector function also include those with one or more substitutions of Fc domain residues 238, 265, 269, 270, 297, 327 and 329 (US Pat. No. 6,737,056) (EU numbering). Such Fc variants include Fc variants with substitutions at two or more of amino acid positions 265, 269, 270, 297 and 327, including so-called "DANA" Fc variants with substitutions of residues 265 and 297 to alanine (US Pat. No. 7,332,581).

[0305] Variant Fc domains can be prepared by amino acid deletion, substitution, insertion or modification using genetic or chemical methods well known in the art. Genetic methods may include site-directed mutagenesis of the encoding DNA sequence, PCR, gene synthesis, etc. The exact nucleotide changes can be verified, for example, by sequencing.

[0306] Binding to Fc receptors can be readily determined, for example, by ELISA or by surface plasmon resonance (SPR) using standard equipment such as the BIACORE® instrument (GE Healthcare), which Fc receptors can be obtained by recombinant expression. Alternatively, the binding affinity of an Fc domain, or a molecule comprising an Fc domain, to an Fc receptor may be assessed using a cell line known to express a particular Fc receptor, for example human NK cells expressing the FcγIIIa receptor.

[0307] The effector function of an Fc domain or a molecule (e.g., an antibody) that contains an Fc domain can be measured by methods known in the art. Suitable assays for measuring ADCC are described herein. Other examples of in vitro assays for evaluating the ADCC activity of a molecule of interest are described in U.S. Pat. No. 5,500,362; Hellstrom et al. Proc Natl Acad Sci USA. 83, 7059-7063 (1986) and Hellstrom et al., Proc Natl Acad Sci USA. 82, 1499-1502 (1985); U.S. Pat. No. 5,821,337; Bruggemann et al., J Exp Med 166, 1351-1361 (1987). Alternatively, non-radioactive assay methods may be utilized (e.g., ACTI for flow cytometry). TM See non-radioactive cytotoxicity assays (CellTechnology, Inc. Mountain View, CA); and CytoTox 96® non-radioactive cytotoxicity assay (Promega, Madison, WI). Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and natural killer (NK) cells. Alternatively, or additionally, ADCC activity of the molecule of interest may be assessed in, for example, an animal model (such as that disclosed in Clynes et al., Proc Natl Acad Sci USA 95, 652-656 (1998)).

[0308] In some embodiments, binding of the Fc domain to complement components, specifically binding to C1q, is reduced. Thus, in some embodiments where the Fc domain has been engineered to have reduced effector function, the reduced effector function includes reduced CDC. A C1q binding assay can be performed to determine whether an Fc domain, or a molecule comprising an Fc domain (e.g., an antibody), can bind C1q and thereby has CDC activity. See, for example, the C1q and C3c binding ELISAs in WO 2006 / 029879 and WO 2005 / 100402. To assess complement activation, a CDC assay can be performed (see, e.g., Gazzano-Santoro et al., J. Immunol. Methods 202, 163 (1996); Cragg et al., Blood 101:1045-1052 (2003); and Cragg and Glennie, Blood 103:2738-2743 (2004)).

[0309] 3. Substitutions, insertions, and deletions In certain examples, the anti-CD20 / anti-CD3 bispecific antibody variants of the pharmaceutical compositions provided herein have one or more amino acid substitutions. Sites of interest for substitutional mutagenesis include HVRs and FRs. Conservative substitutions are shown in Table 3 under the heading of "Preferred Substitutions". More substantial changes are provided in Table 3 under the heading of "Exemplary Substitutions" and as further described below with reference to amino acid side chain classes. Amino acid substitutions can be introduced into the antibody of interest and the products screened for the desired activity, e.g., retained / improved antigen binding, reduced immunogenicity, or improved ADCC or CDC. TIFF2024138235000003.tif168170

[0310] Amino acids can be classified according to common side chain properties. (1) Hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile; (2) Neutral hydrophilic: Cys, Ser, Thr, Asn, Gln; (3) Acidic: Asp, Glu; (4) Basic: His, Lys, Arg; (5) Residues that affect chain orientation: Gly, Pro; (6) Aromatic: Trp, Tyr, Phe.

[0311] Non-conservative substitutions involve exchanging a member of one of these classes for another class.

[0312] Certain substitutional variants involve substituting one or more hypervariable region residues of a parent antibody (e.g., a humanized or human antibody). Generally, the resulting variants selected for further study will have modifications (e.g., improvements) in certain biological properties (e.g., increased affinity, reduced immunogenicity) compared to the parent antibody and / or will substantially retain certain biological properties of the parent antibody. An exemplary substitutional variant is an affinity matured antibody, which may be conveniently generated using, for example, phage display-based affinity maturation techniques as described herein. Briefly, one or more HVR residues are mutated and the variant antibodies are displayed on phage and screened for a particular biological activity (e.g., binding affinity).

[0313] Modifications (e.g., substitutions) may be made, for example, in HVRs to improve antibody affinity. Such modifications may be made in "hot spots" within the HVRs, i.e., residues encoded by codons that undergo frequent mutation during the somatic maturation process (see, e.g., Chowdhury, Methods Mol. Biol. 207:179-196 (2008)), and / or in antigen-facing residues, and the resulting variants VH or VL are tested for binding affinity. Affinity maturation by construction of and reselection from secondary libraries is described, for example, in Hoogenboom et al., in Methods in Molecular Biology 178:1-37 (O'Brien et al., ed., Human Press, Totowa, NJ, (2001)). In some examples of affinity maturation, diversity is introduced into the variable genes selected for maturation by any of a variety of methods (e.g., error-prone PCR, chain shuffling, or oligonucleotide-directed mutagenesis). A secondary library is then generated. This library is then screened to identify any antibody variants with the desired affinity. Another method for introducing diversity involves HVR-directed approaches, where multiple HVR residues (e.g., 4-6 residues at a time) are randomized. HVR residues involved in antigen binding can be specifically identified, for example, using alanine scanning mutagenesis or modeling. CDR-H3 and CDR-L3 in particular are often targeted.

[0314] In certain examples, substitutions, insertions, or deletions may occur within one or more HVRs, so long as such modifications do not substantially reduce the ability of the antibody to bind to the antigen. For example, conservative modifications (e.g., conservative substitutions as described herein) that do not substantially reduce binding affinity may be made in the HVRs. Such modifications may, for example, be outside of the antigen contact residues within the HVRs. In certain examples of the variant VH and VL sequences described above, each HVR is either unmodified or has no more than one, two, or three amino acid substitutions.

[0315] A useful method for identifying antibody residues or regions that can be targeted for mutagenesis is called "alanine scanning mutagenesis" as described in Cunningham and Wells (1989) Science, 244:1081-1085. In this method, target residues or groups (e.g., charged residues such as Arg, Asp, His, Lys, and Glu) are identified and replaced with neutral or negatively charged amino acids (e.g., alanine or polyalanine) to determine whether the interaction of the antigen with the antibody is affected. Further substitutions may be introduced at amino acid positions that show functional sensitivity to the initial substitution. Alternatively, or in addition, a crystal structure of an antigen-antibody complex to identify contact points between the antibody and the antigen. Such contact and adjacent residues may be targeted or eliminated as candidates for substitution. Variants may be screened to determine whether they have the desired properties.

[0316] Amino acid sequence insertions include amino- and / or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing 100 or more residues, as well as intrasequence insertions of single or multiple amino acid residues. An example of a terminal insertion includes an antibody with an N-terminal methionyl residue. Other insertional variants of the antibody molecule include the fusion to the N- or C-terminus of the antibody to an enzyme (e.g., for ADEPT) or a polypeptide which increases the serum half-life of the antibody.

[0317] 4. Glycosylation In certain instances, the anti-CD20 / anti-CD3 bispecific antibodies comprised in the pharmaceutical compositions of the invention may be modified to increase or decrease the extent to which the antibodies are glycosylated. Addition or deletion of glycosylation sites to an anti-CD20 / anti-CD3 bispecific antibody may be conveniently accomplished by modifying the amino acid sequence to create or remove one or more glycosylation sites.

[0318] If the antibody comprises an Fc region, the carbohydrate attached thereto may be modified. Natural antibodies produced by mammalian cells typically comprise a branched, biantennary oligosaccharide that is generally attached to Asn297 of the CH2 domain of the Fc region by an N-linkage. See, for example, Wright et al., TIBTECH 15:26-32 (1997). The oligosaccharide may comprise a variety of carbohydrates, such as mannose, N-acetylglucosamine (GlcNAc), galactose, and sialic acid, as well as fucose attached to the GlcNAc "stem" of the biantennary oligosaccharide structure. In some instances, modifications of the oligosaccharides in the antibody may be made to generate antibody variants with improved specific properties.

[0319] In one example, an anti-CD20 / anti-CD3 bispecific antibody variant has a carbohydrate structure that lacks fucose attached (directly or indirectly) to the Fc region. For example, the amount of fucose in such an antibody can be 1% to 80%, 1% to 65%, 5% to 65%, or 20% to 40%. The amount of fucose is determined by calculating the average amount of fucose in the glycan at Asn297 relative to the sum of all glycan structures attached to Asn297 (e.g., complex structures, hybrid structures, and high mannose structures) measured by MALDI-TOF mass spectrometry, e.g., as described in WO 2008 / 077546. Asn297 refers to an asparagine residue located at about position 297 of the Fc region (EU numbering of Fc region residues); however, Asn297 may also be located upstream or downstream of position 297, i.e., about ±3 amino acids between positions 294 and 300, due to minor sequence variations in the antibody. Such fucosylation variants may have improved ADCC function. See, for example, US Patent Application Publication No. 2003 / 0157108 (Presta, L.); US Patent Application Publication No. 2004 / 0093621 (Kyowa Hakko Kogyo Co., Ltd). Examples of publications relating to "defucosylated" or "fucose-deficient" antibody variants include: US Patent Application Publication No. 2003 / 0157108; International Publication No. 2000 / 61739; International Publication No. 2001 / 29246; US Patent Application Publication No. 2003 / 0115614; International Publication No. 2002 / 0164328; International Publication No. 2004 / 0093621; International Publication No. 2004 / 0093621; International Publication No. 2004 / 0093622; International Publication No. 2004 / 0093623; International Publication No. 2004 / 0093624; International Publication No. 2004 / 0093621; International Publication No. 2004 / 009362 ... 132140; 2004 / 0110704; 2004 / 0110282; 2004 / 0109865; WO 2003 / 085119; 2003 / 084570; 2005 / 035586; 2005 / 035778; 2005 / 053742; 2002 / 031140; Okazaki et al. J. Mol. Biol. 336:1239-1249(2004); Yamane-Ohnuki et al. Biotech. Bioeng. 87: 614(2004).Examples of cell lines capable of producing defucosylated antibodies include Lec13 CHO cells, which are deficient in protein fucosylation (Ripka et al., Arch. Biochem. Biophys. 249:533-545 (1986); US Patent Publication No. 2003 / 0157108, Presta, L; and WO 2004 / 056312, Adams et al. especially Example 11), and knockout cell lines, such as alpha-1,6-fucosyltransferase gene, FUT8, knockout CHO cells (see, e.g., Yamane-Ohnuki et al., Biotech. Bioeng. 87: 614 (2004); Kanda, Y. et al., Biotechnol. Bioeng., 94(4):680-688 (2006); and WO 2003 / 085107).

[0320] In view of the above, in some embodiments, the pharmaceutical composition of the present invention comprises an anti-CD20 / anti-CD3 bispecific antibody variant comprising an aglycosylation site mutation. In some examples, the aglycosylation site mutation reduces the effector function of the antibody. In some examples, the aglycosylation site mutation is a substitution mutation. In some examples, the antibody comprises a substitution mutation in the Fc region that reduces the effector function. In some examples, the substitution mutation is at amino acid residues N297, L234, L235, and / or D265 (EU numbering). In some examples, the substitution mutation is selected from the group consisting of N297G, N297A, L234A, L235A, D265A, and P329G. In some examples, the substitution mutation is at amino acid residue N297. In a preferred example, the substitution mutation is N297A.

[0321] Anti-CD20 / anti-CD3 bispecific antibody variants have bisected oligosaccharides, e.g., biantennary oligosaccharides attached to the Fc region of the antibody, bisected by GlcNAc. Such antibody variants may have reduced fucosylation and / or improved ADCC function. Examples of such antibody variants are described, for example, in WO 2003 / 011878; U.S. Pat. No. 6,602,684; and U.S. Pat. App. Pub. No. 2005 / 0123546. Other antibody variants include at least one galactose residue in the oligosaccharide attached to the Fc region. Such antibody variants may have improved CDC function. Examples of such antibody variants are described, for example, in WO 1997 / 30087; WO 1998 / 58964; and WO 1999 / 22764.

[0322] 5. Antibody derivatives In certain examples, the anti-CD20 / anti-CD3 bispecific antibodies of the pharmaceutical compositions provided herein are further modified to contain additional non-proteinaceous moieties that are known in the art and readily available. Suitable sites for derivatization of antibodies include, but are not limited to, water-soluble polymers. Non-limiting examples of water-soluble polymers include, but are not limited to, polyethylene glycol (PEG), ethylene glycol / propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone, poly-1,3-dioxolane, poly-1,3,6-trioxane, ethylene / maleic anhydride copolymers, polyamino acids (either homopolymers or random copolymers), and dextran or poly(n-vinylpyrrolidone) polyethylene glycol, propropylene glycol homopolymer, polypropylene oxide / ethylene oxide copolymer, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof. Polyethylene glycol propionaldehyde may be advantageous during manufacturing due to its stability in water. The polymers may be of any molecular weight, and may be branched or unbranched. The number of polymers attached to the antibody may vary, and when multiple polymers are attached, they may be the same or different molecules. In general, the number and / or type of polymers used for derivatization may be determined based on considerations including, but not limited to, the particular property or function of the antibody to be improved, whether the antibody derivative will be used therapeutically under defined conditions, etc.

[0323] In another example, a conjugate of an antibody and a non-proteinaceous moiety can be selectively heated by exposure to radiation. In one example, the non-proteinaceous moiety is a carbon nanotube (Kam et al., Proc. Natl. Acad. Sci. USA 102: 11600-11605 (2005)). The radiation can be of any wavelength, including but not limited to wavelengths that are not harmful to normal cells, but heat the antibody non-protective moiety to a temperature that kills cells proximal to the antibody non-protective moiety.

[0324] C. Recombinant Production Methods The anti-CD20 / anti-CD3 bispecific antibodies (e.g., anti-CD20 / anti-CD3 TCB, e.g., glofitamab) of the pharmaceutical compositions of the invention can be produced using recombinant methods and compositions as described, for example, in U.S. Pat. No. 4,816,567, which is incorporated herein by reference in its entirety.

[0325] For recombinant production of an anti-CD20 / anti-CD3 bispecific antibody, nucleic acid encoding the antibody is isolated and inserted into one or more vectors for further cloning and / or expression in a host cell. Such nucleic acid can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes capable of binding specifically to genes encoding the heavy and light chains of the antibody).

[0326] Suitable host cells for cloning or expression of antibody-encoding vectors include prokaryotic or eukaryotic cells as described herein. For example, antibodies may be produced in bacteria, particularly if glycosylation and Fc effector functions are not required. For expression of antibody fragments and polypeptides in bacteria, see, e.g., U.S. Patent Nos. 5,648,237, 5,789,199, and 5,840,523. (See also Charlton, Methods in Molecular Biology, Vol. 248 (BKC Lo, ed., Humana Press, Totowa, NJ, 2003), pp. 245-254, which describes expression of antibody fragments in E. coli.) After expression, the antibodies of the invention may be isolated in a soluble fraction from the bacterial cell paste or may be further purified.

[0327] In addition to prokaryotes, eukaryotic organisms such as filamentous fungi and yeast are suitable as cloning or expression hosts for antibody-encoding vectors, including bacterial and yeast strains that have been "humanized" in their glycosylation pathways to result in the production of antibodies with partially or fully human glycosylation patterns. See Gerngross, Nat. Biotech. 22:1409-1414 (2004) and Li et al., Nat. Biotech. 24:210-215 (2006).

[0328] Suitable host cells for expressing glycosylated antibodies are also derived from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant cells and insect cells. Numerous baculovirus strains have been identified that can be used in conjunction with insect cells, particularly for transfection of Spodoptera frugiperda cells.

[0329] Plant cell cultures can also be used as hosts, see, e.g., U.S. Patent Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (which describe the PLANTIBODIES™ technology for producing antibodies in transgenic plants).

[0330] Vertebrate cells may also be used as hosts. For example, mammalian cell lines that are adapted to grow in suspension may be useful. Other examples of useful mammalian host cell lines include monkey kidney CV1 line transformed with SV40 (COS-7); human embryonic kidney lines (e.g., 293 cells or 293 cells described in Graham et al., J. Gen Virol. 36:59 (1977)); baby hamster kidney cells (BHK); mouse Sertoli cells (e.g., TM4 cells described in Mather, Biol. Reprod. 23:243-251 (1980)); monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK); buffalo rat hepatocytes (BRL 3A); human lung cells (W138); human hepatocytes (HepG2); mouse mammary tumor cells (MMT060562); TRI cells, e.g., as described in Mather et al., Annals NY Acad. Sci. 383:44-68 (1982); MRC Other useful mammalian host cell lines include (DHFR 5 cells; and FS4 cells. - Chinese hamster ovary (CHO) cells, including CHO cells (Urlaub et al. Proc. Natl. Acad. Sci. USA 77:4216 (1980); and myeloma cell lines such as Y0, NS0 and Sp2 / 0. For a review of certain mammalian host cell lines suitable for antibody production, see, e.g., Yazaki and Wu, Methods in Molecular Biology, Vol. 248 (BKC Lo, ed., Humana Press, Totowa, NJ), pp. 255-268 (2003).

[0331] V. METHODS OF TREATMENT AND USES Pharmaceutical compositions comprising the anti-CD20 / anti-CD3 bispecific antibodies described herein can be formulated for use as medicaments to treat a variety of diseases and disorders. Accordingly, the invention features a method comprising intravenous administration of a pharmaceutical composition to a subject in need thereof, e.g., a subject having a disease or disorder, such as cancer. The pharmaceutical compositions of the invention can be used to treat or delay the progression of a cell proliferative disorder in a subject in need thereof (e.g., a human subject in need thereof), or to enhance immune function in a subject having a cell proliferative disorder (e.g., cancer).

[0332] In one aspect, the invention provides a pharmaceutical composition as described herein for use in treating or delaying the progression of a cell proliferative disorder. In one aspect, the invention provides a use of a pharmaceutical composition as described herein in the manufacture of a medicament for treating or delaying the progression of a cell proliferative disorder. In one aspect, the invention provides a method of treating or delaying the progression of a cell proliferative disorder in a subject in need thereof comprising administering to the subject a pharmaceutical composition as described herein.

[0333] In one embodiment, the cell proliferative disorder is a cancer that is non-Hodgkin's lymphoma (NHL). In some embodiments, the NHL is selected from the group consisting of non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), B-cell lymphoma, splenic diffuse red pulp small B-cell lymphoma, B-cell lymphoma with features intermediate between diffuse large B-cell lymphoma and Burkitt's lymphoma, Burkitt-like lymphoma with 11q aberration, B-cell lymphoma with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin's lymphoma, germinal center B-cell-like (GCB) diffuse large B-cell lymphoma (DLBCL), activated B-cell-like (ABC) DLBCL, primary cutaneous follicle center lymphoma, T-cell / histiocytic lymphoma, and / or cutaneous follicular center lymphoma. Large B-cell lymphoma, primary DLBCL of the central nervous system, primary cutaneous DLBCL (crural type), Epstein-Barr virus (EBV) positive DLBCL in elderly people, DLBCL associated with chronic inflammation, primary mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, ALK positive large B-cell lymphoma, large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease, B-cell leukemia, breast cancer, colorectal cancer, non-small cell lung cancer, multiple myeloma, kidney cancer, prostate cancer, liver cancer, head and neck cancer, melanoma, ovarian cancer, mesothelioma, glioblastoma, follicular lymphoma (FL), in situ follicular neoplasm, mantle cell lymphoma (MCL), in The tumor is selected from the group consisting of mantle cell neoplasm in situ, acute myeloid leukemia (AML), marginal zone lymphoma (MZL), small lymphocytic leukemia (SLL), lymphoplasmacytic lymphoma (LL), central nervous system lymphoma (CNSL), Burkitt's lymphoma (BL), B-cell lymphocytic leukemia, splenic marginal zone lymphoma, hairy cell leukemia, splenic lymphoma / leukemia, hairy cell leukemia cytoma, alpha heavy chain disease, gamma heavy chain disease, mu heavy chain disease, plasma cell myeloma, isolated bone plasmacytoma, extraosseous plasmacytoma, extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), nodal marginal zone lymphoma, childhood nodal marginal zone lymphoma, childhood follicular lymphoma, lymphomatoid granulomatosis, plasmablastic lymphoma, primary pleural effusion lymphoma.In certain embodiments, the cancer is germinal center B cell-like (GCB) DLBCL, activated B cell-like (ABC) DLBCL, follicular lymphoma (FL), mantle cell lymphoma (MCL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), marginal zone lymphoma (MZL), small lymphocytic leukemia (SLL), lymphoplasmacytic lymphoma (LL), Waldenstrom's macroglobulinemia (WM), central nervous system lymphoma (CNSL), or Burkitt's lymphoma (BL).

[0334] In some embodiments, the cancer is selected from the group consisting of breast cancer, colorectal cancer, non-small cell lung cancer (NSCLC), multiple myeloma, renal cancer, prostate cancer, liver cancer, head and neck cancer, melanoma, ovarian cancer, mesothelioma, and glioblastoma.

[0335] The anti-CD20 / anti-CD3 bispecific antibody may be formulated for administration to a subject at a dose of 0.5 mg, 2.5 mg, 10 mg, or 30 mg.

[0336] For all of the methods and pharmaceutical formulations described herein, the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, e.g., glofitamab) will be formulated, dosed, and administered in a manner consistent with good medical practice. Factors to consider in this regard include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the administration schedule, and other factors known to medical practitioners. The anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, e.g., glofitamab) does not have to be formulated with one or more agents currently used to prevent or treat the disease in question, but optionally is. The effective amount of such other agents will depend on the amount of anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, e.g., glofitamab) present in the formulation, the type of disorder or treatment, and other factors discussed above. The anti-CD20 / anti-CD3 bispecific antibody (eg, an anti-CD20 / anti-CD3 TCB such as glofitamab) may be suitably administered to the patient over a course of treatment.

[0337] V. Manufactured products In another aspect of the invention, an article of manufacture is provided that contains materials useful for the treatment, prevention, and / or diagnosis of the disorders described above. The article of manufacture includes a container and a label or package insert on or associated with the container. Suitable containers include, by way of example, bottles, vials, syringes, IV solution bags, and the like. The container may be formed from a variety of materials, such as glass or plastic. The container holds a pharmaceutical composition used alone or in combination with another composition effective for treating, preventing, and / or diagnosing a condition, and may have a sterile access port (e.g., the container may be an intravenous solution bag or a vial with a stopper pierceable by a hypodermic needle). At least one active agent in the composition is an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab) as described herein. The label or package insert indicates that the composition is used to treat a selected condition (e.g., cancer) and further includes information related to at least one of the dosing regimens described herein.

[0338] The pharmaceutical composition may be supplied in a container having a volume of 1 ml to 100 ml (e.g., 1 ml to 5 ml, 5 ml to 10 ml, 10 ml to 15 ml, 15 ml to 20 ml, 20 ml to 25 ml, 25 ml to 30 ml, 30 ml to 40 ml, 40 ml to 50 ml, 50 ml to 60 ml, 60 ml to 70 ml, 70 ml to 80 ml, 80 ml to 90 ml, or 90 ml to 100 ml, e.g., about 5 ml, about 10 ml, about 15 ml, about 20 ml, about 25 ml, about 30 ml, about 40 ml, about 50 ml, about 60 ml, about 70 ml, about 80 ml, about 90 ml, or about 100 ml).

[0339] In some embodiments, the container is a stainless steel container, such as a tank, mini-tank, canister, can, or nickel steel alloy container (e.g., HASTELLOY®). In some examples, the pharmaceutical composition in such a container is a drug substance (DS), which can be further diluted prior to use, e.g., into a drug product (DP) (e.g., final vial configuration). Alternatively, the pharmaceutical composition in the container is a DP. In some embodiments, the DP is in a container such as an IV bag or a syringe (e.g., for delivery via a syringe pump).

[0340] In some embodiments, the article of manufacture comprises a vial having a volume of about 1 ml or more, e.g., about 1 ml, about 2 ml, about 3 ml, about 4 ml, about 5 ml, about 6 ml, about 7 ml, about 8 ml, about 9 ml, about 10 ml, about 11 ml, about 12 ml, about 13 ml, about 14 ml, about 15 ml, about 16 ml, about 17 ml, about 18 ml, about 19 ml, about 20 ml, about 25 ml, about 30 ml, about 35 ml, about 40 ml, about 50 ml, or more. In some embodiments, the container is a vial having a volume of about 10 ml. In some embodiments, the vial is disposable. In some embodiments, the vial contains about 1 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg, about 20 mg, or more of an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab). In some embodiments, the container closure system comprises one or more, or all of a glass vial, a stopper, and a cap.

[0341] Additionally, the article of manufacture may include (a) a first container having therein a composition comprising an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., glofitamab) described herein, and (b) a second container having therein a composition comprising an additional cytotoxic agent or other therapeutic agent. Alternatively, or additionally, the article of manufacture may further comprise a second (or third) container comprising a pharma- ceutically acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate buffered saline, Ringer's solution, and dextrose solution. The article of manufacture may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.

[0342] Further aspects of the present invention relate to the invention described herein.

[0343] Implementation Some embodiments of the technology described herein can be defined according to any of the following numbered embodiments.

[0344] I. A liquid pharmaceutical composition comprising: At a pH in the range of about 5.0 to about 6.0, about 1 to 25 mg / ml of anti-CD20 / anti-CD3 bispecific antibody; about 10 to 50 mM buffer; about ≧200 mM tonicity agent; about 0-15 mM methionine; and about ≥ 0.2 mg / ml surfactant; The anti-CD20 / anti-CD3 bispecific antibody comprises: a) at least one antigen-binding domain that specifically binds to CD20, (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:1; (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:2; and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 3 and a heavy chain variable region comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5; and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:6 and a light chain variable region comprising At least one antigen-binding domain that specifically binds to CD20 comprising: b) at least one antigen-binding domain that specifically binds to CD3, (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:9; (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 10; and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 11 and a heavy chain variable region comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 13; and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 14 and a light chain variable region comprising and at least one antigen-binding domain that specifically binds to CD3 comprising: 13. A liquid pharmaceutical composition comprising:

[0345] II. The liquid pharmaceutical composition of embodiment I, wherein the concentration of the anti-CD20 / anti-CD3 bispecific antibody ranges from about 1 to 5 mg / ml.

[0346] III. The liquid pharmaceutical composition of embodiment I or II, wherein the concentration of the anti-CD20 / anti-CD3 bispecific antibody is in the range of about 0.9-1.1 mg / ml.

[0347] IV. The liquid pharmaceutical composition of any one of embodiments I to III, wherein the concentration of the anti-CD20 / anti-CD3 bispecific antibody is about 1 mg / ml.

[0348] V. Anti-CD20 / anti-CD3 bispecific antibodies a) at least one antigen-binding domain that specifically binds to CD20, comprising a heavy chain variable region sequence of SEQ ID NO: 7 and a light chain variable region sequence of SEQ ID NO: 8; b) at least one antigen-binding domain that specifically binds to CD3, comprising a heavy chain variable region sequence of SEQ ID NO: 15 and a light chain variable region sequence of SEQ ID NO: 16; The liquid pharmaceutical composition of any one of embodiments I to IV, comprising:

[0349] VI. Anti-CD20 / anti-CD3 bispecific antibodies a) a first Fab molecule that specifically binds to CD3, in particular CD3 epsilon, in which the variable domains VL and VH of the Fab light and heavy chains are exchanged with each other; b) a second and a third Fab molecule which specifically bind to CD20, in which in the constant domain CL of the second and third Fab molecules the amino acid at position 124 is substituted by lysine (K) (Kabat numbering) and the amino acid at position 123 is substituted by lysine (K) or arginine (R), in particular by arginine (R) (Kabat numbering), and in the constant domain CH1 of the second and third Fab molecules the amino acid at position 147 is substituted by glutamic acid (E) (EU numbering) and the amino acid at position 213 is substituted by glutamic acid (E) (EU numbering); c) an Fc domain composed of a first subunit and a second subunit capable of stable association; The liquid pharmaceutical composition of any one of embodiments I to V, comprising:

[0350] VII. The liquid pharmaceutical composition of any one of embodiments I to VI, wherein the anti-CD20 / anti-CD3 bispecific antibody is glofitamab.

[0351] VIII. The liquid pharmaceutical composition of any one of embodiments I to VII, wherein the buffer is a histidine buffer, optionally a histidine HCl buffer.

[0352] IX. The liquid pharmaceutical composition of any one of embodiments I to VIII, wherein the concentration of the buffer is about 15 to 25 mM.

[0353] X. The liquid pharmaceutical composition of any one of embodiments I to IX, wherein the concentration of the buffer is about 20 mM.

[0354] XI. The liquid pharmaceutical composition of any one of embodiments I to X, wherein the buffer provides a pH of about 5.2 to about 5.8.

[0355] XII. The liquid pharmaceutical composition of any one of embodiments I to XI, wherein the tonicity agent is selected from the group of salts, sugars, and amino acids.

[0356] XIII. The liquid pharmaceutical composition of embodiment XII, wherein the tonicity agent is either sucrose or sodium chloride.

[0357] XIV. The liquid pharmaceutical composition of embodiment XIII, wherein the tonicity agent is sucrose at a concentration of about 200 mM or greater.

[0358] XV. The liquid pharmaceutical composition of embodiment XIII or XIV, wherein the tonicity agent is sucrose at a concentration of about 200 mM to 280 mM.

[0359] XVI. The liquid pharmaceutical composition of any one of embodiments XIII to XV, wherein the tonicity agent is sucrose at a concentration of about 240 mM.

[0360] XVII. The liquid pharmaceutical composition of any one of embodiments I to XVI, wherein the concentration of methionine is about 5-15 mM.

[0361] XVIII. The liquid pharmaceutical composition of embodiment XVII, wherein the concentration of methionine is about 10 mM.

[0362] XIX. The liquid pharmaceutical composition of any one of embodiments I to XVIII, wherein the concentration of the surfactant is about 0.2-0.8 mg / ml.

[0363] XX. The liquid pharmaceutical composition of any one of embodiments I to XIX, wherein the surfactant is polysorbate 20 or poloxamer 188.

[0364] XXI. The liquid pharmaceutical composition of embodiment XX, wherein the surfactant is polysorbate 20 at a concentration of 0.2-0.8 mg / ml.

[0365] XXII. The liquid pharmaceutical composition of embodiment XXI, wherein the surfactant is polysorbate 20 at a concentration of about 0.5 mg / ml.

[0366] XXIII. Liquid pharmaceutical compositions comprising: At a pH of about 5 to about 6, about 1 to 5 mg / ml of anti-CD20 / anti-CD3 bispecific antibody; with about 15-25mM histidine buffer; with approximately 200-280 mM sucrose; with approximately 0-15 mM methionine; with approximately 0.2-0.8mg / ml PS20; The liquid pharmaceutical composition according to any one of embodiments I to XXII, comprising:

[0367] XXIV. Liquid pharmaceutical compositions comprising: At a pH of about 5.5, with glofitamab at approximately 1mg / ml; with about 20 mM histidine buffer; with approximately 240 mM sucrose; with approximately 10 mM methionine; with approximately 0.5mg / ml PS20; XXIII. The liquid pharmaceutical composition of any one of embodiments I to XXIII, comprising:

[0368] XXV. Use of a liquid pharmaceutical composition of any one of embodiments I to XXIV for the preparation of a medicament useful for treating a cell proliferative disorder.

[0369] XXVI. A pharmaceutical composition according to any one of embodiments I to XXIV for use in treating or delaying the progression of a cell proliferative disorder in a subject in need thereof.

[0370] XXVII. A method of treating or delaying the progression of a cell proliferative disorder in a subject in need thereof, comprising administering to the subject a pharmaceutical composition of any one of embodiments I to XXIV.

[0371] XXVIII. The use, liquid pharmaceutical composition for use, or method of any one of embodiments XXV to XXVII, wherein the cell proliferative disorder is cancer.

[0372] XXIX. The invention described above. EXAMPLES

[0373] The following are examples of methods and compositions of the present invention. Given the general description provided above, it will be understood that various other embodiments may be practiced.

[0374] Example 1: In silico analysis of glofitamab RO7082859 / glofitamab is a T-cell bispecific humanized monoclonal antibody (TCB) that binds to human CD20 on tumor cells and to the human CD3 epsilon subunit (CD3ε) of the T-cell receptor complex (TCR) on T cells. It is composed of two different heavy chains and two different light chains. Point mutations in the CH3 domain ("knobs-into-holes") facilitate the assembly of the two different heavy chains. Exchange of the VH and VL domains in the CD3-binding Fab ("CrossMab approach") and point mutations in the CH and CL domains in the CD20-binding Fab ("charge variants") facilitate the correct assembly of the two different light chains and the corresponding heavy chains. The "knobs-into-holes" mutations consist of amino exchanges Y349C, T366S, L368A and Y407V in the heavy chain HC1 and amino exchanges S354C and T366W in the heavy chain HC2 (Kabat EU index numbering). The "charge variant" mutations consist of the amino acid exchanges E123R and Q124K (Kabat numbering) in the light chain LC2 and K147E and K213E (Kabat EU index numbering) in the heavy chain HC1 and HC2.

[0375] Binding to human CD20 occurs in a bivalent binding mode with high affinity, whereas binding to CD3ε is monovalent and low affinity. RO7082859 is a human IgG1 with a modification in the Fc region (the "PG LALA" mutation) that inhibits in vitro binding to Fc gamma receptors (FcγR) and prevents FcγR-mediated coactivation of innate immune effector cells, including natural killer (NK) cells, monocytes / macrophages, and neutrophils, without altering functional binding to FcRn (neonatal Fc receptor). The "PG LALA" mutation consists of the amino acid exchanges P329G, L234A, and L235A ("PG LALA", Kabat EU index numbering) in heavy chain HC1 and heavy chain HC2.

[0376] The recombinant antibody is produced in CHO cells and consists of two heavy chains (449 and 674 amino acid residues, respectively) and three light chains (232 and 219 (2 copies) amino acid residues, respectively), which are arranged asymmetrically as shown in Figure 2.

[0377] Overview of Active Hotspots For the CD3-binding portion of the molecule, in silico predictions indicated that there are two degradation-prone Asn residues and one exposed Trp residue in the CDR3 of the heavy chain. Stress experiments over a 14-day period showed no significant changes in target binding activity after incubation at pH 6.0, but a strong decrease in target binding activity was observed after incubation at physiological pH (PBS pH 7.4, data not shown).

[0378] Example 2: Glofitamab formulation development GLP Tox and introduction into human studies The screen was performed according to the scheme shown in Table 4. During the screen, formulations were exposed to the following conditions: 3 and 6 weeks of storage (5° C., 25° C., and 40° C.), 1 week of shaking and freeze / thaw (F / T) stress (5 cycles) at 5° C. and 25° C. Designated formulations are then followed for up to 52 weeks. TIFF2024138235000004.tif73170

[0379] After 6 weeks of storage at 5° C., 25° C., and 40° C., all formulations showed no significant changes in most of the physical properties tested: visible and subvisible particles, color, turbidity, pH, and protein content. CE-SDS (capillary electrophoresis sodium dodecyl sulfate) data was not critical to the designation and is not shown.

[0380] Visible particle analysis by Seidenader method showed no visible particle formation for any formulation under all storage conditions. The number of particles sub-visible to the naked eye was low (not shown). Under mechanical stress conditions, F2-F5 showed many particles at both 5°C and 25°C. F1 was particle-free under both conditions. With EP and Optima, all compositions were virtually particle-free (0 particles) except for F3 and F4 (both with P188), where particles were present but below the limit (not shown). Under shaking at 5°C, sub-visible particles were significantly worse for F3 (P188+Met) than for F4 (P188). All other formulations showed similar numbers under each condition (not shown).

[0381] Turbidity and color did not change significantly for all formulations under all conditions after 6 weeks. Surfactant content was stable at 5°C and 25°C, and for formulations containing P188 (F3, F4), even at 40°C. A decrease in surfactant content was observed at 40°C for all PS20-containing active formulations (F1, F2, and F5), regardless of whether the formulation contained methionine or not.

[0382] The beneficial effect of methionine was only seen in the placebo formulation containing PS20, and only P2 showed a decrease in PS content at 40 °C (Figure 3). Biochemical characterization revealed differences between the formulations only after storage at 40 °C.

[0383] In size-exclusion chromatography (SEC), the loss of monomer was more pronounced in F2 and F5 and correlated with the increase in HMW (high molecular weight) area. New HMW species appeared, slightly in F3 and F4, more pronounced in F1, and very large in F2 and F5. LMW (low molecular weight) species were found to increase in almost the same proportions in all formulations (Figure 4). A similar trend was observed in ion-exchange chromatography (IEC), where the basic peak areas increased overall and the increase in acidic areas was more pronounced in F2 and F5 (Figure 5).

[0384] Taken together, the data clearly excluded F2 and F5 and showed that F1, F3, and F4 were equally stable, with no clear preference for any of the three. F1 (5 mg / ml glofitamab, 20 mM histidine / histidine HCl, pH 5.5, 240 mM sucrose, 10 mM methionine, 0.05% (w / v) PS20) was designated. A summary of all analytical results for F1 can be seen in Figure 6.

[0385] Example 3: Implementation into GLP Tox / Human Studies Binding by BIACORE® The purity results described above are also reflected in the loss of CD20 binding at 40°C for F2 and F5 and the strong loss of CD3 binding in those preparations of up to 50%, compared to losses of between 10 and 20% for the remaining preparations (Figures 7A and 7B).

[0386] Example 4: Phase III and development studies for commercial formulation This example provides an overview of the pharmaceutical development of the glofitamab formulation. As a result of this development, the glofitamab drug product is provided as a sterile concentrated solution for IV infusion. The drug product consists of 1 mg / ml glofitamab, 240 mM sucrose, 10 mM L-methionine, 0.5 mg / ml polysorbate 20 in 20 mM L-histidine / L-histidine hydrochloride (HCl) buffer at pH 5.5. Glofitamab is the only active ingredient in the drug substance and drug product. Formulation development studies have confirmed that the dosage form and formulation are suitable for the intended use. The formulation is sufficiently robust to ensure that the drug product is stable during manufacture, storage, transportation, and administration.

[0387] Formulations with higher protein concentrations (e.g., 5, 25, or 50 mg / ml glofitamab) were also tested but were not subsequently pursued due to the formation of sub- and visible particles due to degradation of PS20. The release of free fatty acids (lauric and myristic acids) at levels that increased with protein concentration confirmed that the underlying cause of the formation of sub- and visible particles was due to hydrolysis of PS20.

[0388] The liquid dosage form was chosen to reduce handling steps while ensuring product quality during manufacturing and through the end of the drug's shelf life.

[0389] Glofitamab drug product will be commercially available in two vial configurations in two strengths: 2.5 mg / vial in a 6 ml single-use glass vial and 10 mg / vial in a 15 ml single-use glass vial to meet the required clinical doses of 2.5 mg, 10 mg, and 30 mg while minimizing product wastage. In the commercial drug product formulation, the concentration of glofitamab has been reduced to 1 mg / ml without changing the excipient composition.

[0390] Formulation development studies were the basis for selecting the appropriate drug product dosage form, protein concentration, surfactant concentration, buffer type, solution pH, stabilizers, tonicity agents, and vial configuration. The drug substance formulation was optimized taking into account facility compatibility, dilution, and storage considerations.

[0391] Choice of dosage form The liquid dosage form was selected to provide a concentrate for infusion, thereby reducing handling steps while ensuring product quality during manufacturing and through the end of the drug's shelf life.

[0392] Choosing protein concentration A protein concentration of 5 mg / ml was selected for Phase I and maintained until Phase III, after which a protein concentration of 1 mg / ml was selected for the commercial formulation based on formulation development studies and current clinical dosing requirements.

[0393] To tailor the protein concentration to the clinical need, the stability of formulations containing 20 mM L-histidine / L-histidine hydrochloride, 10 mM L-methionine, 240 mM D-sucrose, and 0.5 mg / ml polysorbate 20 (PS20) at pH 5.5 was tested at glofitamab concentrations of 1 mg / ml, 5 mg / ml, and 25 mg / ml. These formulations were evaluated at the initial time point (T0), at several intermediate time points, and at the end of the study after 104 weeks of storage at 2°C to 8°C by assessing glofitamab purity by SE-HPLC and IE-HPLC, PS20 content, and visible / subvisible particle formation.

[0394] Purity by SE-HPLC and IE-HPLC was comparable between the 1 mg / ml and 5 mg / ml formulations throughout the study (Figures 8A and 8B). The number of subvisible particles was also similar. Furthermore, the 1 mg / ml formulation showed no PS20 degradation beyond method variability compared to the 5 mg / ml and 25 mg / ml formulations (Figure 12; see also "Evaluation of Polysorbate 20 Degradation" below). Based on these results and the most recent clinical dosing regimes of 2.5 mg, 10 mg, and 30 mg, the 1 mg / ml formulation was selected as the marketed formulation.

[0395] A concentration range of 0.9-1.1 mg / ml protein was further evaluated in a subsequent multivariate formulation robustness study (see Example 5, Formulation Robustness Study), which confirmed acceptable stability behavior in this concentration range.

[0396] Selection of pH, buffers, stabilizers, and tonicity agents Based on formulation development studies, a 20 mM solution of L-histidine / L-histidine hydrochloride at pH 5.5 was selected as the buffer, along with 10 mM L-methionine as a stabilizer and 240 mM D-sucrose as an isotonicity agent in Phase I and was retained for Phase III and the commercial formulation.

[0397] Studies with glofitamab at 5 mg / ml were tested in 20 mM L-histidine / L-histidine hydrochloride buffers at pH ranges from 5.5 to 6.0, with L-methionine levels of 0 and 10 mM. Additionally, a comparison was performed with 240 mM D-sucrose and 130 mM sodium chloride.

[0398] The impact of pH and stabilizers was evaluated by assessing the purity of glofitamab by SE-HPLC and IE-HPLC and the formation of visible / subvisual particles at the initial time point (T0) and after 6 weeks of storage at 40° C. The choice of tonicity agent was evaluated by determining the formation of visible / subvisual particles measured by SE-HPLC and IE-HPLC at the initial time point (T0) and after 26 weeks of storage at 25° C. The combination of 20 mM L-histidine / L-histidine hydrochloride buffer (pH 5.5) with 10 mM L-methionine showed the least formation of high molecular weight species (HMWS) ( FIG. 9A ) and change in charge variants ( FIG. 9B ) compared to the corresponding formulation without stabilizer or the combination of 20 mM L-histidine / L-histidine hydrochloride buffer / 10 mM L-methionine (pH 6). A concentration of 20 mM L-histidine / L-histidine hydrochloride monohydrate has been shown to be sufficient to maintain during drug product manufacturing and during storage of drug substance and drug product.

[0399] 240 mM D-sucrose was chosen based on a comparison of 240 mM D-sucrose with 130 mM sodium chloride. The number of subvisible particles was comparable between formulations. No subvisible particle formation was observed in the D-sucrose-containing formulations after 26 weeks of storage at 25°C, whereas visible particles were observed in the NaCl-containing formulation (Figure 10).

[0400] Surfactant Selection A concentration of 0.5 mg / ml of PS20 was selected for Phase I based on the results of the stability study and was maintained until commercial formulation. The stabilizing effect of poloxamer 188 (P188) on PS20 was investigated in a study of glofitamab at 50 mg / ml in 20 mM L-histidine / L-histidine hydrochloride buffer, pH 5.5, 10 mM L-methionine and 240 mM D-sucrose. P188 was tested at levels of 0.5, 0.7, and 1.0 mg / ml and PS20 at levels of 0.1, 0.3, and 0.5 mg / ml.

[0401] The effect of added surfactant was evaluated by assessing glofitamab purity by SE-HPLC and IE-HPLC and visible / subvisible particle formation at the initial time point (T0) and after 7 days of shaking at 25°C.

[0402] Visible particle formation was observed at all P188 concentrations; therefore, P188 was excluded as a suitable surfactant for glofitamab (Figure 11). No visible particles were detected in the PS20-containing formulation after 7 days of shaking at 25°C (Figure 11). A significant increase in HMWS and charged variants was observed in the 0.1 mg / ml PS20-containing formulation compared to the 0.5 mg / ml PS20-containing formulation after 7 days of shaking at 25°C, whereas a slight increase in the levels of HMWS and charged variants was observed in the 0.3 mg / ml PS20-containing formulation (Figure 11). The number of subvisible particles was comparable between the different PS20 concentrations. A significant increase in HMWS and charge variants was observed in the 0.1 mg / ml PS20-containing formulation compared to the 0.5 mg / ml PS20-containing formulation after 7 days of shaking at 25 °C, whereas a slight increase in the levels of HMWS and charge variants was observed in the 0.3 mg / ml PS20-containing formulation (Figure 11). Therefore, the 0.5 mg / ml PS20-containing formulation was selected. A level of polysorbate 20 of 0.5 mg / ml was shown to be sufficient to protect glofitamab from stresses that may occur during processing (such as agitation, freeze-thawing, or shear stress), handling, storage, and transportation. A concentration range of 0.2 to 0.8 mg / ml PS20 was further evaluated in a subsequent multivariate formulation robustness study (see Example 5, Formulation robustness study). This study confirmed acceptable stability behavior in this concentration range.

[0403] Example 5: Formulation robustness studies The compositions of the drug substance and drug product can vary within ranges based on manufacturing factors such as weighing tolerances of buffer components. A multivariate formulation robustness study was performed and demonstrated that the relevant quality attributes (QAs) of glofitamab are acceptable at the boundaries of these compositional ranges. A multivariate stability study at two levels was performed for three factors identified as having the potential to affect the critical quality attributes (CQAs) during drug product storage. The following three formulation parameters were evaluated: 1. Protein Concentration 2. pH 3.PS20 concentration. Additionally, three formulation parameters were evaluated separately in the univariate stability study: 4. Buffer strength 5. L-Methionine Concentration 6. D-sucrose concentration.

[0404] A multivariate formulation robustness study demonstrated that the relevant CQAs of glofitamab were acceptable across the full range of claimed formulation compositions.

[0405] Study design A risk assessment was performed to identify the drug substance and drug product formulation parameters that are important for maintaining product quality during the shelf life. Multivariate and univariate analyses were designed accordingly.

[0406] Multivariate Analysis (F6 to F12) A two-level fractional factorial design (resolution III) stability study was performed using three formulation parameters as input factors: protein concentration, pH, and PS20 concentration.

[0407] Univariate analysis (F13 to F20) L-methionine and D-sucrose concentrations (low and high) as well as buffer strengths (low and high levels) were tested.

[0408] One formulation with low protein concentration, low pH, and low PS20 concentration was evaluated in direct comparison with a corresponding formulation with high pH, ​​high protein concentration, and high PS20 concentration.

[0409] One formulation with a PS20 concentration of 0.3 mg / ml was included to support the establishment of acceptance criteria.

[0410] The formulation parameter ranges tested were defined to cover either the drug specification acceptance criteria and / or manufacturing tolerances, as described in Table 5. Table 6 shows the design plan, which included 15 experiments with three center points, corresponding to the target commercial formulation composition. TIFF2024138235000005.tif44170TIFF2024138235000006.tif104170

[0411] The stability of glofitamab in the formulation compositions listed in Table 6 was evaluated as follows: ● Stability studies: Storage conditions: Real-time (2°C to 8°C), accelerated (25°C) Test frequency: Storage under the above storage conditions for 0, 4, 13, 26 (end of storage at 25°C), 39, 52, 78, and 104 weeks ● Stress test: Five freeze-thaw cycles, 〇 Shaking at 2-8℃ for 1 week and shaking at 25℃ for 1 week ● Stability supporting DS: Storage at -40℃ for 0, 26, 52 and 104 weeks QAs evaluated: HMWS (high molecular weight species) and main peak by SE-HPLC LMWS (low molecular weight species) and main peak by non-reduced CE-SDS Acidic peaks 2 and 3, acidic region, basic region, and main peak by IE-HPLC Protein content by UV-Vis spectroscopy Polysorbate 20 content by HPLC-ELSD L-Methionine and L-Histidine Concentrations by RP-HPLC Oxidation and isomerization by peptide mapping (LC-MS) ○ Potency by bioassay 〇 Visible particles Particles invisible to the naked eye Color, transparency / protein light pH Osmotic pressure 〇 Density

[0412] Overall data analysis procedure Data were collected over time for all quality attributes for each formulation. Relative changes over time for each QA were assessed.

[0413] Multivariate analysis: A simple linear regression was fitted for each quality attribute and each formulation over time. Thus, the degradation rate was calculated for each quality attribute and each formulation. If not specified, the degradation rates are reported as degradation rates per week. These degradation rates were evaluated as responses in a Design of Experiments (DoE) study to investigate the effect of three parameters on these degradations: protein concentration, pH, and PS20 concentration. If the quality attributes did not show a meaningful change over time compared to the target formulation, regression analysis and effect estimation were not performed. For quality attributes that showed a meaningful change over time, linear regression was used to estimate the main effects of the three factors on the degradation rate. Additionally, main effect plots were presented to graphically illustrate these effects.

[0414] Univariate analysis: For the parameters tested in univariate analysis, the results after 39 weeks of storage at 2°C to 8°C were evaluated in comparison to TO to identify potential changes. If changes were identified, the degradation rate was calculated and compared to the degradation rate of the target formulation to estimate the impact of the investigated formulation parameters at the boundary. In some cases, the degradation rate per week was converted to the degradation rate observed at 104 weeks by multiplying it by a factor of 104. Regression analyses were performed using JMP® software (SAS Institute, Cary, NC, Version 10.0 or higher).

[0415] Robust formulation stability at recommended storage conditions (2°C to 8°C): The evaluation of the relative changes compared to the target formulation after 39 weeks of storage at 2°C-8°C is summarized in Table 7. An increase in the acidic variant levels (acidic region and acidic peak 2 by IE-HPLC) was observed for all formulations formulated at pH 6 (F8, F9, F20). The observed increase in acidic variants is reflected by a corresponding decrease in the IE-HPLC main peak in the affected formulations. No changes were observed in all other CQAs for all other formulations after 39 weeks of storage at 2°C-8°C. In conclusion, pH was identified as a critical formulation parameter. All other formulation parameters, protein content, PS20, L-methionine and D-sucrose concentrations, as well as buffer strength, did not affect the tested CQAs in the range investigated.

[0416] Robust formulation stability at accelerated storage conditions (25°C): Similar to the data from 2°C to 8°C, an increase in the levels of acidic variants due to deamidation (acidic region and acidic peak 2 by IE-HPLC) was observed in all formulations (F8, F9, F20) formulated at pH 6, which is reflected in a decrease in the IE-HPLC main peak in the affected formulations. Additionally, an increase in the levels of fragmentation was observed in F1 and F2 formulated at pH 5, due to an increase in LMWS by CE-SDS. This increase is reflected in a decrease in the CE-SDS main peak. No changes were observed in any of the other CQAs for all other formulations after 26 weeks of storage at 25°C.

[0417] In conclusion, the data at 25°C confirmed that pH was the critical formulation parameter. All other formulation parameters had no effect on the CQAs. TIFF2024138235000007.tif149170

[0418] Robust formulation stability at recommended API storage conditions (-40°C): To support drug substance stability across the claimed formulation composition range, a stability study was conducted on the drug substance robustness formulation stored at -40° C. The study results confirmed that no significant changes were observed in the quality attributes tested when the formulation was stored at the recommended drug substance storage conditions at -40° C for 26 weeks.

[0419] Robust formulation stability after shaking and freeze / thaw stress: The formulations were shaken for one week at 2° C. to 8° C. or 25° C. Additionally, the formulations were evaluated after five freeze / thaw cycles between -40° C. and 5° C. All samples were virtually free of visible particles upon shaking or freeze / thaw stress.

[0420] In all formulations, shaking and freeze / thaw stress did not alter subvisible particles. Formulations with low PS20 content (0.2 mg / ml, F7, F8, F13) showed no effect on product quality after shaking and freeze / thaw stress compared to all other formulations containing PS20 at levels between 0.3 and 0.8 mg / ml.

[0421] The results confirm that a level of polysorbate 20 of ≥ 0.2 mg / ml is sufficient to protect proteins from shaking and freeze / thaw stress. Similarly, the formulation with a low D-sucrose content (200 mM, F19) showed no impact on product quality after shaking and freeze / thaw stress compared to all other formulations containing D-sucrose at levels of 240-280 mM. The results confirm that a level of D-sucrose of ≥ 200 mM is sufficient to protect proteins from freeze / thaw stress. Other quality attributes showed no significant changes due to shaking or freeze / thaw stress compared to the control samples.

[0422] Linear regression analysis of identified CQAs based on data at recommended storage conditions (2°C - 8°C): A simple linear regression analysis was performed for the affected CQAs (solution pH, protein concentration, and PS20 concentration). pH was identified as the main influence. The calculated weekly degradation rates were extrapolated to the end of shelf life (EoS) by multiplying by 104 weeks (=24 months). The extrapolated results are summarized in Table 8.

[0423] Linear regression analysis demonstrated that the pH range tested had no meaningful impact on the identified CQAs, as all CQAs were within the stability acceptance criteria. However, to control for the increase in the acidic region, the pH acceptance criteria for drug release were tightened to 5.2-5.8. TIFF2024138235000008.tif78170

[0424] Conclusion: Extrapolated data suggests an impact of a high pH of 6.0 on the levels of acidic variants after 24 months (the claimed drug product shelf life). Therefore, the pH acceptance criteria at drug product release were tightened to 5.2-5.8 to limit the formation of acidic formulations during drug product stability.

[0425] This formulation is considered robust until the end of its shelf life: • The CQA meets the release acceptance criteria at t=0 and after 9 months of storage at 2°C-8°C for all formulations at the boundaries of the formulation range. • The CQA meets the stability acceptance criteria for all formulations at the boundaries of the formulation range when degradation rates are used to extrapolate to EoS.

[0426] Example 6: Evaluation of degradation of polysorbate 20 Polysorbate 20 may degrade via oxidative or hydrolytic mechanisms. Hydrolysis of polysorbate 20 results in the formation of free fatty acids (FFAs), such as lauric acid. At certain high concentrations, FFAs may form particles that are sub-visible or visible to the naked eye. Additionally, degradation of polysorbate 20 is also a concern when there is less polysorbate in the formulation than is necessary to protect the protein from agitation stress.

[0427] Due to these concerns, polysorbate 20 degradation was monitored during formulation development. PS20 degradation was observed in glofitamab formulations during formulation development, depending on protein concentration. Significant degradation of PS20 was observed in the 25 mg / ml formulation (Figure 12), with visible particles observed at 2°C to 8°C. In the 5 mg / ml formulation, PS20 degradation was less pronounced, with visible particles observed after 20 months. The number of subvisible particles was not affected. Visible particles were isolated and characterized by Fourier transform infrared (FTIR) analysis, and were found to be FFAs. The 1 mg / ml formulation showed no PS20 degradation (beyond the precision of the method) or visible particle formation throughout the entire 24-month study period. The number of subvisible particles was consistently low. Long-term stability data for nine drug product (DP) batches from four different drug substance (DS) batches supported the absence of visible particles. FIG. 13 provides a visualization of the long-term stability data of an exemplary DP batch.

[0428] Example 7: Physicochemical in-use stability studies Glofitamab drug product is provided as a sterile concentrate for IV infusion. The drug product consists of 1 mg / ml glofitamab, 240 mM sucrose, 10 mM L-methionine, 0.5 mg / ml polysorbate 20 in 20 mM L-histidine / L-histidine hydrochloride buffer, pH 5.5. Glofitamab is a preservative-free drug product supplied in single-use 2.5 ml and 10 ml glass vials. Glofitamab is intended for IV administration by IV bag infusion after dilution with 0.9% or 0.45% sodium chloride. The proposed registration dose and schedule based on a step-up dosing schedule is 2.5 / 10 / 30 mg. Dosages can be placed in IV bags with dosing solution concentrations of 0.05 mg / ml to 0.6 mg / ml. In a bracketing design, dosing solutions of 0.05 mg / ml, 0.1 mg / ml, and 0.6 mg / ml were tested for suitability to cover the entire dose range (Table 9).

[0429] Stability and compatibility studies were performed to support the physicochemical stability of the infusion solution under the recommended conditions of use. These studies demonstrated that glofitamab infusion solutions are stable during typical preparation and administration procedures and can be held under ambient room light conditions at 2°C-8°C for 72 hours and at 30°C for an additional 24 hours, with subsequent infusion times at 25°C not exceeding 16 hours. The nominal protein concentration range in which the infusion solution has been demonstrated to be stable is 0.05 to 0.6 mg / ml.

[0430] Study materials and setup: The physicochemical stability of glofitamab was evaluated after dilution int...

Claims

1. A liquid pharmaceutical composition, pH ranges from approximately 5.0 to approximately 6.

0. Glofitamab at approximately 1 to 5 mg / ml; Approximately 10 to 50 mM buffering material; Isotonic agent of approximately ≥ 200 mM; Approximately 5-15 mM methionine; and Surfactants ≥ approximately 0.2 mg / ml; A liquid pharmaceutical composition containing [the specified ingredient].

2. The liquid pharmaceutical composition according to claim 1, wherein the concentration of grofitamab is in the range of about 0.9 to 1.1 mg / ml.

3. The liquid pharmaceutical composition according to claim 1, wherein the concentration of grofitamab is about 1 mg / ml.

4. The liquid pharmaceutical composition according to claim 1, wherein the buffering agent is histidine buffer, or optionally histidine HCl buffer.

5. The liquid pharmaceutical composition according to claim 1, wherein the concentration of the buffering agent is approximately 15 to 25 mM.

6. The liquid pharmaceutical composition according to claim 1, wherein the concentration of the buffering agent is approximately 20 mM.

7. The liquid pharmaceutical composition according to claim 1, wherein the buffer provides a pH of about 5.2 to about 5.

8.

8. The liquid pharmaceutical composition according to claim 1, wherein the isotonic agent is selected from the group consisting of salts, sugars, and amino acids.

9. The liquid pharmaceutical composition according to claim 8, wherein the isotonic agent is either sucrose or sodium chloride.

10. The liquid pharmaceutical composition according to claim 9, wherein the isotonic agent is sucrose at a concentration of about 200 mM or higher.

11. The liquid pharmaceutical composition according to claim 10, wherein the isotonic agent is sucrose at a concentration of about 200 mM to 280 mM.

12. The liquid pharmaceutical composition according to claim 11, wherein the isotonic agent is sucrose at a concentration of about 240 mM.

13. The liquid pharmaceutical composition according to claim 1, wherein the concentration of methionine is approximately 10 mM.

14. The liquid pharmaceutical composition according to claim 1, wherein the concentration of the surfactant is approximately 0.2 to 0.8 mg / ml.

15. The liquid pharmaceutical composition according to claim 1, wherein the surfactant is polysorbate 20 or poloxamer 188.

16. The liquid pharmaceutical composition according to claim 15, wherein the surfactant is polysorbate 20 at a concentration of 0.2 to 0.8 mg / ml.

17. The liquid pharmaceutical composition according to claim 16, wherein the surfactant is polysorbate 20 at a concentration of about 0.5 mg / ml.

18. At a pH of approximately 5 to approximately 6, With grofitamab at approximately 1 to 5 mg / ml; With approximately 15-25 mM histidine buffer; With approximately 200-280 mM sucrose; With approximately 5-15 mM methionine; PS20 at approximately 0.2–0.8 mg / ml; A liquid pharmaceutical composition according to claim 1, comprising:

19. Use of the liquid pharmaceutical composition according to any one of claims 1 to 18 for the preparation of a pharmaceutical useful for treating a cell proliferation disorder.

20. The use according to claim 19, wherein the cell proliferation disorder is cancer.

21. A liquid pharmaceutical composition according to any one of claims 1 to 18, for use in subjects requiring treatment of or delay of the progression of cell proliferation disorders.

22. The liquid pharmaceutical composition according to claim 21, wherein the cell proliferation disorder is cancer.

Images